Thorne Healthtech (THRN) 10-K 16 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 04, 2022	Jun. 30, 2021
Cover [Abstract]
Entity Registrant Name	THORNE HEALTHTECH, INC.
Entity Central Index Key	0001844280
Document Type	10-K
Document Period End Date	Dec. 31, 2021
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity File Number	001-40826
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Annual Report	true
Document Transition Report	false
Entity Tax Identification Number	27-2877253
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	152 W. 57th Street
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	929
Local Phone Number	251-6321
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	THRN
Security Exchange Name	NASDAQ
ICFR Auditor Attestation Flag	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		52,554,214
Documents Incorporated by Reference [Text Block]	DOCUMENTS INCORPORATED BY REFERENCE Items 10, 11, 12, 13 and 14 of Part III incorporate information by reference from the Registrant's definitive proxy statement relating to its 2022 annual meeting of stockholders to be filed with the Securities and Exchange Commission within 120 days after the close of the Registrant's fiscal year.
Auditor Name	BDO USA, LLP
Auditor Location	Raleigh, North Carolina
Auditor Firm ID	243

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash	$ 51,100,915	$ 15,262,094
Accounts receivable, net	5,285,321	2,288,700
Related party receivables	366,590	225,693
Inventories, net	41,012,124	28,066,024
Prepaid expenses and other current assets	3,494,473	886,328
Total current assets	101,259,423	46,728,839
Restricted Cash	4,900,000	0
Property and equipment, net	27,030,400	23,189,730
Operating lease right-of-use asset, net	17,836,756	17,740,816
Finance lease right-of-use asset	883,076	767,237
Intangible assets, net	6,592,316	7,635,253
Goodwill	14,440,683	14,440,683
Investments	400,000	1,150,000
Equity-method investments	963,685	3,382,147
Other assets	993,538	454,429
Total assets	175,299,877	115,489,134
Current Liabilities
Accounts payable	16,889,756	8,691,430
Accrued payroll	2,526,917	2,592,143
Other accrued expenses	1,144,573	1,232,133
Related party payable	1,634,775	809,080
Current portion of operating lease liability	2,633,236	2,603,930
Current portion of finance lease liability	413,487	269,212
Current portion of long-term debt	494,173	223,400
Total current liabilities	25,736,917	16,421,328
Long-term Liabilities
Revolving line of credit		20,000,000
Operating lease liability, net of current portion	27,605,739	27,284,356
Finance lease liability, net of current portion	482,544	454,857
Long-term debt, net of current portion	1,083,634	469,471
Warrant liability	2,058,566	3,930,930
Other long-term liabilities		280,000
Total liabilities	56,967,400	68,840,942
Commitments and Contingencies (Notes 12 and 19)
Stockholders’ Equity (Deficit)
Additional paid-in capital	250,163,984	52,451,862
Accumulated deficit	(132,158,016)	(132,964,365)
Total stockholders’ equity (deficit)—Thorne HealthTech, Inc.	118,531,510	(80,389,265)
Non-controlling interest	(199,033)	(6,447,074)
Total stockholders’ equity (deficit)	118,332,477	(86,836,339)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	175,299,877	115,489,134
Series E Preferred Stock [Member]
Long-term Liabilities
Series E convertible preferred stock; par value $0.01, 0 and 27,011,500 authorized as of December 31, 2021 and December 31, 2020, respectively; 0 and 27,011,500 issued and outstanding as of December 31, 2021 and December 31, 2020, respectively; aggregate liquidation preference of $134,449,035 as of December 31, 2020		133,484,531
Common Class B [Member]
Stockholders’ Equity (Deficit)
Common Stock, value	0	0
Common Class Undefined [Member]
Stockholders’ Equity (Deficit)
Common Stock, value	$ 525,542	$ 123,238

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000,000	63,190,000
Common Stock, Shares, Issued	52,554,214	12,323,830
Common Stock, Shares, Outstanding	52,554,214	12,323,830
Series E Preferred Stock [Member]
Temporary Equity, Par or Stated Value Per Share	$ 0.01	$ 0.01
Temporary Equity, Shares Authorized	0	27,011,500
Temporary Equity, Shares Issued	0	27,011,500
Temporary Equity, Shares Outstanding	0	27,011,500
Temporary Equity, Liquidation Preference		$ 134,449,035
Common Class B [Member]
Common Stock, Par or Stated Value Per Share	$ 0	$ 0
Common Stock, Shares Authorized	0	0
Common Stock, Shares, Issued	0	0
Common Stock, Shares, Outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net sales	$ 185,246,025	$ 138,454,924
Cost of sales	87,892,579	73,667,333
Gross profit	97,353,446	64,787,591
Operating expenses:
Research and development	5,935,514	4,224,891
Marketing	25,189,326	11,150,514
Selling, general, and administrative	54,913,441	48,397,419
Write-off of acquired Drawbridge in-process research and development	1,563,015
Income from operations	9,752,150	1,014,767
Other (income) expense:
Interest expense, net	449,908	1,125,472
Guarantee fees	336,915	243,040
Change in fair value of warrant liability	(1,872,364)	1,912,487
Loss on Drawbridge Transaction	165,998
Other (income) expense, net	(249,082)	1,119
Total other (income) expense, net	(1,168,625)	3,282,118
Income (loss) before income taxes and loss from equity interests in unconsolidated affiliates	10,920,775	(2,267,351)
Income tax expense	411,919	176,758
Net income (loss) before loss from equity interests in unconsolidated affiliates	10,508,856	(2,444,109)
Loss from equity interests in unconsolidated affiliate	(3,664,058)	(1,509,704)
Net income (loss)	6,844,798	(3,953,813)
Net income non controlling interest	(408,625)	(596,067)
Net income (loss) attributable to Thorne HealthTech, Inc.	7,253,423	(3,357,746)
Undistributed earnings attributable to Series E convertible preferred stockholders	(3,507,892)
Net income (loss) attributable to common stockholders	3,745,531	(3,357,746)
Net income (loss) attributable to common stockholders - Diluted	$ 3,349,308	$ (3,357,746)
Earnings (loss) per share:
Basic	$ 0.14	$ (0.34)
Diluted	$ 0.10	$ (0.34)
Weighted average common shares outstanding:
Basic	27,478,411	9,985,800
Diluted	32,328,565	9,985,800

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Series E Convertible Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]Preferred Stock [Member]	Common Class B [Member]
Beginning Balance at Dec. 31, 2019							$ 133,484,531
Beginning Balance (Share) at Dec. 31, 2019						27,011,500
Beginning Balance at Dec. 31, 2019	$ (106,917,585)	$ 96,427	$ 28,443,614	$ (129,606,619)	$ (5,851,007)
Beginning Balance (Share) at Dec. 31, 2019		9,642,705
Exercise of common stock warrants	22,221,173	$ 43,370	22,177,803
Exercise of common stock warrants (in Shares)		4,336,970
Exercise of stock options	850,681	$ 8,054	842,627
Exercise of stock options (in Shares)		805,450
Repurchase of common stock		$ (24,613)	24,613
Repurchase of common stock (in Shares)		(2,461,295)
Stock-based compensation	963,205		963,205
Net income (loss)	(3,953,813)			(3,357,746)	(596,067)
Ending Balance at Dec. 31, 2020						$ 133,484,531
Ending Balance (Share) at Dec. 31, 2020						27,011,500
Ending Balance at Dec. 31, 2020	(86,836,339)	$ 123,238	52,451,862	(132,964,365)	(6,447,074)
Ending Balance (Share) at Dec. 31, 2020		12,323,830
Common stock issued in exchange for remaining interest in consolidated affiliate				(6,447,074)	6,447,074
Common stock issued in exchange for remaining interest in consolidated affiliate (in Shares)								6,179,270
Noncontrolling interest in acquired subsidiary	209,592				209,592
Conversion of all shares of Class B common stock to common stock		$ 61,793	(61,793)
Conversion of all shares of Class B common stock to common stock (in Shares)		6,179,270						(6,179,270)
Conversion of Series E convertible preferred stock to common stock	133,484,531	$ 270,115	133,214,416			$ (133,484,531)
Conversion of Series E convertible preferred stock to common stock (in Shares)		27,011,500				(27,011,500)
Issuance of common stock in September 2021 IPO at $10.00 per share, net of issuance costs of $9,999,748	60,000,252	$ 70,000	59,930,252
Issuance of common stock in September 2021 IPO at $10.00 per share, net of issuance costs of $9,999,748 (in Shares)		7,000,000
Exercise of stock options	75,619	$ 396	75,223
Exercise of stock options (in Shares)		39,614
Stock-based compensation	4,554,024		4,554,024
Net income (loss)	6,844,798			7,253,423	(408,625)
Ending Balance at Dec. 31, 2021	$ 118,332,477	$ 525,542	$ 250,163,984	$ (132,158,016)	$ (199,033)
Ending Balance (Share) at Dec. 31, 2021		52,554,214

Consolidated Statements of Co_2

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - IPO [Member]	12 Months Ended
	Dec. 31, 2021USD ($)$ / shares
Shares Issued, Price Per Share | $ / shares	$ 10
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $	$ 9,999,748

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities
Net income (loss)	$ 6,844,798	$ (3,953,813)
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Depreciation and amortization	4,453,057	4,295,840
Change in fair value of warrant liability	(1,872,364)	1,912,487
Non-cash lease expense	5,963,123	5,272,409
Stock-based compensation	4,554,024	10,037,396
Change in inventory and receivable reserves	(67,548)	291,619
Loss on sale of equipment		1,129
Loss from equity interests in unconsolidated affiliate	3,664,058	1,509,704
Loss on Drawbridge Transaction	165,998
Write-off of acquired Drawbridge in-process research and development	1,563,015
Change in operating assets and liabilities
Accounts receivable	(2,886,874)	2,607,011
Related party Receivable	(231,191)	(84,340)
Related party payables	825,695	372,831
Inventories	(12,879,268)	(709,519)
Prepaid expenses and other assets	(2,417,918)	(107,336)
Accounts payable and accrued liabilities	6,199,815	1,061,060
Operating lease liabilities	(4,794,134)	(5,399,423)
Net cash provided by operating activities	9,084,286	17,107,055
Cash Flows from Investing Activities
Purchase of property and equipment	(4,311,015)	(1,193,642)
Acquisition of Drawbridge Health assets, net of cash acquired	(1,412,279)
Purchase of investment in equity-method investments	(704,637)	(615,015)
Purchase of investment in unconsolidated subsidiaries		(750,000)
Purchase of license agreements	(750,457)	(1,128,621)
Net cash used in investing activities	(7,178,388)	(3,687,278)
Cash Flows from Financing Activities
Proceeds from issuance of common stock in IPO	70,000,000
Payoff of line of credit	(20,000,000)	(11,204,731)
Repayment of loan from related party		(3,000,000)
Proceeds from revolving line of credit		20,000,000
Payments on long-term debt and finance leases	(1,242,948)	(378,191)
Dividends paid on convertible preferred stock		(3,266,918)
Common stock issuance costs	(9,999,748)
Proceeds from exercise of common stock warrants		22,221,173
Repurchase of common stock		(23,119,913)
Payments for loans to management		(710,000)
Proceeds from repayment of loans to management		710,000
Proceeds from exercise of stock options	75,619	127,249
Net cash provided by financing activities	38,832,923	1,378,669
Net Increase in Cash and restricted cash	40,738,821	14,798,446
Cash and restricted cash, beginning of period	15,262,094	463,648
Cash and restricted cash, end of period	56,000,915	15,262,094
Supplemental Disclosure of Cash Flows Information
Cash paid during the year for interest	383,569	1,136,731
Income taxes, net of refunds	192,618	40,007
Noncash Investing and Financing Activities
Equipment acquired through finance lease obligations	540,433	694,108
Equipment acquired through debt obligations	1,274,601	893,600
Right-of-use assets obtained in exchange for lease liabilities	2,913,002	4,259,688
Conversion of Series E convertible preferred stock to common stock	133,484,531
Conversion of Class B common stock to common stock	$ 61,793

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Nature of Operations	1. Organization and Nature of Operations Thorne HealthTech, Inc. was originally incorporated under the name of Thorne Holding Corp. (the Company) and was incorporated under the laws of the state of Delaware on June 17, 2010, to acquire 100 % of the stock of Thorne Research, Inc. (Thorne Research). On November 13, 2020, the Company changed its name to Thorne HealthTech, Inc. The Company is a science-driven wellness company, pioneering innovative solutions and personalized approaches to health and wellness. The Company is building a new health category to deliver better health outcomes through a proactive, empowered approach. Its unique, vertically integrated brands, Thorne and Onegevity, provide actionable insights and personalized data, products and services that help individuals take a proactive approach to improve and maintain their health over their lifetime. By combining its proprietary multi-omics database, artificial intelligence (AI) and digital health content with its science-backed nutritional supplements, the Company delivers a total system for health and wellness.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The consolidated financial statements include the operations of the Company and all of its wholly-owned subsidiaries, as well as majority-owned subsidiaries over which the Company exercises control and, when applicable, entities for which the Company has a controlling financial interest or variable interest for which the Company is the primary beneficiary. All significant intercompany accounts and transactions have been eliminated in consolidation. On September 10, 2021, the Company approved and effected a 445 -for-1 forward stock split of the Company’s Class A common stock, Class B common stock, and Series E convertible preferred stock. The par value and other terms of the common stock and preferred stock were not affected by the stock split. All related share and per share amounts have been retroactively adjusted in these consolidated financial statements for all periods presented to reflect the 445 -for-1 forward stock split. Furthermore, other related information, including shares of common stock underlying the Company’s warrants, stock options and restricted stock units and their respective exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented to reflect the 445 -for-1 forward stock split. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The Company bases its estimates on its historical experience and on assumptions that the Company believes are reasonable; however, actual results could significantly differ from those estimates. Cash Cash includes all cash balances. At times, cash balances may exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses resulting from these excess deposits. Restricted Cash The Company’s restricted cash consists of cash that the Company is contractually obligated to maintain in accordance with the terms of its Standby Letter of Credit with Sumitomo Mitsui Banking Corporation (SMBC). See Notes 3 and 11 for additional information related to the SMBC Standby Letter of Credit. Accounts Receivable Accounts receivable consist of balances due from customers and are recorded at net realizable value. Past due balances that are delinquent beyond the acceptable terms of credit for each customer are reviewed individually for collectability. The allowance for doubtful accounts was $ 10 thousand and $ 34 thousand as of December 31, 2021 and 2020, respectively. Concentrations of Risk Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. Although the Company places its cash with high quality institutions, these balances often exceed federally insured limits. Concentrations of credit risk primarily relate to unsecured trade receivables. Major customers who accounted for more than 10 % of the Company’s total receivables were as follows: As of December 31, 2021 2020 iHerb, Inc. 41.3 % * Emerson Ecologics, LLC 33.3 % 39.4 % * Represents less than 10% Sales - Major customers who accounted for more than 10 % of the Company’s total sales were as follows: Years ended December 31, 2021 2020 Pattern Inc. 27.0 % 26.1 % iHerb, Inc. * 11.3 % * Represents less than 10% Inventories Raw materials consist primarily of powders, soft gels, and packaging components such as bottles, lids, and labels. Work in process consists of premixed powders and encapsulated powders actively in the manufacturing process, but not yet bottled. Inventories are stated at the lower of cost, as determined on the first-in, first-out method, or net realizable value. Finished goods and work-in-process include the inventory costs of raw materials, direct labor and normal manufacturing overhead. The Company uses an inventory reserve to adjust our inventory costs down to a net realizable value and to reserve for estimated obsolescence of both raw materials and finished goods. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Any purchase discounts received are included in the cost of inventories. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets include annual insurance premiums and annual equipment and software maintenance expense, paid on a non-calendar year basis such that portions of the advance payments relate to future periods. Property and Equipment Property and equipment are stated at historical cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term (including renewals that are reasonably certain to occur) or the estimated useful lives of the improvements. The estimated useful lives of property and equipment are as follows: Machinery and equipment 3 to 15 years Furniture and fixtures 3 to 7 years Office equipment 3 to 7 years Leasehold improvements 3 to 20 years Vehicles 7 years Lab equipment 5 to 10 years Software 7 years Leases The Company has operating and finance lease agreements for its production, shipping and customer service centers and corporate offices. At inception, the Company determines whether an agreement represents a lease and, at commencement, the Company evaluates each lease agreement to determine whether the lease constitutes an operating or financing lease. Some of our lease agreements have renewal options, tenant improvement allowances, rent holidays and rent escalation clauses. The Company accounts for its leases as operating or finance leases under Accounting Standards Codification (ASC) Topic 842. The Company has elected not to separate lease components from non-lease components for all fixed payments. Right-of-use lease assets represent the Company’s right to use the underlying asset for the lease term, and the operating lease obligation represents its commitment to make the lease payments arising from the lease. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Other Assets Other assets are primarily deposits required by contractual obligations for real estate leases. Impairment of Long-lived Assets Management reviews long-lived assets and certain identifiable intangible assets with finite lives for impairment in accordance with ASC 360, “Property, Plant, and Equipment.” Goodwill and intangible assets not subject to amortization are reviewed annually for impairment in accordance with ASC 350, “Intangibles — Goodwill and Other,” or more often if there are indications of possible impairment. The analysis to determine whether or not an asset is impaired requires significant judgment that is dependent on internal forecasts, including estimated future cash flows, estimates of long-term growth rates for the business, the expected life over which cash flows will be realized and assumed discount rates. Changes in these estimates and assumptions could materially affect the determination of fair value and any impairment charge. While the fair value of these assets exceeds their carrying value based on management’s current estimates and assumptions, materially different estimates and assumptions in the future in response to changing economic conditions, changes in the business, increased competition or loss of market share, product innovation or obsolescence, product claims that result in a significant loss of sales or profitability over the product life or for other reasons could result in the recognition of impairment losses. For assets to be held and used, including acquired intangible assets and long-lived assets subject to amortization, the Company initiates a review whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Recoverability of an asset is measured by comparison of its carrying amount, to the future undiscounted cash flows that the asset is expected to generate. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Significant management judgment is required in this process. During the years ended December 31, 2021 and 2020, no impairment losses were identified. Investments The Company has investments in various other entities. The equity method of accounting is used for entities in which the Company exercises significant influence, but does not have a controlling interest or a variable interest in which it is the primary beneficiary. Investments not accounted for using the equity method do not have readily determinable fair values and do not qualify for the practical expedient to measure the investment using a net asset value per share. These investments are recorded using the measurement alternative in which the Company’s equity interests are recorded at cost, less impairments, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer. At each reporting period, the Company assesses if these investments continue to qualify for this measurement alternative. An impairment is recorded when there is evidence that the expected fair value of the investment has declined to below the recorded cost. During the years ended December 31, 2021 and 2020, no impairment losses were identified. Equity Method Investments The Company reports investments in unconsolidated entities, over whose operating and financial policies it has the ability to exercise significant influence but not control, under the equity method of accounting. Under this method of accounting, the Company’s pro rata share of the applicable entity’s earnings or losses are included in the consolidated statements of operations. Initially the investments are recorded based on assets contributed or the cash invested. The Company evaluates its equity-method investments for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. If it is determined that a decline in the fair value of the investments is not temporary, and if such reduced fair value is below its carrying value, an impairment is recorded. Determining fair value involves significant judgment. Estimates consider available evidence including the present value of the expected future cash flows discounted at market rates, general economic conditions and other relevant factors. No impairments were recorded related to our equity-method investments for the years ended December 31, 2021 and 2020. Intangible Assets Intangible assets are initially recorded at fair value and amortized over the estimated period of benefit on a straight line basis and include customer relationships with estimated useful lives of 20 years, trade names with estimated useful lives ranging from 5 to 15 years, existing technology and reformulations with estimated useful lives ranging from 3 to 15 years, research formulas with estimated useful lives of 10 years and license agreements with estimated useful lives of 3 to 15 years. Amortization expense is generally recognized in selling, general and administrative expense. The carrying value of definite life intangibles is reviewed at each balance sheet date if indication of impairment exists. Goodwill Goodwill, which represents the excess of the purchase price paid over the fair value of the identifiable net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value-based test. The Company is organized in one reporting unit and evaluates the goodwill for the Company as a whole. The Company performs its annual goodwill impairment test required by ASC 350 as of December 31st of each year, or more frequently if events or changes in circumstances indicate that the asset might be impaired. As part of the assessment of goodwill, the Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the fair value exceeds the carrying amount, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, then an impairment charge is recognized for the difference, limited to the amount of goodwill recorded. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations. There was no impairment of goodwill for the years ended December 31, 2021 and 2020. Defined Contribution Plan The Company maintains a 401(k) defined contribution plan which covers all employees who meet minimum requirements and elect to participate. The Company is currently matching employee contributions, up to specified percentages of those contributions. Warrant Liability The Company determines the accounting classification of a warrant, as either liability or equity, by first assessing whether the warrant meets liability classification in accordance with ASC 480, Distinguishing Liabilities from Equity (ASC 480), and then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (ASC 815-40). If the warrant does not meet liability classification under ASC 480, the Company assesses the requirements under ASC 815-40, including whether the warrant is indexed to its common stock and whether the warrant meets the other requirements to be classified as equity under ASC 815-40. After all relevant assessments are made, the Company concludes whether the warrant should be classified as liability or equity. The Company has warrants that are classified as a liability on the consolidated balance sheet. The warrants classified as a liability are measured at fair value using the Black-Scholes pricing model which takes into account, as of the valuation date, factors including the current exercise price, the contractual life of the warrant, the current fair value of the underlying stock, its expected volatility, and the risk-free interest rate for the term of the warrant. The warrant liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. As the warrant liability is required to be measured at fair value at each reporting date, it is reasonably possible that these estimates and assumptions could change in the near term. See Note 14 for additional information related to the previously issued and outstanding warrants. Equity-Classified Warrants The Company has common stock warrants that are classified within equity on the consolidated balance sheet. The Company has concluded that these warrants do not meet the requirements to be accounted for as liability under ASC 480 as they are for a fixed number of shares and do not contain provisions that require the Company to cash-settle the warrants. Additionally, the Company determined that these warrants are indexed to the Company’s stock as they do not contain exercise contingencies or adjustments to exercise price that are not an input to a fixed-for-fixed model. The warrants also meet the other equity-classification criteria under ASC 815-40. Equity classified warrants are accounted for at fair value on the issuance date and are not remeasured every reporting period. Revenue Recognition The Company accounts for revenue in accordance with FASB Topic 606, “ Revenue from Contracts with Customers ,” (ASC 606), using the following steps: • identify the contract, or contracts, with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the identified performance obligations; and • recognize revenue when, or as, the Company satisfies the performance obligations. The Company recognizes revenues at a point in time when it satisfies a performance obligation by transferring control over a product and other promised goods and services to a customer. Significant judgments made in the application of ASC 606 include determining the transaction price, and the timing of transfer of control of the performance obligation (i.e., sale of product). The Company considers several factors in determining the point in time at which control transfers to the customer, including when legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership. Professional/B2B Sales: The Company sells to wholesale customers that include health professionals, retail stores and through various online sites operated by authorized resellers. Certain customers resell Company products in online marketplaces; however, no inventories are held on consignment and revenue is recognized when control of the goods is transferred to these customers, which is at the time of shipment. The terms of payment over the recognized receivables from distributors are less than one year and therefore these sales do not have any significant financing components. The Company uses standard price lists in determining the transaction price, adjusted for estimates of variable consideration. Any discounts stated or implied are allocated entirely to the sole performance obligation. DTC Transaction Sales: The Company also sells direct to consumers online through a Company owned and operated website. Revenue from online sales is recognized at time of shipment of the product. In addition, the Company sells testing services and test kits. Testing services and testing kits are recorded as revenue when the testing results are provided to the customer. Shipping and handling costs are considered a fulfillment activity and are expensed as incurred. DTC Subscription Sales: The Company offers its customers the ability to opt into recurring automatic refills on both Thorne.com and Amazon.com. Revenue is recognized under the subscription program when product is shipped to the consumer. No funds are collected at the time a consumer signs up for a subscription and the customer can cancel or modify a subscription at any time at no cost to the customer. On the Company website, customers are allowed to subscribe at a frequency of monthly, every 45 days, every 2 months, every 3 months, or every 4 months. For all frequencies, a 10 % discount is offered on retail refill orders. On Amazon, the discount ranges from 5 to 10 % depending on the number of products to which a customer is subscribed; the average discount on Amazon for the Company’s subscriptions is approximately 6 %. The Company records revenues, net of estimated discounts. If a customer is not satisfied for any reason with a product purchased, the customer can return it to the place of purchase to receive a refund, a credit, or a replacement product. The return or refund request must be submitted within 60 days of the date of purchase. The Company estimates returns and accrues for potential returns based on historical data. There are no material differences in our revenue recognition policy between the DTC subscription program and the DTC transaction program. The Company primarily sells to customers throughout the United States but also sells to international markets. Regardless of customer location, all customers are invoiced and payments are required to be made in U.S. dollars. The Company has elected to exclude sales and use taxes for non-exempt customers from the transaction price and, therefore, sales and use taxes are excluded from revenue. Product Returns, Sales Incentives and Other Forms of Variable Consideration In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include product return rights, discounts, rebates, volume discounts and rebates and promotional offers and other marketing offers that may impact net sales. For the sale of goods with a right of return, the Company only recognizes revenue for the consideration it expects to be entitled to (considering the products to be returned) and records a sales return accrual within other accrued expenses for the amount it expects to credit back to its customers. Given that most product returns cannot be resold to another customer, the Company does not recognize an asset in inventory, or a corresponding adjustment to cost of sales, for the right to recover goods from customers associated with the estimated returns. The sales return accrual includes estimates that directly impact reported net sales. These estimates are calculated based on a history of actual returns and estimated future returns. In addition, as necessary, sales return accruals may be established for significant future known or anticipated events. The types of known or anticipated events that are considered, and will continue to be considered, include the Company’s decision to continue to support new and existing products. Returns are handled on a case-by-case basis, but generally all returns are accepted if the customer is unsatisfied with the product. The Company has accrued an estimate for returns related to a future period. Sales returns accrued for the years ended December 31, 2021 and 2020 were approximately $ 50 thousand and $ 63 thousand, respectively, and reduced net sales. The Company estimates sales incentives and other variable consideration using the expected value method. The variable consideration included in the transaction price is the amount for which, that in the Company's judgment, is probable that a significant future reversal of cumulative revenue under the contract will not occur. Under this method, certain forms of variable consideration are based on volumes of sales to the customer, which requires subjective estimates. These estimates are supported by historical results as well as specific facts and circumstances related to the current period. A select few customers, because of their size, are offered a discount for early payment. The Company also enters into transactions and makes payments to certain of its customers related to advertising, some of which involve cooperative relationships with customers. These activities may be arranged either with unrelated third parties or in conjunction with the customer. To the extent that the Company receives a distinct good or service in exchange for consideration and the fair value of the benefit can be reasonably estimated, the Company’s share of the costs of these transactions (regardless of to whom they were paid) are reflected as selling, general and administrative expenses in the accompanying consolidated statements of operations. The Company also enters into other advertising activities arranged with customers. These activities cannot be arranged with unrelated third parties, no distinct good or service is received in exchange for consideration and the fair value of the benefit is not reasonably estimated. The Company’s share of the costs for these transactions paid to customers are reflected as a reduction in the transaction price within net sales in the accompanying consolidated statements of operations. For certain sales, the Company incurs incremental costs of obtaining the contract through the form of sales commissions. The sales commissions incurred are short-term (less than 12 months in duration) and directly correlated to the sales generated and are therefore expensed as incurred. The following table presents revenue disaggregated by geography, as determined by the country products were shipped to: Year ended December 31, 2021 Year ended December 31, 2020 Amount Percentage Amount Percentage Domestic $ 174,359,631 94.1 % $ 129,061,117 93.2 % Foreign 10,886,394 5.9 % 9,393,807 6.8 % Total sales $ 185,246,025 100.0 % $ 138,454,924 100.0 % The following table presents disaggregated revenues based upon sales channel: Year ended December 31, 2021 Year ended December 31, 2020 Amount Percentage Amount Percentage DTC subscription sales $ 22,172,505 12.0 % $ 15,406,597 11.1 % DTC transaction sales 51,702,198 27.9 % 38,246,752 27.6 % Professional/B2B 111,371,322 60.1 % 84,801,575 61.2 % Total $ 185,246,025 100.0 % $ 138,454,924 100.0 % Cost of Sales Cost of sales includes the cost of inventory sold and includes all direct and indirect costs to bring the product to its saleable condition, including, inbound freight costs associated with inventory, inventory shrinkage costs, labor associated with manufacturing, lab testing, depreciation and amortization of assets used in the manufacturing process, costs to maintain production equipment, quality assurance costs and other costs associated with manufacturing. Selling, General and Administrative Selling, general and administrative expenses consist of payroll and related expenses for employees involved in general corporate functions, including accounting, finance, legal, selling and human resources; costs associated with use by these functions of facilities and equipment, such as depreciation expense and rent, share-based compensation expense, professional fees and other general corporate costs. It also includes shipping costs incurred in operating and staffing distribution operations, including costs attributable to picking, packaging and preparing customer orders for shipment, payment processing and related transaction costs, and responding to inquiries from customers. Shipping and Handling The costs of out-bound freight are included in selling, general and administrative expenses and totaled approximately $ 8.6 million and $ 6.2 million for the years ended December 31, 2021 and 2020, respectively. Advertising The cost of advertising is expensed as incurred. Advertising expense was approximately $ 23.4 million and $ 7.8 million for the years ended December 31, 2021 and 2020, respectively, and is included within marketing expense in the consolidated statements of operations. Research and Development Research and development costs, which are expensed as incurred, totaled approximately $ 5.9 million and $ 4.2 million for the years ended December 31, 2021 and 2020, respectively. Research and development costs include research payroll and payroll related costs, new product development and line extensions, clinical trials, product efficacy research, product shelf-life validation and new dietary ingredient research, among other things. Stock-based Awards The Company follows ASC 718 “Stock Compensation”, which provides guidance in accounting for share-based awards exchanged for services rendered and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of our stock-based payments. The volatility assumption used in the Black-Scholes-Merton model is based on the calculated historical volatility based on an analysis of reported data for a peer group of companies. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjust the estimated forfeiture rate based upon actual experience. Common Stock Valuation Due to the absence of an active market for the Company’s common stock prior to the IPO, the Company has historically utilized methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants’ Audit and Accounting Practice Guide: Valuation of Privately-Held Company Equity Securities Issued as Compensation to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company has considered the fair value of the common stock as of the grant date. The fair value of the common stock has been determined based upon a variety of factors, including the prices at which the Company sold shares of its convertible preferred stock to outside investors in arms-length transactions, if any, and the superior rights, preferences and privileges of the preferred stock relative to the common stock at the time of each grant; the Company’s historical and forecasted performance and operating results and the lack of an active public market for the Company’s common stock. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. We evaluate both the positive and negative evidence that is relevant in assessing whether we will realize the deferred tax assets. A valuation allowance is provided when it is more likely than not that some portion or all of the net def

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	3. Related Party Transactions Transactions with Mitsui & Co. Ltd. and Kirin Holdings Company, Limited Series E Convertible Preferred Stock Financing On July 5, 2018, the Company issued and sold an aggregate of 27,011,500 shares of Series E convertible preferred stock to Mitsui & Co., Ltd. (Mitsui), and Kirin Holdings Company, Limited (Kirin), at a purchase price of $ 5.12 per share for aggregate gross proceeds of approximately $ 138.4 million (the Series E Financing). Immediately prior to the completion of the Company’s IPO on September 22, 2021, all outstanding shares of the Series E convertible preferred stock automatically converted on a one-to-one basis into an aggregate of 27,011,500 shares of common stock. See Note 13 for additional information related to the Series E convertible preferred stock. Kirin and Mitsui Feasibility Review Agreement On March 19, 2019, Onegevity entered into a feasibility review agreement (Feasibility Agreement) with Kirin and Mitsui. Entities affiliated with both Mitsui and Kirin each held more than 5 % of our capital stock as of and for the years ended December 31, 2021 and 2020. Pursuant to the Feasibility Agreement, Onegevity is required to conduct a feasibility study for the successful commercialization of Onegevity’s Gutbio product (Gutbio Product) and in return each of Kirin and Mitsui paid the company $ 500,000 (Feasibility Payment Amount). Under the Feasibility Agreement, Kirin and Mitsui may, acting jointly, any time prior to March 19, 2022, make the decision to commercialize the Gutbio Product. If they choose to commercialize the Gutbio Product, then Onegevity is required to enter into a definitive license agreement to license the Gutbio Product to Kirin and Mitsui for their exclusive use in Japan. If they do not choose to commercialize the Gutbio Product, the Feasibility Agreement requires Onegevity to issue equity securities of Onegevity to each of Kirin and Mitsui in equal amounts in consideration for the Feasibility Payment Amount. This agreement was subsequently amended on June 8, 2021 with the Amendment Agreement extending the date of determination by one year to March 19, 2023; see ‘Kirin and Mitsui Amendment Agreement’ below. Kirin and Mitsui Letter Agreements On July 5, 2018, the Company entered into a letter agreement with Kirin and Mitsui (the Thorne Japan Agreement) in connection with the Company’s Series E convertible preferred stock financing which designates Kirin and Mitsui as the Company’s exclusive strategic partners in Japan, including with respect to the commercialization in Japan of any products and services designed, developed, manufactured, marketed, provided, licensed, sold or bought by the Company from time to time. This agreement further appoints Kirin and Mitsui as the exclusive marketers and distributors of the Company’s products in Japan and provides Kirin and Mitsui with the exclusive right to conduct research and development activities related to the Company’s products in Japan, as well as manage any regulatory approvals required to market or distribute the Company’s products in Japan. This agreement also provides Kirin and Mitsui with an exclusive right of first negotiation with respect to marketing of the Company’s products in any country in Asia, including China, ASEAN member countries, Australia, New Zealand and any other countries in which Kirin and Mitsui have an interest. This agreement expires on July 5, 2028. This agreement was subsequently amended on June 8, 2021 with the Amendment Agreement; see ‘Kirin and Mitsui Amendment Agreement’ below. Also on July 5, 2018, the Company and Onegevity entered into a letter agreement with Kirin and Mitsui (the Onegevity Agreement) in connection with the Company’s Series E convertible stock financing which provided for certain exclusive commitments between the Company and Onegevity. Kirin and Mitsui also received a right of first negotiation with respect to any business collaboration, including with respect to Onegevity products, intellectual property, services or technology, in or with respect to Japan. The agreement also provides Kirin and Mitsui a right of first refusal over any agreement, arrangement or understanding with any third party regarding a business collaboration in the Asia Pacific region other than Japan. This agreement does not expire. This agreement was subsequently amended on June 8, 2021 with the Amendment Agreement; see ‘Kirin and Mitsui Amendment Agreement’ below. Kirin and Mitsui Amendment Agreement On June 8, 2021, the Company entered into an Amendment Agreement with Kirin and Mitsui in order to amend the Feasibility Agreement, the Thorne Japan Agreement and the Onegevity Agreement. This Amendment Agreement removed the requirement from the Thorne Japan Agreement that the parties enter into separate agreements related to the exclusivity provisions discussed above and removed any provisions regarding the establishment of a joint venture in Japan. The Amendment Agreement further removed certain obsolete intercompany commitments between the Company and Onegevity, in light of the Company’s merger with Onegevity. The Amendment Agreement also amended the Onegevity Agreement to replace Onegevity with the Company as a party to the agreement. Finally, the Amendment Agreement amended the Feasibility Agreement discussed above to obligate the Company (rather than Onegevity) to issue equity securities to each of Kirin and Mitsui in the event Kirin and Mitsui elect to not commercialize the Gutbio Product by March 19, 2023. As of December 31, 2021, no equity securities have been issued related to the Feasibility Agreement or the Feasibility Payment Amount. Kirin Juntendo Agreement On October 16, 2020, Onegevity Health, LLC entered into a service agreement (Juntendo Agreement) with Juntendo University and Kirin. Pursuant to the Juntendo Agreement, we shall provide DNA analysis services for up to 600 samples and in return may receive up to $ 129,000 . During the year ended December 31, 2021, we recorded $ 15 thousand in related revenue for analysis service provided under the agreement. During the year ended December 31, 2020, we recognized no revenue under the agreement. As of December 31, 2021, we had no receivables outstanding from Juntendo University and Kirin, related to the service agreement. Kirin Loan to Company On July 24, 2019, Kirin provided the Company with a one-time loan of $ 3.0 million. In February 2020, the Company repaid this loan, along with interest accrued through the date of repayment totaling $ 128 thousand, from proceeds under our revolving line of credit with SMBC. During the year ended December 31, 2020, the Company recorded interest expense of $ 128 thousand related to the one-time loan. As of December 31, 2020, there was no related payable outstanding to Kirin. Kirin and Mitsui Employment Secondments The Company is party to secondment agreements with Kirin’s employee, Mr. Yasuhiro Oki, dated March 18, 2019 (Kirin Secondment Agreement), and Mitsui’s employee, Mr. Shuntaro Yamamoto, dated February 28, 2019 (Mitsui Secondment Agreement), under which they provide full-time services to Thorne and Thorne reimburses Kirin and Mitsui for such services. Under the Kirin Secondment Agreement and the Mitsui Secondment Agreement, we reimburse each of Kirin and Mitsui up to $ 120,000 annually for such services. During each of the years ended December 31, 2021 and 2020, the Company recorded employment related expense of $ 84 thousand, related to the Kirin Secondment Agreement. As of December 31, 2021, and 2020, the Company had an associated and outstanding related party payable to Kirin of $ 21 thousand and $ 21 thousand, respectively, related to the secondment reimbursement. During each of the years ended December 31, 2021 and 2020, the Company recorded employment related expense of $ 120 thousand, related to the Mitsui Secondment Agreement. As of December 31, 2021, and 2020, the Company had an associated and outstanding related party payable to Mitsui of $ 30 thousand and $ 30 thousand, respectively, related to the secondment reimbursement. Kirin and Mitsui Fee Letters for $4.9 Million Letter of Credit Guarantee The Company is party to certain fee letters with Mitsui and Kirin, under which Mitsui and Kirin provide certain guarantees of certain of the Company’s obligations. On November 30, 2018, the Company entered into fee letters with Mitsui (2018 Mitsui Fee Letter) and Kirin (2018 Kirin Fee Letter), whereby both Mitsui and Kirin individually agree to guarantee half of the $ 4.9 million letter of credit under the Reimbursement Agreement with SMBC, dated October 31, 2018 (LC Reimbursement Agreement). Under the 2018 Mitsui Fee Letter and 2018 Kirin Fee Letter, the Company is required to pay each, Mitsui and Kirin, an annual fee equal to twelve-month LIBOR, plus 300 basis points of their half of the $ 4.9 million guarantee. On December 3, 2018, the Company issued an irrevocable standby letter of credit pursuant to the LC Reimbursement Agreement in the amount of $ 4.9 million to serve as security under the lease for the manufacturing facility in Summerville, South Carolina. The irrevocable standby letter of credit had an original expiration date of December 3, 2019 and automatic renewals until October 31, 2037. On October 29, 2021, the Company deposited $ 4.9 million into a restricted interest-bearing account with SMBC to fund the standby letter of credit and release the guarantees provided by Kirin and Mitsui. As of December 31, 2021, we have recorded the $ 4.9 million deposit as restricted cash in our consolidated balance sheet. See Note 11 for additional information related to the standby letter of credit. During the years ended December 31, 2021 and 2020, the Company recorded guarantee fee expense of $ 134 thousand and $ 237 thousand, respectively, related to the $ 4.9 million letter of credit guarantee. Kirin and Mitsui Fee Letters for $20.0 Million Revolver Guarantee On February 14, 2020, the Company entered into additional fee letters with Mitsui (2020 Mitsui Fee Letter) and Kirin (2020 Kirin Fee Letter), whereby both Mitsui and Kirin individually agree to guarantee half of the $ 20.0 million of borrowings under the Uncommitted and Revolving Credit Line Agreement with SMBC, dated February 14, 2020 (2020 Credit Agreement). Under the 2020 Mitsui Fee Letter and 2020 Kirin Fee Letter, the Company is required to pay each, Mitsui and Kirin, an annual fee equal to 2.00% of their half of the $ 20.0 million guarantee. On February 12, 2021, in connection with entering into the Uncommitted and Revolving Credit Line Agreement with SMBC, dated February 12, 2021 (2021 Credit Agreement), the Company entered into new fee letters with Mitsui (2021 Mitsui Fee Letter) and Kirin (2021 Kirin Fee Letter), whereby both Mitsui and Kirin individually agreed to guarantee half of the $ 20.0 million of borrowings. Under the 2021 Mitsui Fee Letter and 2021 Kirin Fee Letter, the Company is required to pay each, Mitsui and Kirin, an annual fee equal to 1.20% of their half of the $ 20.0 million guarantee. During the years ended December 31, 2021 and 2020, the company recorded guarantee fee expense related to the $ 20.0 million guarantees of $ 203 thousand and $ 352 thousand, respectively. On October 4, 2021, the Company repaid the $ 20.0 million of outstanding borrowings under the 2021 Credit Agreement, plus interest accrued and unpaid on the loan through the date of repayment. Upon repayment of the outstanding borrowings under the 2021 Credit Agreement, the related Kirin and Mitsui guarantees were released and terminated. See Note 11 for additional information related to the 2021 Credit Agreement. Kirin and Mitsui Registration Rights Agreement The Company is party to a registration rights agreement, as amended, with certain holders of our capital stock. Under the Company’s registration rights agreement, certain holders of our capital stock, including Mitsui and Kirin, have the right to demand that we file a registration statement or request that their shares of our capital stock be covered by a registration statement that we are otherwise filing. As of and for the year ended December 31, 2021, the Company had incurred no costs associated with a registration or offering of shares of our common stock for Mitsui or Kirin. Kirin and Kyowa Hakko Bio Co., Ltd. Research Agreements The Company provides certain research services under several research contracts with Kirin, a significant shareholder, and Kyowa Hakko Bio Co., Ltd., a subsidiary of Kirin. During the year ended December 31, 2021 and 2020, the Company recognized $ 24 thousand and $ 3 thousand, respectively, of revenue related to these research services. As of December 31, 2021, the Company had recorded deferred revenue of $ 98 thousand related to a research contract with Kirin which has been included in other accrued expenses within the consolidated balance sheets. There was no deferred revenue recorded at December 31, 2020. As of December 31, 2021 and 2020, there was no receivable outstanding from Kirin related to the research agreements. Other Related Party Transactions Merger with Onegevity On January 6, 2021, the Company announced a merger with Onegevity Health, LLC (Onegevity). Paul Jacobson, our Chief Executive Officer, was also the Chief Executive Officer of Onegevity and owned 5,712 ( 4.0 %) of Onegevity’s outstanding shares. The merger transaction was approved by a majority of each of our and Onegevity’s board’s independent board members. The transaction exchanged all outstanding Onegevity equity for 14.1% of the outstanding equity of the combined Thorne and Onegevity entity. This transaction increased Paul Jacobson’s ownership in our company to 4.4% based on our common stock outstanding following the merger transaction. The transaction was completed on March 3, 2021. See Note 4 for additional information related to the Onegevity merger. Merger with Drawbridge On April 21, 2021, the Company entered into a Merger Agreement with Drawbridge to acquire the majority of outstanding shares of Drawbridge, a healthcare technology company. Prior to the merger, the Company owned approximately 11.2 % of the outstanding shares of Drawbridge and accounted for the investment in Drawbridge as an equity method investment, as the Company determined it had significant influence over Drawbridge. The Company’s net equity investment was approximately $ 3.4 million as of December 31, 2020. Our portion of Drawbridge’s loss during 2021, up to the date of the merger, was $0.2 million. As of March 31, 2021 and immediately preceding the merger, the Company’s net equity investment was approximately $ 3.2 million. Under the Merger Agreement, the Company increased its ownership interest in Drawbridge by 76.3 percentage points, to a total ownership of 87.5 %. The Merger Agreement called for the payment of approximately $ 1.4 million in cash and the assumption of certain liabilities of Drawbridge. See Notes 4 and Note 10 for additional information related to the Drawbridge merger. Loans for Executive Option Exercises On April 30, 2019, the Company provided loans to officers Paul Jacobson, Tom McKenna, Will McCamy, Scott Wheeler and Kim Pearson in amounts that would allow them to exercise option grants expiring on July 16, 2020. The notes, totaling $ 1.5 million in aggregate, were issued at a 5.0 % interest rate and were all repaid upon the issuance of the optioned shares on July 16, 2020. Outstanding principal and interest on the notes totaling $ 1.6 million, as well as applicable taxes, were deducted from the number of shares issued to them. Loan amounts, options purchased, loan repayment amounts, and total share issuance values are as follows: Amount Borrowed Shares and Options Purchased Amount Paul Jacobson $ 525,160 $ 801,000 $ 556,813 Tom McKenna 525,160 801,000 556,813 Will McCamy 334,020 667,500 354,152 Scott Wheeler 101,460 135,280 107,575 Kim Pearson 45,980 56,515 48,751 See Note 17 for additional information related to the loans to officers. Alternative Minimum Tax (AMT) Loan to Officers In 2020, the Company issued loans to certain executive officers to pay the AMT associated with the exercise of stock options in 2019. The loans were issued on February 18, 2020 and were repaid on July 14, 2020. The amount of the loans are as follows: Amount Paul Jacobson $ 320,000 Tom McKenna 250,000 Will McCamy 130,000 Scott Wheeler — Kim Pearson 10,000 $ 710,000 The loans carried a 5 % interest rate on them. Interest repaid to the company was $ 14,297 . As of December 31, 2021, and 2020, there were no outstanding loans to our officers. See Note 17 for additional information related to the AMT loans to officers. Supply Agreement with NR Therapeutics, LLC The Company is party to an exclusive supply agreement dated June 5, 2020 with NR Therapeutics, LLC (NR Therapeutics) pursuant to which the Company purchases inventory of nicotinamide riboside (NR). Paul Jacobson, the Company’s Chief Executive Officer, is a member of NR Therapeutics board of directors, and the Company holds a 49% interest in NR Therapeutics. As of December 31, 2021 and 2020, the Company had a related party payable of $ 175 thousand and $ 153 thousand, respectively. During the years ended December 31, 2021 and 2020, the Company purchased inventory from NR Therapeutics totaling $ 4.1 million and $ 153 thousand, respectively. See Note 10 for additional information related to the investment in NR Therapeutics. Letter Agreement with Tecton Group, LLC The Company is party to a letter agreement between the Company, Tecton Group, LLC (Tecton), Kirin and Mitsui (Tecton Letter Agreement) providing the Company with, amongst other things, a right of first offer to commercialize any Tecton product or service. The Tecton Letter Agreement also provides Kirin and Mitsui, with a right of first negotiation for any commercialization of Tecton products or services in Japan. The Company’s Chief Executive Officer, Paul Jacobson is a member of Tecton’s board of directors. During the years ended December 31, 2021 and 2020, we paid certain fees on behalf of Tecton, totaling approximately $ 705 thousand and $ 615 thousand, respectively, in exchange for additional equity interest in Tecton. See Note 10 for additional information related to the investment in Tecton. Supply Agreement with Indena S.p.A. The Company is party to a supply agreement to purchase certain inventory with Indena S.p.A. (Indena), a company focused on the development and production of high-quality active principles derived from plants, for use in the pharmaceutical and health food industries. Indena is a shareholder of the Company and as of December 31, 2021, Indena held less than 1% of the outstanding shares. As of December 31, 2021, and 2020, the Company had a related party payable of $ 1.4 million and $ 613 thousand, respectively. During the years ended December 31, 2021, and 2020, the Company purchased inventory from Indena totaling $ 7.7 million and $ 4.8 million, respectively. Strategic Supplier Agreement with Nutrativa LLC The Company is party to a strategic supplier agreement dated August 2, 2018, as amended, with Nutrativa LLC (Nutrativa). As part of the strategic supplier agreement, the Company serves as Nutrativa’s contract manufacturer for Nutrativa’s Effusio product. The Company also provides support services including customer service, order processing, warehousing and fulfillment, safety and surveillance, production planning, finance, legal and regulatory, human resources, and marketing. All manufacturing and development of Nutrativa products currently reside within the Company’s facilities located in Summerville, South Carolina. Paul Jacobson, the Company’s Chief Executive Officer, is the Chief Executive Officer of Nutrativa. As of December 31, 2021 and 2020, the Company had recorded a related party receivable with Nutrativa of approxim ately $ 364 thousand and $ 59 thousand, respectively. During the years ended December 31, 2021 and 2020, the Company recognized revenue related to the supply agreement of $ 125 thousand and $ 28 thousand, respectively. Investment in Oova, Inc. As of December 31, 2021, the Company had a related party receivable with Oova, Inc. (Oova), an entity in which the Company has invested, of approximately $ 2 thousand for payment of certain contractual handling costs related to the fulfillment and distribution of Oova’s product from the Company’s distribution facility. As of December 31, 2020, the Company had recorded a related party receivable with Oova of approximately $ 4 thousand. During the year ended December 31, 2021, the Company recognized $ 28 thousand of revenue related to the contractual fulfillment services. See Note 9 for additional information related to the investment in Oova. Other Related Party Transactions As of December 31, 2021, and December 31, 2020, the Company had a related party payable of $ 43 thousand to Chief Executive Officer, Paul Jacobson.

Mergers and Acquisitions

Mergers and Acquisitions	12 Months Ended
	Dec. 31, 2021
Business Combination And Asset Acquisition [Abstract]
Mergers and Acquisitions	4. Mergers and Acquisitions As of December 31, 2020, the Company’s ownership in Onegevity Health, LLC (Onegevity) was approximately 50 %. Since Onegevity’s inception in 2018, the Company determined that it had been the primary beneficiary of Onegevity, and has accordingly, consolidated the assets and liabilities of Onegevity in accordance with ASC 810, Consolidations (ASC 810). During the first quarter of 2021, the Company merged with Onegevity. As part of the merger, the legal entity Onegevity Health, LLC was dissolved; its wholly owned subsidiary, Health Elements, LLC (Health Elements), became a wholly owned subsidiary of the Company. To effect the merger, the Company issued 6,179,270 shares of Class B common stock, 472,590 which were subject to time-based restrictions, to the minority shareholders of Onegevity, plus an additional 1,959,335 stock options with various strike prices to key managers of Onegevity who had stock options in Onegevity in a tax-free exchange. No cash was involved in the transaction. The shares of Class B common stock did not have voting rights among other restrictions. Immediately prior to the completion of the Company’s IPO on September 22, 2021, all outstanding shares of the Class B common stock automatically converted on a one-to-one basis into shares of common stock. As of December 31, 2021, there were no shares of Class B common stock outstanding. The merger did not lead to a change in control and therefore the transaction was recorded in the equity section of the Company’s balance sheet. On April 26, 2021, the Company entered into a merger agreement (the Merger Agreement) with Drawbridge Health, Inc. (Drawbridge), to acquire the majority of the outstanding shares of Drawbridge, a healthcare technology company (the Drawbridge Transaction). Prior to the merger, the Company owned approximately 11.2 % of the outstanding shares of Drawbridge and accounted for its investment in Drawbridge as an equity-method investment, because the Company determined it had significant influence over Drawbridge. The Company’s net equity investment was approximately $ 3.2 million as of March 31, 2021. Under the Merger Agreement, the Company increased its ownership of Drawbridge by 76.3 percentage points to a total ownership of 87.5 %. The Merger Agreement calls for the payment of approximately $ 1.4 million in cash and the assumption of certain liabilities of Drawbridge. The Drawbridge Transaction was accounted for as an asset acquisition because the Company concluded the assets acquired and liabilities assumed did not constitute a business under ASC 805, Business Combinations (ASC 805). The Company performed a reassessment of Drawbridge as a variable interest entity under ASC 810, and concluded Drawbridge to be a variable interest entity as of the date of the transaction. Furthermore, the Company determined it was the primary beneficiary of Drawbridge as of the transaction date. Accordingly, the Drawbridge Transaction was accounted for as an asset acquisition under ASC 810, rather than under ASC 805. Under ASC 810, the Company is required to recognize a gain (loss) on the acquisition, equal to the sum of the consideration paid, the carrying value of the existing equity-method investment, and the fair value of the resulting non-controlling interest less the fair value of the net assets acquired. The Company concluded the carrying value of the Company’s existing Drawbridge investment of approximately $ 3.2 million was impaired in the second quarter of 2021 prior to the transaction and recorded a loss from equity interest in unconsolidated affiliates of approximately $ 3.0 million within the consolidated statements of operations for the year ended December 31, 2021. Additionally, a loss on the Drawbridge Transaction of approximately $ 0.2 million was recorded during the year ended December 31, 2021 within other (income) expense in the consolidated statements of operations. The net tangible and intangible assets acquired, and liabilities assumed, in connection with the Drawbridge Transaction were recorded based on their fair values as of the acquisition date and the value associated with in-process research and development was expensed because it was determined to have no alternative future use. The in-process research and development costs of approximately $ 1.6 million are recorded as an operating expense on the consolidated statement of operations. Subsequent to the acquisition, the operations of Drawbridge were fully consolidated in the Company’s consolidated financial statements, and a non-controlling interest of approximately $ 0.2 million was recorded for the 12.5 % equity interest held by other investors. The assets and liabilities acquired based on their fair value were as follows: Cash $ 11,823 Accounts receivable 8,686 Prepaid expenses and other current assets 711,389 Inventories 10,051 Property and equipment 914,716 Operating lease right-of-use asset 410,732 Intangible asset consisting of in process research and development 1,563,015 Other assets 22,782 Accounts payable ( 701,242 ) Other accrued expenses ( 864,483 ) Current portion of operating lease obligations ( 263,509 ) Long term operating lease, net of current portion ( 147,223 ) Net assets acquired $ 1,676,737 Less: non-controlling interest ( 209,592 ) Net assets acquired by Thorne HealthTech, Inc. $ 1,467,145

Consolidated Variable Interest

Consolidated Variable Interest Entities	12 Months Ended
	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Consolidated Variable Interest Entities	5. Consolidated Variable Interest Entities The Company consolidates variable interest entities where the Company is determined to be the primary beneficiary, under ASC 810. The Company consolidates into its consolidated financial statements two legal entities (Health Elements, LLC and Onegevity Health, LLC) in which it holds a controlling interest. The Company presents non-controlling interest as a component of stockholders’ deficit on its consolidated balance sheet and reports net loss-non-controlling interest in the consolidated statements of operations. The Company’s acquisition or disposal of ownership interests in the variable interest entities is a reconsideration event that requires a reassessment of whether the entity continues to be a variable interest entity and whether the primary beneficiary has changed. If after making these reassessments, the primary beneficiary remains the same (i.e., a controlling financial interest is maintained), and the transaction is in the scope of ASC 810, the Company accounts for the acquisition or disposal of a non-controlling interest as an equity transaction, consistent with the principles of ASC 810-10. Any difference between the price paid and the carrying amount of the non-controlling interest is not be reflected in net income, but instead reflected directly in equity. Health Elements, LLC (Health Elements) . As of January 1, 2020, the Company owned approximately 60.1 % of Health Elements and determined that it is the primary beneficiary of Health Elements as it has the power to direct activities most significantly impacting Health Elements’ economic performance. On July 31, 2020, the Company exchanged its interest in Health Elements for additional shares of Onegevity which eliminated the Company’s direct investment in Health Elements. This transaction increased the number of shares owned by the Company in Onegevity from 50,000 shares to 58,252 . See below for further discussion of Onegevity. Summary information for Health Elements, excluding intercompany activity with the Company and Onegevity, is included in the consolidated balance sheets and statements of operations as follows, as of and for the year ended December 31: 2020 Total assets $ — Less liabilities — Net assets (liabilities) $ — Revenue $ 566,000 Net loss $ ( 112,000 ) Health Elements had been consolidated into the Company’s financial statements since its inception in 2011 and Onegevity had been consolidated into the Company’s financial statements since its inception in 2018. The Company owned approximately 60 % of the outstanding shares of Health Elements and approximately 50 % of the outstanding shares of Onegevity immediately prior to the transaction on July 31, 2020. Both entities were consolidated under ASC 810 as of and for the year ended December 31, 2020, as the Company determined that it is the primary beneficiary of both entities. The exchange of Health Elements shares for Onegevity shares in 2020 by the Company did not change the Company’s ability to control the variable interest entities and therefore the transaction was recorded in equity. The non-controlling interest in Health Elements converted to a non-controlling interest in Onegevity. Onegevity Health, LLC. As of January 1, 2020, the Company owned 50,000 shares of Onegevity capital stock, which equated to approximately a 45 % ownership interest. As discussed above, on July 31, 2020, the Company exchanged its 60 % investment in Health Elements for an additional 8,252 shares of Onegevity. During the cashless tax-free exchange, Onegevity obtained a 100 % ownership in Health Elements, and as a result all assets and liabilities have been consolidated into Onegevity’s financial information. This transaction increased the Company’s ownership in Onegevity to 58,252 shares, or approximately 50 % ownership as of December 31, 2020. After evaluating relevant factors, the Company determined that it is the primary beneficiary of Onegevity and has accordingly consolidated the assets and liabilities of Onegevity in accordance with ASC 810, as of and for the years ended December 31, 2020. Summary information for Onegevity, excluding intercompany activity with the Company and Health Elements, is included in the consolidated balance sheets and statements of operations as follows, as of and for the year ended December 31: 2020 Total assets $ 1,728,000 Less liabilities 545,000 Net assets (liabilities) $ 1,183,000 Revenue $ 2,776,000 Net loss $ ( 881,000 ) During the first quarter of 2021, the Company merged with Onegevity. As part of the merger, the legal entity Onegevity Health, LLC was dissolved; its wholly owned subsidiary, Health Elements, LLC, became a wholly owned subsidiary of the Company. The merger did not lead to a change in control, and therefore, the transaction was recorded in the equity section of the Company’s balance sheet. See Note 4 for additional information related to the Onegevity merger. As of December 31, 2020, the Company’s ownership in Onegevity was approximately 50%. Since Onegevity’s inception in 2018, the Company determined that it had been the primary beneficiary of Onegevity, and has accordingly, consolidated the assets and liabilities of Onegevity in accordance with ASC 810 as of and for the year ended December 31, 2020.

Inventories,net

Inventories,net	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory,net	6. Inventories, net Inventories are as follows: December 31, 2021 2020 Raw materials $ 22,620,773 $ 13,751,348 Work in process 422,196 7,224 Finished goods 18,413,853 14,808,931 Reserve for slow moving and obsolete inventory ( 444,698 ) ( 501,479 ) Inventory, net $ 41,012,124 $ 28,066,024

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Property and Equipment, Net	7. Property and Equipment, net Property and equipment are as follows: December 31, 2021 2020 Machinery and equipment $ 9,937,510 $ 7,248,706 Furniture and fixtures 491,173 351,935 Office equipment 1,111,141 1,032,311 Leasehold improvements 19,431,916 18,858,225 Vehicles 98,282 98,282 Lab equipment 2,930,059 1,755,985 Purchased software 2,107,327 1,716,069 Total property and equipment 36,107,408 31,061,513 Less accumulated depreciation and amortization ( 11,262,651 ) ( 8,603,098 ) In-process assets including deposits on new equipment 2,185,643 731,315 Property and equipment, net $ 27,030,400 $ 23,189,730 In-process assets are stated at cost, which includes the cost of construction and other directly attributable costs. No provision for depreciation is made on in-process assets until the relevant assets are completed and available for intended use. Depreciation and amortization expense of property and equipment was approximately $ 2.7 million and $ 2.2 million for the years ended December 31, 2021 and 2020, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	8. Goodwill and Intangible Assets Goodwill In June 2010, the Company acquired all the outstanding shares of capital stock of Thorne Research, which is now a wholly owned subsidiary of the Company. The Company accounted for the transaction as a business combination in accordance with ASC 805, Business Combinations, and recorded the consideration transferred and assets acquired, and liabilities assumed at their fair values, resulting in the recording of goodwill of approximately $ 14.4 million. Finite-lived Intangible Assets Finite-lived intangible assets are as follows: December 31, 2021 Gross Carrying Value Accumulated Amortization Net Customer relationships $ 6,500,000 $ ( 3,737,500 ) $ 2,762,500 Trade names 8,640,000 ( 6,866,667 ) 1,773,333 Existing technology/reformulations 3,207,923 ( 2,694,590 ) 513,333 Research and development formulas 800,000 ( 800,000 ) — License agreements 8,591,822 ( 7,048,672 ) 1,543,150 $ 27,739,745 $ ( 21,147,429 ) $ 6,592,316 December 31, 2020 Gross Carrying Value Accumulated Amortization Net Customer relationships $ 6,500,000 $ ( 3,412,500 ) $ 3,087,500 Trade names 8,640,000 ( 6,360,000 ) 2,280,000 Existing technology/reformulations 3,207,923 ( 2,547,923 ) 660,000 Research and development formulas 800,000 ( 800,000 ) — License agreements 7,841,365 ( 6,233,612 ) 1,607,753 $ 26,989,288 $ ( 19,354,035 ) $ 7,635,253 The Company’s intangible assets include intangible assets acquired through the Thorne Research acquisition in 2010. As of December 31, 2021 and 2020, the net book value of such intangible assets was approximately $ 5.0 million and $ 6.0 million, respectively. Intangible assets also include payments under license agreements related to trademarks and content, which had a net book value as of December 31, 2021 and 2020, of $ 1.5 million and $ 1.6 million, respectively. Amortization expense totaled $ 1.8 million and $ 2.1 million for the years ended December 31, 2021 and 2020, respectively. The Company's finite-lived intangible assets had the following remaining lives as of December 31, 2021: Weighted-Average Remaining Life Customer relationships 8.5 Trade names 3.5 Existing technology/reformulations 3.5 Research and development formulas — License agreements 4.3 Following is the future amortization of the finite-lived intangible assets as of December 31, 2021: Year Ending December 31, Amount 2022 $ 1,637,067 2023 1,416,233 2024 1,105,817 2025 685,400 2026 358,734 Thereafter 1,389,065 $ 6,592,316

Investments

Investments	12 Months Ended
	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Investments	9. Investments Oova. As of December 31, 2021 and 2020, the Company had an investment of $ 400,000 in Oova, representing a 3.46 % equity interest. As management has determined it does not have the ability to exercise significant influence over the operating and financial activities of the investee, and the fair value of the investment is not readily determinable, the Company’s investment in Oova is accounted for at cost minus impairment, in accordance with ASC 321, Equity Securities. As there were not any observable price changes in identical or similar securities to Oova, the Company has not adjusted the value of this investment upward or downward, either on a cumulative basis or in either of the years ended December 31, 2021 or 2020. Since the Company invested in Oova, the investee has successfully brought its product to market. Although there are no restrictions on the Company’s ability to sell this investment, the timing of when or if the Company would sell this asset is unknown at this time. There are no unfunded commitments related to the Company’s investment. Management concluded that no impairment was necessary for the years ended December 31, 2021 or 2020.

Investments - Equity Method

Investments - Equity Method	12 Months Ended
	Dec. 31, 2021
Equity Method Investments And Joint Ventures [Abstract]
Investments - Equity Method	10. Equity-method Investments Equity-method investments are as follows: December 31, 2021 December 31, 2020 Carrying Economic Carrying Economic Drawbridge Health, Inc. (1) $ — 87.5 % $ 3,382,147 11.2 % Tecton Group LLC — 30.0 % — 44.4 % NR Therapeutics LLC 963,685 49.0 % — — Total $ 963,685 $ 3,382,147 (1) On April 26, 2021, the Company entered into a merger agreement with Drawbridge Health, Inc., to acquire the majority of the remaining outstanding shares. See Note 4 for additional information related to the Drawbridge merger transaction. The following summarizes the (loss) income of equity-method investees: Years ended December 31, 2021 2020 Drawbridge Health, Inc. (1) $ ( 3,173,106 ) $ ( 894,689 ) Tecton Group LLC ( 704,637 ) ( 615,015 ) NR Therapeutics LLC 213,685 — Total $ ( 3,664,058 ) $ ( 1,509,704 ) (1) Represents the Company’s proportionate share of net loss for the period of January 1, 2021 through April 26, 2021 (the date of merger). Drawbridge Health, Inc. (Drawbridge) is a privately held healthcare technology company that has developed a blood draw device that is regulated as a Class II medical device and received 510(k) clearance in 2019. The Company’s Chief Executive Officer was a member of the board of directors for Drawbridge until 2020. Management has determined it does have the ability to exercise significant influence over Drawbridge’s operating and financial activities due to its equity ownership and board representation, which began in 2019. The investment, therefore, was accounted for using the equity method, and the Company’s proportionate share of the net loss of the investee was reported under the line item captioned “loss from equity interest in unconsolidated affiliates” in the consolidated statements of operations. Tecton Group LLC (Tecton) is a privately held company focused on the development of a revolutionary nutrition technology providing improved cognitive and physical performance in addition to fueling the brain to protect against concussion and secondary damage of traumatic brain injury. After evaluating the relevant factors, the Company determined that it has significant influence with respect to Tecton, and accounted for the investment using the equity method, with the investee’s proportionate share of the net loss of the investee reported under the line item captioned “loss from equity interest in unconsolidated affiliates” in the consolidated statements of operations. As of December 31, 2021, the total suspended loss in the investee was approximately $ 138,566 , for which the Company has no further obligation. As of December 31, 2020, the Company's ownership interest was 44 %. During the year ended December 31, 2021, Tecton issued additional equity to investors, which the Company did not participate, reducing our ownership interest to 30 % as of December 31, 2021. The Company is also party to a letter agreement between us, Tecton, Kirin and Mitsui (Tecton Letter Agreement) providing us with, amongst other things, a right of first offer to commercialize any Tecton product or service. The Tecton Letter Agreement also provides Kirin and Mitsui, with a right of first negotiation for any commercialization of Tecton products or services in Japan. Paul Jacobson, our Chief Executive Officer, also is a member of Tecton’s board of directors. NR Therapeutics LLC (NR) is a privately held company focused on the sale and distribution of nicotinamide riboside, a natural compound present in almost all living organisms. During the year ended December 31, 2020, the Company purchased 49 common units for $ 750,000 from NR Therapeutics Holdings, Inc., representing 49 % ownership in NR Therapeutics LLC. The Company accounted for the investment using the cost method, recording the investment at historical cost, as of and for the year ended December 31, 2020. During the year ended December 31, 2021, the Company determined that it has significant influence with respect to NR, and began accounting for the investment using the equity method, with the investee’s proportionate share of the net income of the investee reported under the line item captioned “loss from equity interest in unconsolidated affiliates” in the consolidated statements of operations. Management concluded that there was no impairment for the years ended December 31, 2021 and 2020.

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	11. Debt Long-term Debt Long-term debt balances and associated interest rates and maturities are as follows: December 31, December 31, Note payable with quarterly principal and interest payments of $ 30,917 per quarter, with fixed interest of 6.94 % and maturity August 12, 2024 . $ 286,255 $ 346,436 Note payable with quarterly principal and interest payments of $ 30,917 per quarter, with fixed interest of 6.94 % and maturity July 15, 2023 . 202,142 346,435 Note payable with quarterly principal and interest payments of $ 56,548 per quarter, with fixed interest of 4.89 % and maturity March 20, 2025 . 675,836 — Note payable with quarterly principal and interest payments of $ 8,250 per quarter, with fixed interest of 5.44 % and maturity September 10, 2026 . 413,574 — 1,577,807 692,871 Less current maturities ( 494,173 ) ( 223,400 ) Long-term debt $ 1,083,634 $ 469,471 During each of the years ended December 31, 2021, and 2020, the Company entered into two financing agreements associated with certain equipment purchases. The notes are collateralized by the original purchased equipment and had aggregate net book value of $ 1.9 million as of December 31, 2021. Credit Facilities In December 2018, the Company entered into an asset-based line of credit. The amount of the loans available to the Company was $ 20.0 million and was limited to the amount of qualified current receivables and inventory owned by the Company. The interest rate paid was 0.25 % on any unused line of credit and LIBOR plus 1.75 % on the used portion of the line of credit. Interest payments were due monthly, and the principal balance was due upon maturity in December 2023 . The Company had borrowing of $ 11.2 million on this line of credit that were paid off and closed out in March 2020. On February 14, 2020, the Company entered into an Uncommitted and Revolving Credit Line Agreement (2020 Credit Agreement) with SMBC to provide a revolving line of credit of up to $ 20.0 million. Upon closing, the Company borrowed $ 20.0 million from the revolving line of credit and used the proceeds to paydown and close the previous line of credit, as well as pay off the dividend payable and related party payable. There were no debt issuance costs incurred to secure this financing. Borrowings under the 2020 Credit Agreement bear interest paid on a variable interest rate based on rates quoted by the bank. The Company can choose an interest rate, based on current market rates and on the number of days it chooses to lock in the interest rate. The number of days range from 30 days to 365 days. On February 12, 2021, the Company entered into a new Uncommitted and Revolving Credit Line Agreement (2021 Credit Agreement) with SMBC to refinance and replace the 2020 Credit Agreement. The terms of the 2021 Credit Agreement are substantially similar to the terms of the 2020 Credit Agreement. Under the 2021 Credit Agreement, SMBC may in its sole discretion elect to make unsecured loans to the Company until February 11, 2022, in an aggregate principal amount up to, but not exceeding, $ 20.0 million at any time. Each loan made under the 2021 Credit Agreement may have a maturity date that is not less than one day and not more than twelve months after the date that such loan is disbursed, as the Company and SMBC mutually agree. SMBC may, in its sole discretion at any time, terminate in whole or partially reduce the unused portion of the credit line under the 2021 Credit Agreement. SMBC is not obligated to make any loan under the 2021 Credit Agreement. The Company may prepay any outstanding loans under the 2021 Credit Agreement in whole, or in part, at any time without penalty, other than customary prepayment fees or additional costs as determined by SMBC. Any loans under the 2021 Credit Agreement bears interest at a per annum rate quoted by SMBC and agreed to by the Company when such loan is made. Interest on a loan is payable in arrears on the maturity date of such loan. The interest accrued on a loan and paid to the bank is a variable interest rate, based on rates quoted by the bank. The Company can choose an interest rate, based on current market rates and on the number of days it chooses to lock in the interest rate. The number of days range from 30 days to 365 days. On September 14, 2021, the Company locked in an interest rate for 30 days through October 13, 2021, at a rate of 0.595 %. On October 4, 2021, the Company repaid the $ 20.0 million of outstanding borrowings under the 2021 Credit Agreement, plus interest accrued and unpaid on the loan through the date of repayment. Upon repayment, the 2021 Credit Agreement was terminated. The Company incurred incremental fees related to the payoff totaling $ 7 thousand. Upon repayment of the outstanding borrowings under the 2021 Credit Agreement, the related Kirin and Mitsui guarantees were released and terminated. The 2021 Credit Agreement contains customary affirmative covenants, including covenants regarding the payment of taxes and other obligations, maintenance of insurance, reporting requirements and compliance with applicable laws and regulations, and customary negative covenants limiting the Company’s ability, among other things, to merge or consolidate, dispose of all or substantially all the Company’s assets, liquidate or dissolve, and grant liens, subject to certain exceptions. Upon the occurrence and during the continuance of an event of default, SMBC may declare all outstanding principal of, and accrued and unpaid interest on, loans made under the 2021 Credit Agreement immediately due and payable and may exercise the other rights and remedies provided for under the 2021 Credit Agreement and related loan documents. The events of default under the 2021 Credit Agreement include, subject to grace periods in certain instances, payment defaults, cross defaults with certain other material indebtedness, certain material judgments, breaches of covenants or representations and warranties, change in control of the Company, a material adverse change as defined in the 2021 Credit Agreement, and certain bankruptcy and insolvency events. Both the 2020 Credit Agreement and 2021 Credit Agreement (together, the Credit Agreements) were guaranteed by two significant Company stockholders, Kirin and Mitsui. Each stockholder guaranteed 50 % of the total amount of the loan, or $ 10 million. Under the respective Fee Letters dated February 12, 2021, between the Company and each, Mitsui (2021 Mitsui Fee Letter), and Kirin (2021 Kirin Fee Letter), the Company has agreed to reimburse Mitsui and/or Kirin in cash for any amounts that Mitsui and/or Kirin pays under its respective guarantee of the 2021 Credit Agreement. However, if the Company is unable to reimburse such amounts wholly or partially to Mitsui and/or Kirin, then the Company and Mitsui and/or Kirin may agree to deem such unreimbursed amounts to be made for the Company’s benefit in consideration for its debt or equity securities on terms reasonably satisfactory to Mitsui and/or Kirin and the Company. The guarantee fee during the period of February 14, 2020 through February 13, 2021 was calculated as 2.00 % of the outstanding borrowings under the Credit Agreements, to be paid by the borrower on an annual basis. Beginning February 12, 2021, the guarantee fee was calculated as 1.20 % of the outstanding borrowings under the Credit Agreements. Upon repayment of the outstanding borrowings under the 2021 Credit Agreement, the related Kirin and Mitsui guarantees were released and terminated. The Company recorded $ 203 thousand and $ 352 thousand of related expense during the years ended December 31, 2021, and 2020, respectively, which are included in the guarantee fees in the consolidated statements of operations. As of December 31, 2020, the Company had accrued guarantee fees related to the Credit Agreements of $ 351 thousand which is included in other accrued expenses in the consolidated balance sheets. Standby Letter of Credit In 2018, an irrevocable standby letter of credit was issued by a bank on the Company’s behalf as required by the landlord of the South Carolina production facility, and guarantees were issued by related parties (see Note 8). The standby letter of credit is for $ 4.9 million and had an original expiration date of December 3, 2019 , with automatic renewals until October 31, 2037 . The guarantee fee is based on the 12-month USD LIBOR rate, plus 3 % on the amount of the guarantee. The letter of credit has an annual fee of $ 20 thousand. The standby letter of credit is guaranteed 50 % by Kirin and Mitsui, to whom the Company pays an annual guarantee fee. On October 29, 2021, the Company deposited $ 4.9 million into a restricted interest-bearing account with SMBC to fund the standby letter of credit and release the guarantees provided by Kirin and Mitsui. The Company incurred total guarantee fee expense for the standby letter of credit for the years ended December 31, 2021 and 2020 of $ 134 thousand and $ 237 thousand, respectively, which have been included in guarantee fees in the consolidated statements of operations. As of December 31, 2020, the Company had accrued guarantee fees related to the standby letter of credit totaling $ 13 thousand which have been included in other accrued expenses in the consolidated balance sheets. Debt Maturities The contractual maturities of the Company's long-term debt as of December 31, 2021 are as follows: Year Ending December 31, Amount 2022 $ 494,173 2023 493,044 2024 369,827 2025 148,170 2026 72,593 Thereafter — $ 1,577,807

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	12. Leases The Company leases real estate, vehicle, and equipment for use in its operations. The Company’s leases generally have lease terms of 1 to 30 years, some of which include options to terminate, or to extend leases. The Company includes options that are reasonably certain to be exercised as part of the determination of lease terms. The Company may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within operating leases. In addition to base rent payments, the leases may require the Company to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. The Company's corporate headquarters is located in New York, New York, and consists of two separate office suites totaling 7,700 square-feet. The leases for these office spaces expires in 2022 . The Company currently leases and operates three industrial facilities in Summerville, South Carolina and a fourth industrial facility located in Benicia, California. The Company's primary manufacturing and administrative facility is located in Summerville, South Carolina. The 272,000 square-foot facility is located on 25.8 acres and houses manufacturing and production, research and development, medical affairs, engineering, quality management, laboratory testing, brand marketing, inside sales, customer service, finance, legal, human resources, warehousing and materials management, procurement and safety functions. The lease expires in October 2037 . The Company has the right to renew for two additional terms of five years each. On January 26, 2021, the Company entered into a five-year lease agreement for 115,500 square feet within a 136,500 square foot building for the Company's fulfillment and distribution operations, located in Summerville, South Carolina. Rent was abated for the first three months while the Company installed racking, packing stations, and other required equipment, prior to the Company's shipping operations to this facility. This lease terminates in July 2026 . The lease has two renewal options for three years each. On July 28, 2021, the Company entered into a lease agreement for a 360,320 square foot industrial building for the Company's finished goods warehousing and shipping operations, located in Summerville, South Carolina. The building is currently under construction and the lease will commence on the date of which the landlord completes construction of the facility and required tenant improvements, currently estimated to be during the first quarter of 2023, and will terminate upon the thirteenth anniversary of the commencement date. The lease has one renewal option for a five-year term. The lease provides for an allowance for tenant improvements of up to $ 1.26 million. The annual base rent for the first year will be $ 1.98 million and is subject to an annual escalation of 2.0 % on each anniversary. The Company has funded a customary security deposit of $ 331 thousand upon execution of the lease which has been recorded in other assets with our consolidated balance sheets at December31, 2021. The Company maintains a 16,896 square-foot warehouse in Benicia, California for distribution and fulfillment operations. This lease terminates in January 2025 . The Company has the right to renew for one additional term of five years . The Company also leases a 2,500 square-foot administrative and support facility in Madison, Wisconsin. The lease for this office expires in October 2024 . The balances for the operating and finance leases where the Company is the lessee are presented as follows within the consolidated balance sheets: December 31, 2021 December 31, 2020 Operating lease: Operating lease right-of-use assets $ 17,836,756 $ 17,740,816 Current portion of operating lease obligations 2,633,236 2,603,930 Operating lease obligations, net of current portion 27,605,739 27,284,356 Total operating lease liabilities $ 30,238,975 $ 29,888,286 Finance lease: Finance right-of-use assets $ 883,076 $ 767,237 Current portion of finance lease obligations 413,487 269,212 Finance lease obligation, net of current portion 482,544 454,857 Total finance lease liabilities $ 896,031 $ 724,069 The components of lease expense are as follows within our consolidated statement of operations: Years ended December 31, 2021 2020 Operating lease expense: Operating lease cost (1) $ 5,692,735 $ 5,062,144 Finance lease expense: Amortization of leased assets 424,961 210,262 Interest on lease liabilities 52,511 22,947 Total lease expense $ 6,170,207 $ 5,295,353 (1) Includes short-term leases and variable lease costs, which are immaterial. The weighted average remaining lease term and weighted average discount rate at December 31, were as follows: December 31, 2021 December 31, 2020 Weighted average remaining lease term (years) Operating leases 13.73 years 15.53 years Finance leases 2.33 years .02 years Weighted average discount rate applied Operating leases 9.2 % 12.1 % Finance leases 6.1 % 4.7 % Supplemental cash flow information related to leases where the Company is the lessee is as follows: Years ended December 31, 2021 2020 Operating cash outflows from operating leases $ 4,794,134 $ 5,399,423 Operating cash outflows from finance leases (interest payments) 52,511 22,947 Financing cash outflows from finance leases 377,880 177,461 Leased assets obtained in exchange for finance lease liabilities 540,433 694,108 Leased assets obtained in exchange for operating lease liabilities 2,913,002 4,259,688 As of December 31, 2021, the maturities of the operating and finance lease liabilities are as follows: Period Operating leases Finance leases 2022 $ 5,120,933 $ 452,669 2023 3,497,422 326,112 2024 3,589,920 140,146 2025 3,559,583 16,764 2026 3,325,639 38,942 Thereafter 35,705,778 — Total minimum lease payments $ 54,799,275 $ 974,633 Less: imputed interest 24,560,300 78,602 Total present value of lease liabilities $ 30,238,975 $ 896,031 Less: current portion 2,633,236 413,487 Long-term portion of lease liabilities $ 27,605,739 $ 482,544 In 2016, the Company entered into a new lease agreement for office, warehouse and production space in Summerville, South Carolina. The Company was required to provide the landlord with a $ 4.9 million irrevocable letter of credit as a security deposit (see Note 11). The required security deposit may be reduced upon the attainment of certain EBITDA levels.

Convertible Preferred Stock and

Convertible Preferred Stock and Stockholders' Deficit	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Convertible Preferred Stock and Stockholders' Deficit	13. Convertible Preferred Stock and Stockholders’ Deficit On July 5, 2018, the Company issued 27,011,500 Series E convertible preferred stock to Kirin and Mitsui for $ 138.4 million. A summary of the significant rights and privileges of the Series E convertible preferred stock is as follows: A summary of the significant rights and privileges of the Series E convertible preferred stock is as follows: Conversion - Each share of Series E preferred stock is convertible at the option of the holder into common stock on a one-for-one basis. Each share of Series E preferred stock shall automatically be converted into shares of common stock at the then effective conversion price immediately after the consummation of a qualified public offering. Additionally, each share of preferred stock is automatically converted immediately upon the conversion or vote to convert by the holders of a majority of the then outstanding preferred stock. Liquidation - Upon any liquidation, dissolution, or winding-up of the business, the assets of the Company available for distribution to its stockholders shall be distributed first to the holders of shares of Series E convertible preferred stock up to their original issue prices. Voting Rights - The holder of each share of preferred stock shall be entitled to vote on all matters and shall be entitled to that number of votes equal to the total number of shares of common stock into which the preferred stock are convertible. Dividends - In the event the Board of Directors declares the payment of dividends, they shall be distributed first to the holders of shares of Series E convertible preferred stock up to their original issue prices. Thereafter, the amounts remaining shall be distributed pro rata based on the number of shares of common stock then held by each shareholder (assuming conversion of all outstanding shares of Series E convertible preferred stock into common stock). The agreement for the Series E convertible preferred stock issuance also resulted in $ 3.0 million of dividends becoming payable to stockholders related to the issuance of preferred stock and increased the accumulated deficit in the Company’s stockholders’ equity (deficit). These dividends were approved by the Board of Directors and declared payable in 2018 and were accrued for as of December 31, 2018. These dividends along with interest accrued on the dividends at the rate of 7.5 % of $ 266,918 were paid during the year ended December 31, 2020. The Company’s Series E convertible preferred stock was classified as temporary equity on the accompanying consolidated balance sheet in accordance with authoritative guidance for the classification and measurement of redeemable securities. Upon certain change in control events outside of the Company’s control, including liquidation, sale, or transfer of control of the Company, holders of the Series E convertible preferred stock can cause its redemption. The carrying values of the Series E convertible preferred stock was not adjusted to the liquidation preferences of such shares because the Series E convertible preferred stock was not currently redeemable and not probable of becoming redeemable due to the uncertainty of whether or when the contingent events would occur. Immediately prior to the completion of the Company’s IPO on September 22, 2021, all outstanding shares of the Series E convertible preferred stock automatically converted on a one-to-one basis into an aggregate of 27,011,500 shares of common stock. As of December 31, 2021, there were no shares of Series E convertible preferred stock outstanding. As of December 31, 2020, the Company had 27,011,500 shares of Series E convertible preferred stock outstanding that were recorded in the financial statements as temporary equity.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2021
Warrants And Rights Note Disclosure [Abstract]
Warrants	14. Warrants On October 10, 2018, the Company issued to Kirin and Mitsui each 2,225,000 warrants, for a total of 4,450,000 warrants, to purchase the Company’s common stock. The warrants have an exercise price of $ 5.12 and an expiration date of October 11, 2028 . In July 2020, each shareholder exercised 2,168,485 warrants for a total of $ 22.2 million in gross proceeds. As of December 31, 2021, and 2020, 113,030 , of the original 4,450,000 warrants, remain outstanding. These warrants are classified as equity within the consolidated balance sheets as of December 31, 2021, and 2020. On June 23, 2010, the Company issued 2,532,000 warrants to a related-party stockholder, with a strike price of $ 6.74 and an original expiration date of June 23, 2020 . In May 2019, the Board of Directors extended the term of the warrants for an additional 10 years to June 23, 2030. As of December 31, 2021, and 2020, none of the 2,532,000 warrants have been exercised and all common stock warrants remained outstanding. These warrants are classified as equity within the consolidated balance sheets at December 31, 2021, and 2020. On May 10, 2011, the Company issued 453,455 warrants to purchase common stock to a related-party stockholder, with a strike price of $ 6.74 per warrant. In May 2019, the Board of Directors extended the term of the warrants for an additional 10 years to June 23, 2030. The extension was determined by management to be a modification of the warrant. Due to these warrants containing certain down-round protections, which are not associated with the underlying Company’s equity that may trigger in the event of a modification of certain other outstanding warrant instruments, the Company has classified these warrants as liabilities within the consolidated balance sheets as of December 31, 2021 and 2020. The warrant liability is remeasured at fair value at each reporting date and have a fair value of $ 2.1 million and $ 3.9 million as of December 31, 2021, and 2020, respectively. To calculate the fair value of the warrants, certain assumptions were made, including the fair market value of the underlying common stock, risk-free interest rate, volatility, and remaining contractual life. Changes to the assumptions could cause significant adjustments to the valuation. Due to the fact that the Company had no publicly available stock price information prior to the IPO and limited publicly available stock price information subsequent to the IPO, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of the grant for treasury securities of similar maturity or expected term. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Black-Scholes model was used to value the liability-classified warrants. The following assumptions were used: December 31, 2021 2020 Fair market value $ 6.21 $ 6.67 Exercise Price $ 6.74 $ 6.74 Term 8.5 9.5 Volatility 75 % 68 % Annual dividend — — Risk-free interest rate 1.48 % 0.13 % The fair value of financial instruments measured on a recurring basis is as follows: As of December 31, 2021 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 2,058,566 — — $ 2,058,566 As of December 31, 2020 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 3,930,930 — — $ 3,930,930 The following table summarizes the change in fair value, as determined by Level 3 inputs, for all assets and liabilities using unobservable Level 3 inputs: Warrant Balance at December 31, 2019 $ 2,018,443 Change in fair value for 2020 1,912,487 Balance at December 31, 2020 3,930,930 Change in fair value for 2021 ( 1,872,364 ) Balance at December 31, 2021 $ 2,058,566

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes The components of income tax expense consist of the following: Years Ended 2021 2020 Current Federal $ — $ — State 411,919 176,758 Net income tax expense $ 411,919 $ 176,758 The significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2021 2020 Deferred tax assets: Net operating losses $ 19,538,932 $ 13,547,317 AMT/Federal credit 897,616 — State credits 2,485,652 2,031,797 Lease liability ASC 842 7,271,783 7,152,442 Disallowed interest expense 164,921 164,984 Share-based compensation 495,960 — Impairment 464,720 — Other 691,010 976,746 Total deferred tax assets $ 32,010,594 $ 23,873,286 Deferred tax liabilities: Basis difference on fixed assets $ ( 4,114,426 ) $ ( 3,569,913 ) Basis difference on intangibles ( 1,427,816 ) ( 1,066,468 ) Prepaid expenses ( 709,653 ) ( 100,995 ) Right-of-use asset ASC 842 ( 4,372,138 ) ( 4,324,325 ) Other ( 72,714 ) — Total deferred liabilities ( 10,696,747 ) ( 9,061,701 ) Net deferred tax asset 21,313,847 14,811,585 Less valuation allowance ( 21,313,847 ) ( 14,811,585 ) Net deferred tax asset (liability) post valuation allowance $ — $ — Deferred tax assets are evaluated and a valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company has recorded a substantial deferred tax asset related to temporary differences between book and tax basis of assets and liabilities. As of December 31, 2021 and 2020, the Company has provided a full valuation allowance against all of its deferred tax assets as the history of operating losses have been given more weight than projected future income when determining the need for a valuation allowance. The effective tax rate differs from the statutory federal tax rate as follows: Years Ended December 31, 2021 2020 Federal income tax at the statutory rate U.S. federal rate $ 1,851,313 21.0 % $ ( 835,808 ) 21.0 % State taxes, net of federal 325,416 3.8 % 128,075 ( 3.2 %) Permanent items 693,699 7.9 % 2,571,620 ( 64.6 %) Change in valuation allowance ( 2,383,291 ) ( 27.0 %) ( 1,659,594 ) 41.7 % Return to provision adjustments 8,665 0.1 % — 0.0 % Nondeductible expenses and other ( 83,883 ) ( 1.0 %) ( 27,535 ) 0.7 % Income tax expense $ 411,919 $ 176,758 Effective income tax rate 4.7 % 4.4 % As discussed in Note 2, Health Elements made a federal election during 2013 to be taxed as a Subchapter C corporation. Since that time, Health Elements has filed a consolidated income tax return. The Company has continued to file a separate consolidated income tax return, which includes the activity of Thorne Research. As such, separate tax returns are filed and therefore net operating losses are unique to each tax group. As of December 31, 2020, the Company had federal net operating loss carryforwards of approximately $ 50.1 million and state operating loss carryforwards of $ 50.1 million, including Health Elements. As of December 31, 2021, the Company had federal net operating loss carryforwards of approximately $ 70.2 million and state operating loss carryforwards of $ 69.7 million, including Health Elements. If not utilized, the federal operating loss carryforwards incurred before January 1, 2020 will begin to expire in 2030 . The federal operating losses incurred in 2019 and beyond do not expire. The state operating loss carryforwards do not expire. For the year ended December 31, 2018, management has not yet conducted a formal analysis to determine the impact of the Company’s move from Idaho to South Carolina, for purposes of its state apportionment. Management estimates that the combined Idaho and South Carolina operating loss for the year ended December 31, 2018, was approximately $ 11.4 million. Under current law, the Idaho portion of the overall operating loss will expire December 31, 2038 , whereas the South Carolina portion of the operating loss has an indefinite carryforward period. Management does not believe there are any uncertain tax positions. The Company has net operating loss carryforwards in various other state jurisdictions that are not material to the consolidated financial statements. Internal Revenue (Code) Section 382 can potentially limit the future utilization of net operating loss carryforwards when certain ownership changes occur. During 2021, we completed a Section 382 study and concluded that while there were no deemed changes in ownership related to the prior equity transactions of Thorne that may limit our NOLs as of December 31, 2021, the merger with Drawbridge Health during 2021 did constitute a deemed change in ownership under Section 382, resulting in a Section 382 limitation that applies to all Drawbridge Health NOLs generated prior to the merger, or deemed ownership change date. As a result of the identified ownership change related to Drawbridge Health at the time of the merger, the portion of NOL carryforwards attributable to the pre-ownership change periods are subject to a substantial limitation under Section 382. The Company has adjusted its NOL carryforwards to address the impact of the Section 382 ownership changes. This resulted in a reduction of available federal and state NOLs of $ 8.1 million and $ 8.1 million, respectively. All of the remaining federal and state NOLs are subject to a full valuation allowance at December 31, 2021. The Company is subject to taxation in the U.S. and various states. The Company does no t have any unrecognized tax benefits. As of December 31, 2021, and 2020, there is no accrued interest or penalties recorded in the consolidated financial statements.

Employee Compensation Plans

Employee Compensation Plans	12 Months Ended
	Dec. 31, 2021
Compensation Related Costs [Abstract]
Employee Compensation Plans	16. Employee Compensation Plans The Company maintains a qualified defined contribution profit sharing plan (Profit Sharing Plan) for all eligible employees. Employees age 21 or older are eligible to participate on the first day of the following month from their hire date. The amount of contribution is determined annually by the Board of Directors. Effective January 1, 2019, the Company began making safe harbor contributions to the Profit Sharing Plan. The contribution will match 100 % of the elective deferrals for the first 3 % contributed by the employee, with another 50% of deferrals over 3 % up to 5 % of the compensation. This safe harbor plan requires that all matching contributions are 100 % vested at the time of contribution. The total employer safe harbor contributions to the Profit Sharing Plan during the years ended December 31, 2021 and 2020 were $ 0.9 million and $ 0.7 million, respectively. Any profit-sharing contributions would be fully vested at the end of six or more years of service, with 20% each year starting in the second year of service. There were no profit-sharing contributions to the Profit Sharing Plan in 2021 or 2020. The Company has a non-qualified deferred compensation plan for select groups of management that was established in August 2015 (Deferred Compensation Plan). The purpose of the Deferred Compensation Plan is to attract and retain a select group of management or highly compensated employees and to provide them an opportunity to defer compensation on a pre-tax basis and accumulate tax-deferred earnings. Each participant in the Deferred Compensation Plan has a fully vested and non-forfeitable interest in each year’s contribution, including interest credited thereto, and in any Company matching contributions, if applicable. The Company may make discretionary credits to the deferred compensation account of each participant in an amount determined each plan year by the Company. The Company has not made any discretionary credits to the Deferred Compensation Plan since inception.

Share-based Compensation

Share-based Compensation	12 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-based Compensation	17. Share-based Compensation Prior to the Company’s IPO, the Company’s Board of Directors adopted, and the stockholders approved the Company’s 2021 Equity Incentive Plan (2021 Plan). The 2021 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to Company employees and parent and subsidiary corporations’ employees, and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards (RSAs), restricted stock units (RSUs), and performance awards to employees, directors, and consultants and parent and subsidiary corporations’ employees and consultants. Subject to the adjustment provisions of and the automatic increase described in the 2021 Plan, a total of 3,480,510 shares of the Company’s common stock is reserved for issuance pursuant to the 2021 Plan. In addition, subject to the adjustment provisions of the 2021 Plan, the shares reserved for issuance under the 2021 Plan will also include shares subject to awards granted under the Company’s 2010 Equity Incentive Plan (2010 Plan) or the Company’s Restated 2020 Onegevity Health Equity Plan, as amended (Onegevity Plan) that, on or after September 22, 2021 (the effective date of the IPO), expire or otherwise terminate without having been exercised or issued in full, are tendered to or withheld by the Company for payment of an exercise price or for satisfying tax withholding obligations, or are forfeited to or repurchased by the Company due to failure to vest (provided the maximum number of shares that may be added to the 2021 Plan, pursuant to outstanding awards under the 2010 Plan, or Onegevity Plan, is 10,615,030 shares). Subject to the adjustment provisions of the 2021 Plan, the number of shares available for issuance under the 2021 Plan will also include an annual increase on the first day of each fiscal year beginning with the 2022 fiscal year and ending on the tenth anniversary of the date the Company’s Board of Directors approved the 2021 Plan, in an amount equal to the least of: • 8,701,275 shares; • five percent ( 5 %) of the outstanding shares of the Company’s common stock as of the last day of the immediately preceding fiscal year; or • such other amount as the Company’s Board of Directors may determine. The 2021 Plan is administered by the Company’s Compensation Committee, a sub-committee of the Board of Directors. Options are granted at the discretion of the 2021 Plan’s administrator and have a term of not greater than 10 years from issuance. Options are exercisable when vested. Vesting requires continuous employment up to the vesting date and the vesting schedule is determined by the 2021 Plan. Options generally vest over a four-year period. Prior to the 2021 Plan becoming effective, the Company previously issued stock-based awards under the 2010 Plan. The 2010 Plan was created by the Company’s Board of Directors and has been amended from time to time to grant additional options. The plan provides for the grant of stock options, RSAs, RSUs, and performance awards to employees, directors, and consultants and parent and subsidiary corporations’ employees and consultants. Options are granted at the discretion of the Company’s Board of Directors and have a term of not greater than 10 years from issuance. Options are exercisable when vested. Vesting requires continuous employment up to the vesting date and the vesting schedule is determined by the Plan. Options generally vest over a four-year period. In 2018, certain members of management and the Company entered into an agreement whereby certain members of management received a put right from the Company, in which management could receive cash from the Company for the fair value of 2,538,280 common stock options, with an exercise price of $ 0.85 per share, were set to expire in 2020 and 2021. Per the terms of the Agreement, the fair value to be paid in cash equaled the fair value of the underlying common stock less the exercise price of the stock options. On May 1, 2019, certain members of management exercised 1,793,795 of the 2,568,095 options granted under the 2010 Plan, whereby promissory notes totaling $ 1.5 million, representing the exercise price of $ 0.85 per share, were executed in exchange for 1,793,795 shares of common stock. The promissory notes to management bear interest at 5.0 %, with a maturity date of June 22, 2020 . In addition, in May 2019, these same members of management and the Company entered into an additional put right agreement in which management could request the Company to purchase the 1,793,795 shares of common stock for cash. Due to the terms of the promissory notes with management and the put right on both the stock options and common stock, the Company determined the put rights represent a liability of the Company to management and is remeasured at each balance sheet date. The change in liability is charged to stock-based compensation expense within selling, general, and administration expense in the consolidated statements of operations. As of December 31, 2019, the stock-based compensation liability was $ 14.8 million and was recorded as a short-term liability on the consolidated balance sheet as of December 31, 2019. In June 2020, members of management exercised 667,500 of the remaining options outstanding, via a cashless exercise, subject to the put rights. At that time, the Company agreed to purchase the common stock from these members of management at fair value. The stock-based compensation liability was again remeasured just prior to the exercise date of the stock options. Stock compensation expense related to the remeasurement of the options and common stock was $ 1.1 million and $ 9.0 million, respectively, during the year ended December 31, 2020. There was no stock compensation expense related to the remeasurement of the options and commons stock recorded during the year ended December 31, 2021. The Company paid $ 23.1 million to management and relieved the liability on July 14, 2020, in the amount of $ 23.8 million, and one option holder elected to cash exercise 106,800 options. In February 2020, promissory notes to key members of management of the Company were executed totaling $ 0.7 million. The notes bear interest at 5.0 %, with a maturity date of June 30, 2020. The promissory notes were issued so management would have the appropriate funds to pay taxes associated with the exercise of 1,793,795 stock options into common stock. These notes were paid off in July 2020. During the year ended December 31, 2020, management repaid all promissory notes at maturity. In June 2020, the Company issued promissory notes to key members of management totaling $ 6.3 million in connection with the buyout of management stock options and the repurchase of common stock. Subsequently, the common stock and stock options were canceled. The notes bore interest at 5.0 %, with a maturity date of July 31, 2020. These notes, including all accrued and unpaid interest, were repaid by the Company at maturity in July 2020, as part of the $ 23.1 million payment discussed above. The effect of the repayment during the year ended December 31, 2020 is included as a financing activity related to the repurchase of common stock within consolidated statements of cash flows. On September 22, 2021, and upon the 2021 Plan becoming effective, the Company terminated the 2010 Plan , but all terms and conditions of the outstanding awards remained in effect with no changes. As of December 31, 2021, there were 949,510 shares available for issuance under the 2021 Plan and 13,106,416 share-based awards outstanding, comprised of 9,699,656 stock option awards and 3,406,760 restricted stock units. Stock Options During the year ended December 31, 2021 and 2020, there were no grants of stock options. The following table summarizes all stock option activity for the year ended December 31, 2021: Options Outstanding Weighted- Weighted Average Remaining Contractual Term (Years) Aggregate (1) Outstanding as of January 1, 2021 7,811,975 $ 4.66 6.30 N/A Granted (2) 1,959,335 7.65 Exercised ( 39,614 ) 1.91 Cancelled/forfeited ( 32,040 ) 5.12 Outstanding as of December 31, 2021 9,699,656 5.28 6.22 $ 12.3 Vested and expected to vest after December 31, 2021 9,699,656 $ 5.28 6.22 $ 12.3 Exercisable, December 31, 2021 5,691,541 $ 4.29 5.73 $ 10.9 (1) Aggregate intrinsic value represents the difference between the closing fair value of the underlying common stock and the exercise price of outstanding, in-the-money options on the date of measurement. (2) During the year ended December 31, 2021, the Company issued 1,959,335 stock options in exchange for outstanding stock options of Onegevity at the time of, and in conjunction with the merger agreement as further discussed in Note 4. As a result of the stock option exchange being determined to be materially a “like-for-like” transaction, there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the stock options immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. These stock options contain an accelerated vesting provision whereby upon the completion of an IPO by the Company or qualified change-in-control, any related and unvested stock options would become fully vested. Upon the Company’s IPO on September 22, 2021, all 1,959,335 stock options issued in connection with the Onegevity merger fully vested. The following information summarizes the Company’s stock options outstanding for the periods presented: For the year ended December 31, 2021 2020 Weighted-average grant date fair value of stock options granted (1) N/A N/A Grant date fair value of stock options vested (2) $ 963,205 $ 963,205 Intrinsic value of stock options exercised (3) $ 219,813 N/A (1) During the years ended December 31, 2021 and 2020, there were no options granted by the Company. During the year ended December 31, 2021 and in connection with the Onegevity merger, the Company issued 1,959,335 options in exchange for outstanding stock options of Onegevity. As a result of the stock option exchange being determined to be materially a “like-for-like” transaction, there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the stock options immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. These stock options issued in connection with the Onegevity merger have been excluded from the information presented for the year ended December 31, 2021. (2) During the year ended December 31, 2021 and in connection with the Onegevity merger, the Company issued 1,959,335 options in exchange for outstanding stock options of Onegevity. These stock options contained an accelerated vesting provision whereby upon the completion of an IPO by the Company or qualified change-in-control, any related and unvested stock options would become fully vested. Upon the Company’s IPO on September 22, 2021, all 1,959,335 stock options issued in connection with the Onegevity merger fully vested. These vested stock options issued in connection with the Onegevity merger have been excluded from the information presented for the year ended December 31, 2021. (3) Shares of the Company’s common stock, traded under the symbol “THRN,” have been publicly traded since September 23, 2021, when the Company’s common stock was listed and began trading on the Nasdaq Global Select Market (the “Nasdaq”). No market for the Company’s stock existed prior to September 23, 2021. Accordingly, the total intrinsic value of stock options exercised excludes options exercised for the year ended December 31, 2020, prior to the IPO date. There were no stock option exercises prior to the IPO date during the year ended December 31, 2021. During the year ended December 31, 2021, and 2020, the Company recorded stock-based compensation expense related to stock options of $ 2.8 million and $ 10.0 million, respectively. The stock-based compensation expense of the year ended December 31, 2020 includes the expense related to the remeasurement of the stock options and common stock. These amounts are classified as selling, general and administrative on the consolidated statements of operations. As of December 31, 2021, the unrecognized stock-based compensation expense related to outstanding stock options was approximately $ 713 thousand and is expected to be recognized as expense over approximately nine months . Restricted Stock Units On July 29, 2021 and December 1, 2021, the Company issued RSUs to certain employees for an aggregate 875,760 and 2,531,000 shares, respectively, which vest ratably over a 4-year period. The following table summarizes all RSU activity for the year ended December 31, 2021: Number Weighted- Outstanding as of December 31, 2020 — $ — Granted (1) 3,879,350 9.99 Released 472,590 11.17 Cancelled/forfeited — — Outstanding as of December 31, 2021 3,406,760 $ 9.82 Vested and expected to vest after December 31, 2021 3,406,760 $ 9.82 (1) 472,590 RSUs granted during the year ended December 31, 2021 were granted in exchange for profits interest units held by employees of Onegevity in conjunction with the merger agreement as further discussed in Note 4. As a result of the RSU exchange, there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the RSUs immediately before and after the exchange and determined that the exchange resulted in no incremental compensation expense. These RSUs contain an accelerated vesting provision whereby upon the completion of an IPO by the Company or qualified change-in-control, any unvested shares would become fully vested. Upon the Company’s IPO on September 22, 2021, all restrictions on the 472,590 unvested RSUs were released. During the year ended December 31, 2021, the Company recorded stock-based compensation expense related to RSUs of $ 1.8 million. There was no compensation expense related to RSUs recorded during the year ended December 31, 2020. These amounts are classified as selling, general and administrative on the consolidated statements of operations. As of December 31, 2021, the unrecognized stock-based compensation expense related to outstanding RSUs was approximately $ 31.7 million and is expected to be recognized as expense over approximately 3.9 years. The following table summarizes additional information related to RSUs for the periods presented: For the year ended December 31, 2021 2020 Weighted-average grant date fair value of RSUs granted (1)(2) $ 9.99 N/A Grant date fair value of RSUs vested (2)(3) $ - $ - Intrinsic value of RSUs released (2)(4) $ - $ - (1) During the year ended December 31, 2021, there were 875,760 RSUs issued prior to the Company’s IPO and an additional 2,531,000 RSUs issued after the IPO and prior to December 31, 2021. Shares of the Company’s common stock, traded under the symbol “THRN,” have been publicly traded since September 23, 2021, when the Company’s common stock was listed and began trading on the Nasdaq Global Select Market (Nasdaq). Accordingly, no market for the Company’s stock existed prior to September 23, 2021. Accordingly, the total intrinsic value of RSUs granted excludes the 875,760 RSUs granted prior to the IPO date. There were no RSUs granted during the year ended December 31, 2020. (2) During the year ended December 31, 2021 and in connection with the Onegevity merger, the Company issued 472,590 RSUs in exchange for outstanding profits interest units held by employees of Onegevity. As a result of the RSU exchange being determined to be materially a “like-for-like” transaction, there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the RSUs immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. These RSUs issued in connection with the Onegevity merger have been excluded from the information presented for the year ended December 31, 2021. (3) During the years ended December 31, 2021 and 2020, there were no RSUs that vested. (4) During the years ended December 31, 2021 and 2020, there were no RSUs that were released.

Basic and Diluted Net Income (L

Basic and Diluted Net Income (Loss) per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Basic and Diluted Net Income (Loss) per Share	18. Basic and Diluted Net Income (Loss) per Share Basic net income (loss) per share is calculated by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common stock and common stock equivalents outstanding for the period. Holders of Series E convertible preferred stock met the definition of participating securities, which required the Company to apply the two-class method to compute both basic and diluted net income (loss) per share. The two-class method is an earnings allocation formula that treats participating securities as having rights to earnings that would otherwise have been available to common stockholders. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all earnings for the period had been distributed. In the event the Board of Directors declared dividends or any distributions, the available distributions would be distributed (i) first, to the Series E convertible preferred stock until such holders have received on a cumulative basis an amount per share equal to the Series E original issue price, and (ii) second, to the holders of common stock and Series E convertible preferred stock (on an as converted basis) on a pro rata, pari passu, basis. The attribution of earnings to the Series E convertible preferred stockholders was based on its contractual rights to receive dividends and, for the quarter in which they converted, the attribution was calculated using a weighted-average method. The Series E convertible preferred stock did not contractually participate in the Company’s net losses, and therefore, undistributed losses were not allocated to Series E convertible preferred stock. Immediately prior to the completion of the Company’s IPO on September 22, 2021, all outstanding shares of the Series E convertible preferred stock automatically converted on a one-to-one basis into an aggregate of 27,011,500 shares of common stock. See Note 13 for additional information related to the Series E convertible preferred stock. The dilutive effect of stock options, warrants, and unvested nonparticipating restricted stock is based on the treasury stock method while the dilutive effect of the convertible preferred stock is based on the if-converted method. These potential common stock equivalents are only included in the calculations when their effect is dilutive. The Company presents the more dilutive of the two-class method or if-converted method as diluted net income (loss) per share during the period. For the year ended December 31, 2021, the Company presented diluted net income per share under the two-class method. The following table presents information necessary to calculate net income (loss) per share for the year ended December 31, 2021 and 2020: Year Ended December 31, 2021 2020 Numerator: Net income (loss) attributable to Thorne HealthTech, Inc. $ 7,253,423 $ ( 3,357,746 ) Undistributed earnings attributable to Series E convertible preferred stockholders ( 3,507,892 ) — Numerator for basic EPS—net income (loss) available to Thorne HealthTech, Inc. common stockholders (A) 3,745,531 ( 3,357,746 ) Effect of dilutive securities: Change in fair value of warrant liability ( 1,872,364 ) — Undistributed earnings attributable to Series E convertible preferred stockholders—basic 3,507,892 Undistributed earnings attributable to Series E convertible preferred stockholders—diluted ( 2,031,751 ) — ( 396,223 ) — Numerator for diluted EPS—net income (loss) available to Thorne HealthTech, Inc. common stockholders (C) 3,349,308 ( 3,357,746 ) Denominator: Denominator for basic EPS - weighted average shares (B) 27,478,411 9,985,800 Effect of dilutive securities: Stock options 3,608,128 — RSUs 159,668 — Warrants 1,082,358 — Dilutive potential common shares 4,850,154 — Denominator for diluted EPS—adjusted weighted average common stock and common stock equivalents (D) 32,328,565 9,985,800 Basic EPS (A/B) $ 0.14 $ ( 0.34 ) Diluted EPS (C/D) $ 0.10 $ ( 0.34 ) (1) Approximately 4.2 million warrants and stock-based awards were excluded from the computation of diluted EPS for the years ended December 31, 2020, because the effect would have been anti-dilutive under the treasury stock method. (2) For the year ended December 31, 2020, diluted EPS is the same as basic EPS because the effects of potentially dilutive securities are anti-dilutive. (3) For the year ended December 31, 2021 and 2020, 19,611,089 and 27,011,500 of Series E convertible preferred stock were excluded from the computation of diluted EPS because the effect would have been anti-dilutive under the 'if-converted' method

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	19. Commitments and Contingencies Royalties and Other Agreements - The Company has entered into various agreements that require future payments. The agreements call for future payments to a major hospital for use of their trademarks and tradenames in advertising the benefits of supplements and provides the Company access to research information owned by the hospital and provides for the hospital to perform clinical trials and to support the Company’s products. As of December 31, 2021, future annual minimum commitments under these agreements are as follows: Amount 2022 $ 1,030,000 2023 562,500 Total $ 1,592,500 The Company also has various royalty agreements, that are dependent on future sales. Total royalties paid during each of the years ended December 31, 2021, and 2020, were $ 616 thousand and $ 488 thousand, respectively. Other - In 2017, the Company received incentives totaling $ 0.8 million from Berkeley County, South Carolina, which includes certain performance obligations that must be met over the next seven years and maintained by the company for five years once attained. The grant agreement includes the potential for repayment of proceeds in whole or in part for failure to satisfy the performance obligations. As of December 31, 2021, Berkeley County has not asked for repayment of these proceeds. The Company, like other manufacturers of products that are ingested, faces an inherent risk of exposure to product liability claims if, among other things, the use of its product results in personal injury. The Company maintains product liability insurance to manage these risks. However, there can be no assurance the amount of insurance would be sufficient to cover all product liability claims. In addition to the matter discussed below, occasionally the Company is involved in lawsuits arising in the ordinary course of its operations. The Company’s management does not expect the ultimate resolution of pending legal actions to have a material effect on the consolidated financial statements of the Company. The Company is aware of two third-party U.S. patents that have claims relating to compositions of nicotinamide riboside – an ingredient contained in several of the Company’s nutritional supplement products – issued to the Trustees of Dartmouth College and licensed to ChromaDex Corporation (Chromadex), of Los Angeles, California. On December 1, 2020, and February 1, 2021, the Company filed separate petitions for inter partes review against U.S. Patent No. 8,383,086 and U.S. Patent No. 8,197,807, respectively, at the U.S. Patent Trial and Appeal Board to seek to invalidate these two patents. On June 10, 2021, the U.S. Patent Trial and Appeal Board issued a decision granting institution of inter partes review against U.S. Patent No. 8,383,086, and on August 12, 2021, the U.S. Patent Trial and Appeal Board issued a decision granting institution of inter partes review against U.S. Patent No. 8,197,807. On May 12, 2021, the Trustees of Dartmouth College and ChromaDex filed a complaint against the Company in the U.S. District Court for the Southern District of New York, alleging the Company’s infringement of U.S. Patent Nos. 8,383,086 and 8,197,807. The complaint seeks to enjoin the Company from selling its nutritional supplement products that contain nicotinamide riboside and further seeks monetary damages for alleged infringement of the patents. On August 20, 2021, the trial judge in the patent infringement litigation issued an Order to Stay the litigation during the pendency of the two inter partes review, in which decisions will likely be made in mid-2022. The Company has not recorded a loss in connection with this matter because the Company believes that a loss is currently neither probable nor estimable.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events The Company has evaluated subsequent events through the date the consolidated financial statements were issued. Thorne and Mitsui Joint Venture (Thorne HealthTech Asia PTE, LTD.) On January 10, 2022, Thorne entered into an agreement (the Joint Venture Agreement) with Mitsui and TM HealthTech Pte. Ltd. (TM HealthTech), a wholly owned subsidiary of Mitsui, to form a joint venture entity, Thorne HealthTech Asia PTE, LTD. (the Thorne Asia JV), to exclusively market, distribute and sell Thorne’s products across Singapore, Hong Kong, Taiwan, Thailand, Indonesia, Malaysia, Australia, the Philippines, Vietnam, India, and New Zealand. Thorne and Mitsui contributed approximately $ 2.7 million and $ 2.6 million, respectively, in cash and hold 51 % and 49 %, respectively, of the total issued share capital of Thorne Asia JV. The board of directors of the Joint Venture initially will be composed of five directors, of which three shall be nominated by Thorne, and two by Mitsui. Each director shall be appointed for a term of office of one year and shall be eligible for re-election. 2021 Plan Share Reserve Increase On January 1, 2022 and in accordance with the adjustment provisions of the 2021 Plan, the number of shares available for issuance under the 2021 Plan were increased on the first day of the 2022 fiscal year by 2,627,710 shares, representing five percent ( 5 %) of the outstanding shares of the Company’s common stock as of the last day of the immediately preceding fiscal year. On January 26, 2022 the Company registered the shares reserved pursuant to the automatic increase on Form S-8. Acquisition of Nutrativa LLC On February 28, 2022, the Company closed individual equity purchase agreements to acquire all outstanding membership interests of Nutrativa LLC (Nutrativa), for an aggregate purchase price of $ 15.0 million (the Nutrativa Acquisition). The Company funded the purchase price with available cash on hand. Paul Jacobson, the Company’s Chief Executive Officer, is the Chief Executive Officer and Board member of Nutrativa. A special committee of independent directors (the “Special Committee”) of Thorne’s Board of Directors negotiated and approved the Nutrativa Acquisition in consultation with an independent advisory firm. See Note 3 for additional information regarding the related party relationship with Nutrativa. Retirement of Executive Officer On March 10, 2022, Scott Wheeler notified the Board of his intent to retire as Chief Financial Officer, effective in April 2022. Thorne has initiated an external search for a new Chief Financial Officer and Mr. Wheeler has agreed to stay on board through this process and serve in a consulting role through the transition. There were no other subsequent events requiring recognition or disclosure in the accompanying consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The consolidated financial statements include the operations of the Company and all of its wholly-owned subsidiaries, as well as majority-owned subsidiaries over which the Company exercises control and, when applicable, entities for which the Company has a controlling financial interest or variable interest for which the Company is the primary beneficiary. All significant intercompany accounts and transactions have been eliminated in consolidation. On September 10, 2021, the Company approved and effected a 445 -for-1 forward stock split of the Company’s Class A common stock, Class B common stock, and Series E convertible preferred stock. The par value and other terms of the common stock and preferred stock were not affected by the stock split. All related share and per share amounts have been retroactively adjusted in these consolidated financial statements for all periods presented to reflect the 445 -for-1 forward stock split. Furthermore, other related information, including shares of common stock underlying the Company’s warrants, stock options and restricted stock units and their respective exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented to reflect the 445 -for-1 forward stock split.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The Company bases its estimates on its historical experience and on assumptions that the Company believes are reasonable; however, actual results could significantly differ from those estimates.
Cash	Cash Cash includes all cash balances. At times, cash balances may exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses resulting from these excess deposits.
Restricted Cash	Restricted Cash The Company’s restricted cash consists of cash that the Company is contractually obligated to maintain in accordance with the terms of its Standby Letter of Credit with Sumitomo Mitsui Banking Corporation (SMBC). See Notes 3 and 11 for additional information related to the SMBC Standby Letter of Credit.
Accounts Receivable	Accounts Receivable Accounts receivable consist of balances due from customers and are recorded at net realizable value. Past due balances that are delinquent beyond the acceptable terms of credit for each customer are reviewed individually for collectability. The allowance for doubtful accounts was $ 10 thousand and $ 34 thousand as of December 31, 2021 and 2020, respectively.
Concentrations of Risk	Concentrations of Risk Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. Although the Company places its cash with high quality institutions, these balances often exceed federally insured limits. Concentrations of credit risk primarily relate to unsecured trade receivables. Major customers who accounted for more than 10 % of the Company’s total receivables were as follows: As of December 31, 2021 2020 iHerb, Inc. 41.3 % * Emerson Ecologics, LLC 33.3 % 39.4 % * Represents less than 10% Sales - Major customers who accounted for more than 10 % of the Company’s total sales were as follows: Years ended December 31, 2021 2020 Pattern Inc. 27.0 % 26.1 % iHerb, Inc. * 11.3 % * Represents less than 10%
Inventory	Inventories Raw materials consist primarily of powders, soft gels, and packaging components such as bottles, lids, and labels. Work in process consists of premixed powders and encapsulated powders actively in the manufacturing process, but not yet bottled. Inventories are stated at the lower of cost, as determined on the first-in, first-out method, or net realizable value. Finished goods and work-in-process include the inventory costs of raw materials, direct labor and normal manufacturing overhead. The Company uses an inventory reserve to adjust our inventory costs down to a net realizable value and to reserve for estimated obsolescence of both raw materials and finished goods. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Any purchase discounts received are included in the cost of inventories.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets include annual insurance premiums and annual equipment and software maintenance expense, paid on a non-calendar year basis such that portions of the advance payments relate to future periods.
Property, Plant and Equipment	Property and Equipment Property and equipment are stated at historical cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the remaining lease term (including renewals that are reasonably certain to occur) or the estimated useful lives of the improvements. The estimated useful lives of property and equipment are as follows: Machinery and equipment 3 to 15 years Furniture and fixtures 3 to 7 years Office equipment 3 to 7 years Leasehold improvements 3 to 20 years Vehicles 7 years Lab equipment 5 to 10 years Software 7 years
Leases	Leases The Company has operating and finance lease agreements for its production, shipping and customer service centers and corporate offices. At inception, the Company determines whether an agreement represents a lease and, at commencement, the Company evaluates each lease agreement to determine whether the lease constitutes an operating or financing lease. Some of our lease agreements have renewal options, tenant improvement allowances, rent holidays and rent escalation clauses. The Company accounts for its leases as operating or finance leases under Accounting Standards Codification (ASC) Topic 842. The Company has elected not to separate lease components from non-lease components for all fixed payments. Right-of-use lease assets represent the Company’s right to use the underlying asset for the lease term, and the operating lease obligation represents its commitment to make the lease payments arising from the lease. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one-year or less. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.
Other Assets	Other Assets Other assets are primarily deposits required by contractual obligations for real estate leases.
Impairment of Long-Lived Assets	Impairment of Long-lived Assets Management reviews long-lived assets and certain identifiable intangible assets with finite lives for impairment in accordance with ASC 360, “Property, Plant, and Equipment.” Goodwill and intangible assets not subject to amortization are reviewed annually for impairment in accordance with ASC 350, “Intangibles — Goodwill and Other,” or more often if there are indications of possible impairment. The analysis to determine whether or not an asset is impaired requires significant judgment that is dependent on internal forecasts, including estimated future cash flows, estimates of long-term growth rates for the business, the expected life over which cash flows will be realized and assumed discount rates. Changes in these estimates and assumptions could materially affect the determination of fair value and any impairment charge. While the fair value of these assets exceeds their carrying value based on management’s current estimates and assumptions, materially different estimates and assumptions in the future in response to changing economic conditions, changes in the business, increased competition or loss of market share, product innovation or obsolescence, product claims that result in a significant loss of sales or profitability over the product life or for other reasons could result in the recognition of impairment losses. For assets to be held and used, including acquired intangible assets and long-lived assets subject to amortization, the Company initiates a review whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Recoverability of an asset is measured by comparison of its carrying amount, to the future undiscounted cash flows that the asset is expected to generate. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Significant management judgment is required in this process. During the years ended December 31, 2021 and 2020, no impairment losses were identified.
Investment	Investments The Company has investments in various other entities. The equity method of accounting is used for entities in which the Company exercises significant influence, but does not have a controlling interest or a variable interest in which it is the primary beneficiary. Investments not accounted for using the equity method do not have readily determinable fair values and do not qualify for the practical expedient to measure the investment using a net asset value per share. These investments are recorded using the measurement alternative in which the Company’s equity interests are recorded at cost, less impairments, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer. At each reporting period, the Company assesses if these investments continue to qualify for this measurement alternative. An impairment is recorded when there is evidence that the expected fair value of the investment has declined to below the recorded cost. During the years ended December 31, 2021 and 2020, no impairment losses were identified.
Equity Method Investments	Equity Method Investments The Company reports investments in unconsolidated entities, over whose operating and financial policies it has the ability to exercise significant influence but not control, under the equity method of accounting. Under this method of accounting, the Company’s pro rata share of the applicable entity’s earnings or losses are included in the consolidated statements of operations. Initially the investments are recorded based on assets contributed or the cash invested. The Company evaluates its equity-method investments for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. If it is determined that a decline in the fair value of the investments is not temporary, and if such reduced fair value is below its carrying value, an impairment is recorded. Determining fair value involves significant judgment. Estimates consider available evidence including the present value of the expected future cash flows discounted at market rates, general economic conditions and other relevant factors. No impairments were recorded related to our equity-method investments for the years ended December 31, 2021 and 2020.
Intangible Assets	Intangible Assets Intangible assets are initially recorded at fair value and amortized over the estimated period of benefit on a straight line basis and include customer relationships with estimated useful lives of 20 years, trade names with estimated useful lives ranging from 5 to 15 years, existing technology and reformulations with estimated useful lives ranging from 3 to 15 years, research formulas with estimated useful lives of 10 years and license agreements with estimated useful lives of 3 to 15 years. Amortization expense is generally recognized in selling, general and administrative expense. The carrying value of definite life intangibles is reviewed at each balance sheet date if indication of impairment exists.
Goodwill	Goodwill Goodwill, which represents the excess of the purchase price paid over the fair value of the identifiable net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value-based test. The Company is organized in one reporting unit and evaluates the goodwill for the Company as a whole. The Company performs its annual goodwill impairment test required by ASC 350 as of December 31st of each year, or more frequently if events or changes in circumstances indicate that the asset might be impaired. As part of the assessment of goodwill, the Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the fair value exceeds the carrying amount, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, then an impairment charge is recognized for the difference, limited to the amount of goodwill recorded. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations. There was no impairment of goodwill for the years ended December 31, 2021 and 2020.
Defined Contribution Plan	Defined Contribution Plan The Company maintains a 401(k) defined contribution plan which covers all employees who meet minimum requirements and elect to participate. The Company is currently matching employee contributions, up to specified percentages of those contributions.
Warrant Liability	Warrant Liability The Company determines the accounting classification of a warrant, as either liability or equity, by first assessing whether the warrant meets liability classification in accordance with ASC 480, Distinguishing Liabilities from Equity (ASC 480), and then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (ASC 815-40). If the warrant does not meet liability classification under ASC 480, the Company assesses the requirements under ASC 815-40, including whether the warrant is indexed to its common stock and whether the warrant meets the other requirements to be classified as equity under ASC 815-40. After all relevant assessments are made, the Company concludes whether the warrant should be classified as liability or equity. The Company has warrants that are classified as a liability on the consolidated balance sheet. The warrants classified as a liability are measured at fair value using the Black-Scholes pricing model which takes into account, as of the valuation date, factors including the current exercise price, the contractual life of the warrant, the current fair value of the underlying stock, its expected volatility, and the risk-free interest rate for the term of the warrant. The warrant liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. As the warrant liability is required to be measured at fair value at each reporting date, it is reasonably possible that these estimates and assumptions could change in the near term. See Note 14 for additional information related to the previously issued and outstanding warrants.
Equity Classified Warrants	Equity-Classified Warrants The Company has common stock warrants that are classified within equity on the consolidated balance sheet. The Company has concluded that these warrants do not meet the requirements to be accounted for as liability under ASC 480 as they are for a fixed number of shares and do not contain provisions that require the Company to cash-settle the warrants. Additionally, the Company determined that these warrants are indexed to the Company’s stock as they do not contain exercise contingencies or adjustments to exercise price that are not an input to a fixed-for-fixed model. The warrants also meet the other equity-classification criteria under ASC 815-40. Equity classified warrants are accounted for at fair value on the issuance date and are not remeasured every reporting period.
Revenue Recognition	Revenue Recognition The Company accounts for revenue in accordance with FASB Topic 606, “ Revenue from Contracts with Customers ,” (ASC 606), using the following steps: • identify the contract, or contracts, with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the identified performance obligations; and • recognize revenue when, or as, the Company satisfies the performance obligations. The Company recognizes revenues at a point in time when it satisfies a performance obligation by transferring control over a product and other promised goods and services to a customer. Significant judgments made in the application of ASC 606 include determining the transaction price, and the timing of transfer of control of the performance obligation (i.e., sale of product). The Company considers several factors in determining the point in time at which control transfers to the customer, including when legal title transfers to the customer, the Company has a present right to payment, and the customer has assumed the risks and rewards of ownership. Professional/B2B Sales: The Company sells to wholesale customers that include health professionals, retail stores and through various online sites operated by authorized resellers. Certain customers resell Company products in online marketplaces; however, no inventories are held on consignment and revenue is recognized when control of the goods is transferred to these customers, which is at the time of shipment. The terms of payment over the recognized receivables from distributors are less than one year and therefore these sales do not have any significant financing components. The Company uses standard price lists in determining the transaction price, adjusted for estimates of variable consideration. Any discounts stated or implied are allocated entirely to the sole performance obligation. DTC Transaction Sales: The Company also sells direct to consumers online through a Company owned and operated website. Revenue from online sales is recognized at time of shipment of the product. In addition, the Company sells testing services and test kits. Testing services and testing kits are recorded as revenue when the testing results are provided to the customer. Shipping and handling costs are considered a fulfillment activity and are expensed as incurred. DTC Subscription Sales: The Company offers its customers the ability to opt into recurring automatic refills on both Thorne.com and Amazon.com. Revenue is recognized under the subscription program when product is shipped to the consumer. No funds are collected at the time a consumer signs up for a subscription and the customer can cancel or modify a subscription at any time at no cost to the customer. On the Company website, customers are allowed to subscribe at a frequency of monthly, every 45 days, every 2 months, every 3 months, or every 4 months. For all frequencies, a 10 % discount is offered on retail refill orders. On Amazon, the discount ranges from 5 to 10 % depending on the number of products to which a customer is subscribed; the average discount on Amazon for the Company’s subscriptions is approximately 6 %. The Company records revenues, net of estimated discounts. If a customer is not satisfied for any reason with a product purchased, the customer can return it to the place of purchase to receive a refund, a credit, or a replacement product. The return or refund request must be submitted within 60 days of the date of purchase. The Company estimates returns and accrues for potential returns based on historical data. There are no material differences in our revenue recognition policy between the DTC subscription program and the DTC transaction program. The Company primarily sells to customers throughout the United States but also sells to international markets. Regardless of customer location, all customers are invoiced and payments are required to be made in U.S. dollars. The Company has elected to exclude sales and use taxes for non-exempt customers from the transaction price and, therefore, sales and use taxes are excluded from revenue.
Product Returns Sales Incentives And Other Forms Of Variable Consideration	Product Returns, Sales Incentives and Other Forms of Variable Consideration In measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Such elements of variable consideration include product return rights, discounts, rebates, volume discounts and rebates and promotional offers and other marketing offers that may impact net sales. For the sale of goods with a right of return, the Company only recognizes revenue for the consideration it expects to be entitled to (considering the products to be returned) and records a sales return accrual within other accrued expenses for the amount it expects to credit back to its customers. Given that most product returns cannot be resold to another customer, the Company does not recognize an asset in inventory, or a corresponding adjustment to cost of sales, for the right to recover goods from customers associated with the estimated returns. The sales return accrual includes estimates that directly impact reported net sales. These estimates are calculated based on a history of actual returns and estimated future returns. In addition, as necessary, sales return accruals may be established for significant future known or anticipated events. The types of known or anticipated events that are considered, and will continue to be considered, include the Company’s decision to continue to support new and existing products. Returns are handled on a case-by-case basis, but generally all returns are accepted if the customer is unsatisfied with the product. The Company has accrued an estimate for returns related to a future period. Sales returns accrued for the years ended December 31, 2021 and 2020 were approximately $ 50 thousand and $ 63 thousand, respectively, and reduced net sales. The Company estimates sales incentives and other variable consideration using the expected value method. The variable consideration included in the transaction price is the amount for which, that in the Company's judgment, is probable that a significant future reversal of cumulative revenue under the contract will not occur. Under this method, certain forms of variable consideration are based on volumes of sales to the customer, which requires subjective estimates. These estimates are supported by historical results as well as specific facts and circumstances related to the current period. A select few customers, because of their size, are offered a discount for early payment. The Company also enters into transactions and makes payments to certain of its customers related to advertising, some of which involve cooperative relationships with customers. These activities may be arranged either with unrelated third parties or in conjunction with the customer. To the extent that the Company receives a distinct good or service in exchange for consideration and the fair value of the benefit can be reasonably estimated, the Company’s share of the costs of these transactions (regardless of to whom they were paid) are reflected as selling, general and administrative expenses in the accompanying consolidated statements of operations. The Company also enters into other advertising activities arranged with customers. These activities cannot be arranged with unrelated third parties, no distinct good or service is received in exchange for consideration and the fair value of the benefit is not reasonably estimated. The Company’s share of the costs for these transactions paid to customers are reflected as a reduction in the transaction price within net sales in the accompanying consolidated statements of operations. For certain sales, the Company incurs incremental costs of obtaining the contract through the form of sales commissions. The sales commissions incurred are short-term (less than 12 months in duration) and directly correlated to the sales generated and are therefore expensed as incurred. The following table presents revenue disaggregated by geography, as determined by the country products were shipped to: Year ended December 31, 2021 Year ended December 31, 2020 Amount Percentage Amount Percentage Domestic $ 174,359,631 94.1 % $ 129,061,117 93.2 % Foreign 10,886,394 5.9 % 9,393,807 6.8 % Total sales $ 185,246,025 100.0 % $ 138,454,924 100.0 % The following table presents disaggregated revenues based upon sales channel: Year ended December 31, 2021 Year ended December 31, 2020 Amount Percentage Amount Percentage DTC subscription sales $ 22,172,505 12.0 % $ 15,406,597 11.1 % DTC transaction sales 51,702,198 27.9 % 38,246,752 27.6 % Professional/B2B 111,371,322 60.1 % 84,801,575 61.2 % Total $ 185,246,025 100.0 % $ 138,454,924 100.0 %
Cost of Sales	Cost of Sales Cost of sales includes the cost of inventory sold and includes all direct and indirect costs to bring the product to its saleable condition, including, inbound freight costs associated with inventory, inventory shrinkage costs, labor associated with manufacturing, lab testing, depreciation and amortization of assets used in the manufacturing process, costs to maintain production equipment, quality assurance costs and other costs associated with manufacturing.
Selling, General and Administrative Expenses	Selling, General and Administrative Selling, general and administrative expenses consist of payroll and related expenses for employees involved in general corporate functions, including accounting, finance, legal, selling and human resources; costs associated with use by these functions of facilities and equipment, such as depreciation expense and rent, share-based compensation expense, professional fees and other general corporate costs. It also includes shipping costs incurred in operating and staffing distribution operations, including costs attributable to picking, packaging and preparing customer orders for shipment, payment processing and related transaction costs, and responding to inquiries from customers.
Shipping and Handling	Shipping and Handling The costs of out-bound freight are included in selling, general and administrative expenses and totaled approximately $ 8.6 million and $ 6.2 million for the years ended December 31, 2021 and 2020, respectively.
Advertising	Advertising The cost of advertising is expensed as incurred. Advertising expense was approximately $ 23.4 million and $ 7.8 million for the years ended December 31, 2021 and 2020, respectively, and is included within marketing expense in the consolidated statements of operations.
Research and Development	Research and Development Research and development costs, which are expensed as incurred, totaled approximately $ 5.9 million and $ 4.2 million for the years ended December 31, 2021 and 2020, respectively. Research and development costs include research payroll and payroll related costs, new product development and line extensions, clinical trials, product efficacy research, product shelf-life validation and new dietary ingredient research, among other things.
Stock-based Awards	Stock-based Awards The Company follows ASC 718 “Stock Compensation”, which provides guidance in accounting for share-based awards exchanged for services rendered and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of our stock-based payments. The volatility assumption used in the Black-Scholes-Merton model is based on the calculated historical volatility based on an analysis of reported data for a peer group of companies. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjust the estimated forfeiture rate based upon actual experience.
Common Stock Valuation	Common Stock Valuation Due to the absence of an active market for the Company’s common stock prior to the IPO, the Company has historically utilized methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants’ Audit and Accounting Practice Guide: Valuation of Privately-Held Company Equity Securities Issued as Compensation to estimate the fair value of its common stock. In determining the exercise prices for options granted, the Company has considered the fair value of the common stock as of the grant date. The fair value of the common stock has been determined based upon a variety of factors, including the prices at which the Company sold shares of its convertible preferred stock to outside investors in arms-length transactions, if any, and the superior rights, preferences and privileges of the preferred stock relative to the common stock at the time of each grant; the Company’s historical and forecasted performance and operating results and the lack of an active public market for the Company’s common stock. Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.
Income Tax	Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. We evaluate both the positive and negative evidence that is relevant in assessing whether we will realize the deferred tax assets. A valuation allowance is provided when it is more likely than not that some portion or all of the net deferred tax assets will not be realized. This projected realization is directly related to our future projections of the performance of our business and management’s planning initiatives at any point in time. As a result, valuation allowances are subject to change as proven business trends and planning initiatives develop. In accordance with the accounting standard for uncertainty in income taxes, liabilities for uncertain tax positions are recognized based on the two-step process prescribed by the accounting standards. The first step is to recognize the tax benefit from uncertain tax positions if it is more likely than not the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The second step is that the tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes interest and penalties related to income tax matters in income tax expense. Health Elements, LLC made a previous election to be taxed as a Subchapter C corporation. As such, a provision for income taxes has been made for this entity and is included in the consolidated financial statements. See Note 15 for additional information related to the provision for income taxes. In accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50 % within a three-year period results in an annual limitation on the Company’s ability to utilize its net operating loss carryforwards and general business credits, including the research and development credits, created during the tax periods prior to the change in ownership. During the course of preparing the Company’s consolidated financial statements as of and for the year ended December 31 2021, the Company completed an Internal Revenue Code Section 382 analysis of its historical net operating loss and tax credit carryforward amounts. As a result, a portion of the prior year net operating loss and tax credit carryforwards were determined to be limited. See Note 15 for additional information regarding the results of the Company's Section 382 analysis and related limitations. If the Company experiences another change in equity ownership which exceeds the Section 382 threshold, the Company’s net operating loss carryforwards and research and development credits may be subject to additional limitations.
Segments	Segments The Company operates in one reportable segment: the selling of innovative solutions and personalized approaches to health and wellness. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results and where the best future opportunities arise.
Loss Contingencies	Loss Contingencies Certain conditions may exist which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company, or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability is estimable, the liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed. Unasserted claims that are not considered probable of being asserted and those for which an unfavorable outcome is not reasonably possible have not been disclosed.
Fair Value Measurements	Fair Value Measurements ASC 820 , Fair Value Measurements and Disclosures, establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: • Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date. • Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. The carrying amounts of certain financial instruments, which include cash, receivables, accounts payable, accrued expenses, long-term debt and the line of credit approximate their fair values at December 31, 2021 and 2020 due to their short-term nature and management’s belief that their carrying amounts approximate the amount for which the assets could be sold or the liabilities could be settled.
Recent Accounting Pronouncements – Adopted	Recently Adopted Accounting Pronouncements ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. In December 2019, the FASB issued this ASU to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This ASU also clarifies and simplifies other aspects of the accounting for income taxes. This update became effective at the beginning of the Company’s 2021 fiscal year. The adoption of this ASU did not have any impact on the consolidated financial statements and related disclosures. Recent Accounting Pronouncements ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. In June 2016, the FASB issued this ASU to amend the current accounting guidance which requires the measurement of all expected losses to be based on historical experience, current conditions and reasonable and supportable forecasts. For trade receivables, loans, and other financial instruments, the Company will be required to use a forward-looking expected loss model that reflects probable losses rather than the incurred loss model for recognizing credit losses. This ASU was amended by ASU 2019-10 to be effective for smaller reporting companies beginning after December 15, 2022. The Company does not believe the adoption of this ASU will have a material impact on its consolidated financial statements and related disclosures. ASU 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting. In March 2020, the FASB issued guidance providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020 and can be applied through December 31, 2022, has not impacted the Company’s consolidated financial statements. The Company has various contracts that reference LIBOR and is assessing how this standard may be applied to specific contract modifications through December 31, 2022. ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. In August 2020, the FASB issued this ASU to simplify the accounting for convertible instruments. This ASU also requires entities to use the if-converted method for all convertible instruments in calculating diluted earnings-per-share. The ASU is effective for annual periods beginning after December 15, 2021 with early adoption permitted. The Company is currently evaluating the impact that this guidance may have on its consolidated financial statements and related disclosures. ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force. In May 2021, the FASB issued this ASU to provide explicit guidance on accounting by issuers for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after the modification or exchange. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact that this guidance may have on its consolidated financial statements and related disclosures. ASU 2021-08, Business Combinations – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . In October 2021, the FASB issued guidance intended to improve the accounting for acquired revenue contracts with customer in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to fair value on the date of acquisition. The standard will be effective for business combinations occurring after January 1, 2023. Early adoption is permitted. The Company is currently evaluating the impact that this guidance may have on its consolidated financial statements and related disclosures. No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our consolidated financial statements. COVID-19 Pandemic and CARES Act On January 30, 2020, the World Health Organization (WHO) announced a global health emergency because of a new strain of coronavirus (COVID-19) and the risks to the international community as the virus spreads globally. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. The Company is a manufacturer of nutritional supplement products, a category of food that is regulated by the U.S. Food and Drug Administration. Based on guidance issued by the U.S. Department of Homeland Security and the Cybersecurity and Infrastructure Security Agency, and in particular, specific guidance therein regarding the food and agriculture industries, the Company’s manufacturing facility has been designated as “Essential Critical Infrastructure Workers” and would therefore be exempt from any “shelter in place” restrictions that might be imposed by the State of South Carolina. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the impact this pandemic on the Company’s financial condition. Management is actively monitoring the impact of this virus on its financial condition, liquidity, operations, suppliers, customers and workforce. On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property. The Company deferred the employer portion of payroll taxes during the year ended December 31, 2020. During the year ended December 31, 2021, the Company paid $ 0.5 million of the deferred payroll taxes. As of December 31, 2021, the remaining total amount deferred was approximately $ 0.5 million and will be payable by December 31, 2022 . The Company’s consolidated financial statements presented herein reflect the latest estimates and assumptions made by management that affect the reported amounts of assets and liabilities and related disclosures as of the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting periods presented.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Concentration of Risk	Major customers who accounted for more than 10 % of the Company’s total receivables were as follows: As of December 31, 2021 2020 iHerb, Inc. 41.3 % * Emerson Ecologics, LLC 33.3 % 39.4 % * Represents less than 10% Sales - Major customers who accounted for more than 10 % of the Company’s total sales were as follows: Years ended December 31, 2021 2020 Pattern Inc. 27.0 % 26.1 % iHerb, Inc. * 11.3 % * Represents less than 10%
Schedule of Estimated Useful Lives Property and Equipment	The estimated useful lives of property and equipment are as follows: Machinery and equipment 3 to 15 years Furniture and fixtures 3 to 7 years Office equipment 3 to 7 years Leasehold improvements 3 to 20 years Vehicles 7 years Lab equipment 5 to 10 years Software 7 years
Summary of Revenue Disaggregated by Geography	The following table presents revenue disaggregated by geography, as determined by the country products were shipped to: Year ended December 31, 2021 Year ended December 31, 2020 Amount Percentage Amount Percentage Domestic $ 174,359,631 94.1 % $ 129,061,117 93.2 % Foreign 10,886,394 5.9 % 9,393,807 6.8 % Total sales $ 185,246,025 100.0 % $ 138,454,924 100.0 %
Summary of Revenues Based Upon Sales Channel	The following table presents disaggregated revenues based upon sales channel: Year ended December 31, 2021 Year ended December 31, 2020 Amount Percentage Amount Percentage DTC subscription sales $ 22,172,505 12.0 % $ 15,406,597 11.1 % DTC transaction sales 51,702,198 27.9 % 38,246,752 27.6 % Professional/B2B 111,371,322 60.1 % 84,801,575 61.2 % Total $ 185,246,025 100.0 % $ 138,454,924 100.0 %

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Summary of Loan amounts, options purchased, loan repayment amounts, and total share issuance values	Loan amounts, options purchased, loan repayment amounts, and total share issuance values are as follows: Amount Borrowed Shares and Options Purchased Amount Paul Jacobson $ 525,160 $ 801,000 $ 556,813 Tom McKenna 525,160 801,000 556,813 Will McCamy 334,020 667,500 354,152 Scott Wheeler 101,460 135,280 107,575 Kim Pearson 45,980 56,515 48,751
Summary of Company-issued Loans to Certain Executive Officers to Pay the AMT Associated	The amount of the loans are as follows: Amount Paul Jacobson $ 320,000 Tom McKenna 250,000 Will McCamy 130,000 Scott Wheeler — Kim Pearson 10,000 $ 710,000

Mergers and Acquisitions (Table

Mergers and Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combination And Asset Acquisition [Abstract]
Summary of the Assets and Liabilities Acquired	The assets and liabilities acquired based on their fair value were as follows: Cash $ 11,823 Accounts receivable 8,686 Prepaid expenses and other current assets 711,389 Inventories 10,051 Property and equipment 914,716 Operating lease right-of-use asset 410,732 Intangible asset consisting of in process research and development 1,563,015 Other assets 22,782 Accounts payable ( 701,242 ) Other accrued expenses ( 864,483 ) Current portion of operating lease obligations ( 263,509 ) Long term operating lease, net of current portion ( 147,223 ) Net assets acquired $ 1,676,737 Less: non-controlling interest ( 209,592 ) Net assets acquired by Thorne HealthTech, Inc. $ 1,467,145

Consolidated Variable Interes_2

Consolidated Variable Interest Entities (Tables)	12 Months Ended
	Dec. 31, 2021
Health Elements L L C [Member]
Variable Interest Entity [Line Items]
Schedule of Variable Interest Entities	Summary information for Health Elements, excluding intercompany activity with the Company and Onegevity, is included in the consolidated balance sheets and statements of operations as follows, as of and for the year ended December 31: 2020 Total assets $ — Less liabilities — Net assets (liabilities) $ — Revenue $ 566,000 Net loss $ ( 112,000 )
Onegevity Health L L C [Member]
Variable Interest Entity [Line Items]
Schedule of Variable Interest Entities	Summary information for Onegevity, excluding intercompany activity with the Company and Health Elements, is included in the consolidated balance sheets and statements of operations as follows, as of and for the year ended December 31: 2020 Total assets $ 1,728,000 Less liabilities 545,000 Net assets (liabilities) $ 1,183,000 Revenue $ 2,776,000 Net loss $ ( 881,000 )

Inventories, net (Tables)

Inventories, net (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories are as follows: December 31, 2021 2020 Raw materials $ 22,620,773 $ 13,751,348 Work in process 422,196 7,224 Finished goods 18,413,853 14,808,931 Reserve for slow moving and obsolete inventory ( 444,698 ) ( 501,479 ) Inventory, net $ 41,012,124 $ 28,066,024

Property and Equipment, net (Ta

Property and Equipment, net (Table)	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Components of Property and Equipment	Property and equipment are as follows: December 31, 2021 2020 Machinery and equipment $ 9,937,510 $ 7,248,706 Furniture and fixtures 491,173 351,935 Office equipment 1,111,141 1,032,311 Leasehold improvements 19,431,916 18,858,225 Vehicles 98,282 98,282 Lab equipment 2,930,059 1,755,985 Purchased software 2,107,327 1,716,069 Total property and equipment 36,107,408 31,061,513 Less accumulated depreciation and amortization ( 11,262,651 ) ( 8,603,098 ) In-process assets including deposits on new equipment 2,185,643 731,315 Property and equipment, net $ 27,030,400 $ 23,189,730

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Table)	12 Months Ended
	Dec. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Finite-lived intangible assets are as follows: December 31, 2021 Gross Carrying Value Accumulated Amortization Net Customer relationships $ 6,500,000 $ ( 3,737,500 ) $ 2,762,500 Trade names 8,640,000 ( 6,866,667 ) 1,773,333 Existing technology/reformulations 3,207,923 ( 2,694,590 ) 513,333 Research and development formulas 800,000 ( 800,000 ) — License agreements 8,591,822 ( 7,048,672 ) 1,543,150 $ 27,739,745 $ ( 21,147,429 ) $ 6,592,316 December 31, 2020 Gross Carrying Value Accumulated Amortization Net Customer relationships $ 6,500,000 $ ( 3,412,500 ) $ 3,087,500 Trade names 8,640,000 ( 6,360,000 ) 2,280,000 Existing technology/reformulations 3,207,923 ( 2,547,923 ) 660,000 Research and development formulas 800,000 ( 800,000 ) — License agreements 7,841,365 ( 6,233,612 ) 1,607,753 $ 26,989,288 $ ( 19,354,035 ) $ 7,635,253
Schedule Of Finite Lived Intangible Asset Weighted Average Remaining Lives	The Company's finite-lived intangible assets had the following remaining lives as of December 31, 2021: Weighted-Average Remaining Life Customer relationships 8.5 Trade names 3.5 Existing technology/reformulations 3.5 Research and development formulas — License agreements 4.3
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Following is the future amortization of the finite-lived intangible assets as of December 31, 2021: Year Ending December 31, Amount 2022 $ 1,637,067 2023 1,416,233 2024 1,105,817 2025 685,400 2026 358,734 Thereafter 1,389,065 $ 6,592,316

Equity-method Investments (Tabl

Equity-method Investments (Tables)	12 Months Ended
	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Schedule Of Equity-method investments	Equity-method investments are as follows: December 31, 2021 December 31, 2020 Carrying Economic Carrying Economic Drawbridge Health, Inc. (1) $ — 87.5 % $ 3,382,147 11.2 % Tecton Group LLC — 30.0 % — 44.4 % NR Therapeutics LLC 963,685 49.0 % — — Total $ 963,685 $ 3,382,147 (1) On April 26, 2021, the Company entered into a merger agreement with Drawbridge Health, Inc., to acquire the majority of the remaining outstanding shares. See Note 4 for additional information related to the Drawbridge merger transaction.
Summary of income (loss) of equity-method investees	The following summarizes the (loss) income of equity-method investees: Years ended December 31, 2021 2020 Drawbridge Health, Inc. (1) $ ( 3,173,106 ) $ ( 894,689 ) Tecton Group LLC ( 704,637 ) ( 615,015 ) NR Therapeutics LLC 213,685 — Total $ ( 3,664,058 ) $ ( 1,509,704 ) (1) Represents the Company’s proportionate share of net loss for the period of January 1, 2021 through April 26, 2021 (the date of merger).

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-term debt balances and associated interest rates and maturities are as follows: December 31, December 31, Note payable with quarterly principal and interest payments of $ 30,917 per quarter, with fixed interest of 6.94 % and maturity August 12, 2024 . $ 286,255 $ 346,436 Note payable with quarterly principal and interest payments of $ 30,917 per quarter, with fixed interest of 6.94 % and maturity July 15, 2023 . 202,142 346,435 Note payable with quarterly principal and interest payments of $ 56,548 per quarter, with fixed interest of 4.89 % and maturity March 20, 2025 . 675,836 — Note payable with quarterly principal and interest payments of $ 8,250 per quarter, with fixed interest of 5.44 % and maturity September 10, 2026 . 413,574 — 1,577,807 692,871 Less current maturities ( 494,173 ) ( 223,400 ) Long-term debt $ 1,083,634 $ 469,471
Schedule of Aggregate Maturities of Long-term Debt	The contractual maturities of the Company's long-term debt as of December 31, 2021 are as follows: Year Ending December 31, Amount 2022 $ 494,173 2023 493,044 2024 369,827 2025 148,170 2026 72,593 Thereafter — $ 1,577,807

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Summary of Operating and Finance Leases	December 31, 2021 December 31, 2020 Operating lease: Operating lease right-of-use assets $ 17,836,756 $ 17,740,816 Current portion of operating lease obligations 2,633,236 2,603,930 Operating lease obligations, net of current portion 27,605,739 27,284,356 Total operating lease liabilities $ 30,238,975 $ 29,888,286 Finance lease: Finance right-of-use assets $ 883,076 $ 767,237 Current portion of finance lease obligations 413,487 269,212 Finance lease obligation, net of current portion 482,544 454,857 Total finance lease liabilities $ 896,031 $ 724,069
Summary of Lease Expense	The components of lease expense are as follows within our consolidated statement of operations: Years ended December 31, 2021 2020 Operating lease expense: Operating lease cost (1) $ 5,692,735 $ 5,062,144 Finance lease expense: Amortization of leased assets 424,961 210,262 Interest on lease liabilities 52,511 22,947 Total lease expense $ 6,170,207 $ 5,295,353 (1) Includes short-term leases and variable lease costs, which are immaterial.
Schedule of Lease Terms and Discount Rate	The weighted average remaining lease term and weighted average discount rate at December 31, were as follows: December 31, 2021 December 31, 2020 Weighted average remaining lease term (years) Operating leases 13.73 years 15.53 years Finance leases 2.33 years .02 years Weighted average discount rate applied Operating leases 9.2 % 12.1 % Finance leases 6.1 % 4.7 %
Summary of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases where the Company is the lessee is as follows: Years ended December 31, 2021 2020 Operating cash outflows from operating leases $ 4,794,134 $ 5,399,423 Operating cash outflows from finance leases (interest payments) 52,511 22,947 Financing cash outflows from finance leases 377,880 177,461 Leased assets obtained in exchange for finance lease liabilities 540,433 694,108 Leased assets obtained in exchange for operating lease liabilities 2,913,002 4,259,688
Summary of Maturities of Operating and Finance Lease Liabilities	As of December 31, 2021, the maturities of the operating and finance lease liabilities are as follows: Period Operating leases Finance leases 2022 $ 5,120,933 $ 452,669 2023 3,497,422 326,112 2024 3,589,920 140,146 2025 3,559,583 16,764 2026 3,325,639 38,942 Thereafter 35,705,778 — Total minimum lease payments $ 54,799,275 $ 974,633 Less: imputed interest 24,560,300 78,602 Total present value of lease liabilities $ 30,238,975 $ 896,031 Less: current portion 2,633,236 413,487 Long-term portion of lease liabilities $ 27,605,739 $ 482,544

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Warrants And Rights Note Disclosure [Abstract]
Schedule Fair Value Measurement Inputs and Valuation Techniques	The Black-Scholes model was used to value the liability-classified warrants. The following assumptions were used: December 31, 2021 2020 Fair market value $ 6.21 $ 6.67 Exercise Price $ 6.74 $ 6.74 Term 8.5 9.5 Volatility 75 % 68 % Annual dividend — — Risk-free interest rate 1.48 % 0.13 %
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	As of December 31, 2021 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 2,058,566 — — $ 2,058,566 As of December 31, 2020 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 3,930,930 — — $ 3,930,930
Summary Of Change in Fair value, as Determined by Level 3 inputs, for all Assets and Liabilities	The following table summarizes the change in fair value, as determined by Level 3 inputs, for all assets and liabilities using unobservable Level 3 inputs: Warrant Balance at December 31, 2019 $ 2,018,443 Change in fair value for 2020 1,912,487 Balance at December 31, 2020 3,930,930 Change in fair value for 2021 ( 1,872,364 ) Balance at December 31, 2021 $ 2,058,566

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	The following table summarizes all stock option activity for the year ended December 31, 2021: Options Outstanding Weighted- Weighted Average Remaining Contractual Term (Years) Aggregate (1) Outstanding as of January 1, 2021 7,811,975 $ 4.66 6.30 N/A Granted (2) 1,959,335 7.65 Exercised ( 39,614 ) 1.91 Cancelled/forfeited ( 32,040 ) 5.12 Outstanding as of December 31, 2021 9,699,656 5.28 6.22 $ 12.3 Vested and expected to vest after December 31, 2021 9,699,656 $ 5.28 6.22 $ 12.3 Exercisable, December 31, 2021 5,691,541 $ 4.29 5.73 $ 10.9 (1) Aggregate intrinsic value represents the difference between the closing fair value of the underlying common stock and the exercise price of outstanding, in-the-money options on the date of measurement. (2) During the year ended December 31, 2021, the Company issued 1,959,335 stock options in exchange for outstanding stock options of Onegevity at the time of, and in conjunction with the merger agreement as further discussed in Note 4. As a result of the stock option exchange being determined to be materially a “like-for-like” transaction, there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the stock options immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. These stock options contain an accelerated vesting provision whereby upon the completion of an IPO by the Company or qualified change-in-control, any related and unvested stock options would become fully vested. Upon the Company’s IPO on September 22, 2021, all 1,959,335 stock options issued in connection with the Onegevity merger fully vested.
Schedule Of Stock Options Outstanding	The following information summarizes the Company’s stock options outstanding for the periods presented: For the year ended December 31, 2021 2020 Weighted-average grant date fair value of stock options granted (1) N/A N/A Grant date fair value of stock options vested (2) $ 963,205 $ 963,205 Intrinsic value of stock options exercised (3) $ 219,813 N/A (1) During the years ended December 31, 2021 and 2020, there were no options granted by the Company. During the year ended December 31, 2021 and in connection with the Onegevity merger, the Company issued 1,959,335 options in exchange for outstanding stock options of Onegevity. As a result of the stock option exchange being determined to be materially a “like-for-like” transaction, there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the stock options immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. These stock options issued in connection with the Onegevity merger have been excluded from the information presented for the year ended December 31, 2021. (2) During the year ended December 31, 2021 and in connection with the Onegevity merger, the Company issued 1,959,335 options in exchange for outstanding stock options of Onegevity. These stock options contained an accelerated vesting provision whereby upon the completion of an IPO by the Company or qualified change-in-control, any related and unvested stock options would become fully vested. Upon the Company’s IPO on September 22, 2021, all 1,959,335 stock options issued in connection with the Onegevity merger fully vested. These vested stock options issued in connection with the Onegevity merger have been excluded from the information presented for the year ended December 31, 2021. (3) Shares of the Company’s common stock, traded under the symbol “THRN,” have been publicly traded since September 23, 2021, when the Company’s common stock was listed and began trading on the Nasdaq Global Select Market (the “Nasdaq”). No market for the Company’s stock existed prior to September 23, 2021. Accordingly, the total intrinsic value of stock options exercised excludes options exercised for the year ended December 31, 2020, prior to the IPO date. There were no stock option exercises prior to the IPO date during the year ended December 31, 2021.
Schedule of Non Vested Restricted Stock Shares Activity	The following table summarizes all RSU activity for the year ended December 31, 2021: Number Weighted- Outstanding as of December 31, 2020 — $ — Granted (1) 3,879,350 9.99 Released 472,590 11.17 Cancelled/forfeited — — Outstanding as of December 31, 2021 3,406,760 $ 9.82 Vested and expected to vest after December 31, 2021 3,406,760 $ 9.82 (1) 472,590 RSUs granted during the year ended December 31, 2021 were granted in exchange for profits interest units held by employees of Onegevity in conjunction with the merger agreement as further discussed in Note 4. As a result of the RSU exchange, there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the RSUs immediately before and after the exchange and determined that the exchange resulted in no incremental compensation expense. These RSUs contain an accelerated vesting provision whereby upon the completion of an IPO by the Company or qualified change-in-control, any unvested shares would become fully vested. Upon the Company’s IPO on September 22, 2021, all restrictions on the 472,590 unvested RSUs were released.
Schedule of RSUs	The following table summarizes additional information related to RSUs for the periods presented: For the year ended December 31, 2021 2020 Weighted-average grant date fair value of RSUs granted (1)(2) $ 9.99 N/A Grant date fair value of RSUs vested (2)(3) $ - $ - Intrinsic value of RSUs released (2)(4) $ - $ - (1) During the year ended December 31, 2021, there were 875,760 RSUs issued prior to the Company’s IPO and an additional 2,531,000 RSUs issued after the IPO and prior to December 31, 2021. Shares of the Company’s common stock, traded under the symbol “THRN,” have been publicly traded since September 23, 2021, when the Company’s common stock was listed and began trading on the Nasdaq Global Select Market (Nasdaq). Accordingly, no market for the Company’s stock existed prior to September 23, 2021. Accordingly, the total intrinsic value of RSUs granted excludes the 875,760 RSUs granted prior to the IPO date. There were no RSUs granted during the year ended December 31, 2020. (2) During the year ended December 31, 2021 and in connection with the Onegevity merger, the Company issued 472,590 RSUs in exchange for outstanding profits interest units held by employees of Onegevity. As a result of the RSU exchange being determined to be materially a “like-for-like” transaction, there was no incremental stock compensation expense recorded by the Company. The Company compared the fair value of the RSUs immediately before and after the exchange and determined that the exchange did not result in incremental compensation expense. These RSUs issued in connection with the Onegevity merger have been excluded from the information presented for the year ended December 31, 2021. (3) During the years ended December 31, 2021 and 2020, there were no RSUs that vested. (4) During the years ended December 31, 2021 and 2020, there were no RSUs that were released.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense	The components of income tax expense consist of the following: Years Ended 2021 2020 Current Federal $ — $ — State 411,919 176,758 Net income tax expense $ 411,919 $ 176,758
Schedule of Deferred Tax Assets and Liabilities	The significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2021 2020 Deferred tax assets: Net operating losses $ 19,538,932 $ 13,547,317 AMT/Federal credit 897,616 — State credits 2,485,652 2,031,797 Lease liability ASC 842 7,271,783 7,152,442 Disallowed interest expense 164,921 164,984 Share-based compensation 495,960 — Impairment 464,720 — Other 691,010 976,746 Total deferred tax assets $ 32,010,594 $ 23,873,286 Deferred tax liabilities: Basis difference on fixed assets $ ( 4,114,426 ) $ ( 3,569,913 ) Basis difference on intangibles ( 1,427,816 ) ( 1,066,468 ) Prepaid expenses ( 709,653 ) ( 100,995 ) Right-of-use asset ASC 842 ( 4,372,138 ) ( 4,324,325 ) Other ( 72,714 ) — Total deferred liabilities ( 10,696,747 ) ( 9,061,701 ) Net deferred tax asset 21,313,847 14,811,585 Less valuation allowance ( 21,313,847 ) ( 14,811,585 ) Net deferred tax asset (liability) post valuation allowance $ — $ —
Schedule of Effective Tax Rate Differs from Statutory Federal Tax Rate	The effective tax rate differs from the statutory federal tax rate as follows: Years Ended December 31, 2021 2020 Federal income tax at the statutory rate U.S. federal rate $ 1,851,313 21.0 % $ ( 835,808 ) 21.0 % State taxes, net of federal 325,416 3.8 % 128,075 ( 3.2 %) Permanent items 693,699 7.9 % 2,571,620 ( 64.6 %) Change in valuation allowance ( 2,383,291 ) ( 27.0 %) ( 1,659,594 ) 41.7 % Return to provision adjustments 8,665 0.1 % — 0.0 % Nondeductible expenses and other ( 83,883 ) ( 1.0 %) ( 27,535 ) 0.7 % Income tax expense $ 411,919 $ 176,758 Effective income tax rate 4.7 % 4.4 %

Basic and Diluted Net Income _2

Basic and Diluted Net Income (Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Summary of Net Income (loss) Per Share	The following table presents information necessary to calculate net income (loss) per share for the year ended December 31, 2021 and 2020: Year Ended December 31, 2021 2020 Numerator: Net income (loss) attributable to Thorne HealthTech, Inc. $ 7,253,423 $ ( 3,357,746 ) Undistributed earnings attributable to Series E convertible preferred stockholders ( 3,507,892 ) — Numerator for basic EPS—net income (loss) available to Thorne HealthTech, Inc. common stockholders (A) 3,745,531 ( 3,357,746 ) Effect of dilutive securities: Change in fair value of warrant liability ( 1,872,364 ) — Undistributed earnings attributable to Series E convertible preferred stockholders—basic 3,507,892 Undistributed earnings attributable to Series E convertible preferred stockholders—diluted ( 2,031,751 ) — ( 396,223 ) — Numerator for diluted EPS—net income (loss) available to Thorne HealthTech, Inc. common stockholders (C) 3,349,308 ( 3,357,746 ) Denominator: Denominator for basic EPS - weighted average shares (B) 27,478,411 9,985,800 Effect of dilutive securities: Stock options 3,608,128 — RSUs 159,668 — Warrants 1,082,358 — Dilutive potential common shares 4,850,154 — Denominator for diluted EPS—adjusted weighted average common stock and common stock equivalents (D) 32,328,565 9,985,800 Basic EPS (A/B) $ 0.14 $ ( 0.34 ) Diluted EPS (C/D) $ 0.10 $ ( 0.34 ) (1) Approximately 4.2 million warrants and stock-based awards were excluded from the computation of diluted EPS for the years ended December 31, 2020, because the effect would have been anti-dilutive under the treasury stock method. (2) For the year ended December 31, 2020, diluted EPS is the same as basic EPS because the effects of potentially dilutive securities are anti-dilutive. (3) For the year ended December 31, 2021 and 2020, 19,611,089 and 27,011,500 of Series E convertible preferred stock were excluded from the computation of diluted EPS because the effect would have been anti-dilutive under the 'if-converted' method

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Annual Minimum Commitments	Amount 2022 $ 1,030,000 2023 562,500 Total $ 1,592,500

Organization and Nature of Op_2

Organization and Nature of Operations - Additional Information (Details)	Jun. 17, 2010
Thorne Research Inc
Business combination, Percentage of voting interest acquired	100.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	Sep. 10, 2021	Dec. 31, 2021USD ($)Number	Dec. 31, 2020USD ($)
Summary Of Significant Accounting Policies [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio	445
Allowance for doubtful accounts		$ 10,000
Impairment losses		0	$ 0
Impairment Losses, Investments		0	0
Equity Method Investment on Temporary Impairment		$ 0	0
Finite-Lived Intangible Asset, Useful Life		20 years
Finite-Lived Intangible Assets, Net		$ 6,592,316	7,635,253
Goodwill, Impairment Loss		0	0
Goodwill		$ 14,440,683	14,440,683
Revenue Performance Obligation Subscription Timing Allowed To Customer		45 days
Accrued Sales Returns Current		$ 50,000	63,000
Selling, general, and administrative		54,913,441	48,397,419
Advertising Expense		23,400,000	7,800,000
Research and development		$ 5,935,514	4,224,891
Number of Reportable Segments | Number		1
Operating lease right-of-use asset, net		$ 17,836,756	17,740,816
Operating Lease, Liability		30,238,975	29,888,286
Coronavirus Aid Relief And Economic Security Cares Act
Summary Of Significant Accounting Policies [Line Items]
Deferred payroll taxes, Paid		500,000
Deferred Payroll Taxes Accrued		$ 500,000
Deferred Payroll Taxes Payable, Date		Dec. 31, 2022
Outbound Freight [Member]
Summary Of Significant Accounting Policies [Line Items]
Selling, general, and administrative		$ 8,600,000	6,200,000
Sales Channel Professional Business To Business Sales [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue Performance Obligation Funds Collected At The Time Of Subscription		0
Revenue Performance Obligation Costs Collected At The Time Of Cancelation Or Modification Of Subscription		$ 0
Sales Channel Directly To Consumer Subscription Sales [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition Percentage Of Sales Discount Offered		10.00%
Number Of Days Within The Date Of Purchase Within Which Return Or Refund Request Must Be Submitted		60 days
Sales Channel Directly To Consumer Subscription Sales [Member] | Every Two Months Subscription
Summary Of Significant Accounting Policies [Line Items]
Revenue Performance Obligation Subscription Timing Allowed To Customer		2 months
Sales Channel Directly To Consumer Subscription Sales [Member] | Every Three Months Subscription
Summary Of Significant Accounting Policies [Line Items]
Revenue Performance Obligation Subscription Timing Allowed To Customer		3 months
Sales Channel Directly To Consumer Subscription Sales [Member] | Every Four Months Subscription
Summary Of Significant Accounting Policies [Line Items]
Revenue Performance Obligation Subscription Timing Allowed To Customer		4 months
Customer Relationships
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Net		$ 2,762,500	3,087,500
Trade Names
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Net		$ 1,773,333	2,280,000
In Process Research and Development
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		10 years
Finite-Lived Intangible Assets, Net
Licensing Agreements
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Net		$ 1,543,150	1,607,753
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Allowance for doubtful accounts			$ 34,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Change in equity ownership		50.00%
Minimum | Sales Channel Directly To Consumer Subscription Sales [Member] | Amazon
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition Percentage Of Sales Discount Offered		5.00%
Minimum | Trade Names
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		5 years
Minimum | Developed Technology Rights
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		3 years
Minimum | Licensing Agreements
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		3 years
Minimum | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		10.00%
Minimum | Customer Concentration Risk [Member] | Total Sales [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		10.00%
Maximum | Sales Channel Directly To Consumer Subscription Sales [Member] | Amazon
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition Percentage Of Sales Discount Offered		10.00%
Maximum | Trade Names
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		15 years
Maximum | Developed Technology Rights
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		15 years
Maximum | Licensing Agreements
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		15 years
Weighted Average | Sales Channel Directly To Consumer Subscription Sales [Member] | Amazon
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition Percentage Of Sales Discount Offered		6.00%
Machinery and equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		3
Machinery and equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		15
Furniture and fixtures | Minimum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		3
Furniture and fixtures | Maximum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		7
Office equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		3
Office equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		7
Leasehold improvements | Minimum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		3
Leasehold improvements | Maximum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		20
Vehicles
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		7
Lab equipment [Member] | Minimum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		5
Lab equipment [Member] | Maximum
Summary Of Significant Accounting Policies [Line Items]
Machinery and equipment		10

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Concentrations of Risk (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Total Receivable [Member] | Emerson Ecologics LLC [Member]
Concentration Risk [Line Items]
Concentration risk percentage	33.30%	39.40%
Total Receivable [Member] | iHerb, Inc. [Member]
Concentration Risk [Line Items]
Concentration risk percentage	41.30%
Total Sales [Member] | iHerb, Inc. [Member]
Concentration Risk [Line Items]
Concentration risk percentage		11.30%
Total Sales [Member] | Pattern Inc. [Member]
Concentration Risk [Line Items]
Concentration risk percentage	27.00%	26.10%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Machinery And Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	15
Machinery And Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	3
Furniture And Fixtures [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	7
Furniture And Fixtures [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	3
Office Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	7
Office Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	3
Leasehold Improvements [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	20
Leasehold Improvements [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	3
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	7
Lab equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	10
Lab equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	5
Software [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment Estimated Useful Lives	7

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Revenue Disaggregated by Geography (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Amount	$ 185,246,025	$ 138,454,924
Percentage of Total	100.00%	100.00%
Domestic Member [Member]
Disaggregation Of Revenue [Line Items]
Amount	$ 174,359,631	$ 129,061,117
Percentage of Total	94.10%	93.20%
Foreign Member [Member]
Disaggregation Of Revenue [Line Items]
Amount	$ 10,886,394	$ 9,393,807
Percentage of Total	5.90%	6.80%

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Summary of Revenues Based Upon Sales Channel (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Amount	$ 185,246,025	$ 138,454,924
Percentage of Total	100.00%	100.00%
Sales Channel Directly To Consumer Subscription Sales [Member]
Disaggregation Of Revenue [Line Items]
Amount	$ 22,172,505	$ 15,406,597
Percentage of Total	12.00%	11.10%
Sales Channel Directly To Consumer Transaction Sales [Member]
Disaggregation Of Revenue [Line Items]
Amount	$ 51,702,198	$ 38,246,752
Percentage of Total	27.90%	27.60%
Sales Channel Professional Business To Business Sales [Member]
Disaggregation Of Revenue [Line Items]
Amount	$ 111,371,322	$ 84,801,575
Percentage of Total	60.10%	61.20%

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	Oct. 04, 2021USD ($)	Apr. 21, 2021	Feb. 12, 2021USD ($)	Jan. 06, 2021shares	Oct. 16, 2020USD ($)Number	Feb. 14, 2020USD ($)	Apr. 30, 2019USD ($)	Mar. 19, 2019USD ($)	Feb. 28, 2019USD ($)	Dec. 03, 2018USD ($)	Jul. 05, 2018USD ($)$ / sharesshares	Feb. 28, 2020USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Oct. 29, 2021USD ($)	Sep. 22, 2021shares	Jul. 24, 2019USD ($)	Nov. 30, 2018USD ($)
Related Party Transaction [Line Items]
Ownership interest														3.46%
Revenues														$ 185,246,025	$ 138,454,924
Loan given															20,000,000
Related party receivables														366,590	225,693
Related party payable														1,634,775	809,080
Purchase of investment in equity-method investments														(704,637)	(615,015)
Security Deposit, Letter of credit														331,000
Restricted Cash														4,900,000	0
Ownership Percentage		11.20%		4.00%									87.50%
Shares Outstanding | shares				5,712
Net equity investment													$ 3,200,000		3,400,000
Certain liabilities paid in cash														1,400,000
Notes Issued							$ 1,500,000
Interest rate							5.00%
Repayment of Outstanding principal and interest														1,600,000
Agreement extending								one year
Mitsui Secondment Agreement [Member]
Related Party Transaction [Line Items]
Employment related expense														120,000
Related party payable														30,000	30,000
Paul Jacobson [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Purchases from Related Party														801,000
Kirin Holdings Company Limited [Member]
Related Party Transaction [Line Items]
Preferred Stock Shares Issued and Sold | shares											27,011,500
Purchase price | $ / shares											$ 5.12
Gross Proceeds from Issuance of Convertible Preferred Stock											$ 138,400,000
Series E convertible preferred stock converted into common stock | shares																	27,011,500
Kirin Holdings Company Limited [Member] | Revolving Credit Facility [Member]
Related Party Transaction [Line Items]
Loan given																		$ 3,000,000
Repayments Of Lines Of Credit												$ 128,000
Related party payable															0
Interest Expense															128,000
Kirin Holdings Company Limited [Member] | Juntendo Agreement [Member]
Related Party Transaction [Line Items]
DNA Services Samples | Number					600
Proceeds from DNA Sample Services					$ 129,000
Revenues														15,000	0
Receivables														0
Indena S P [Member] | Purchases Of Inventory [Member]
Related Party Transaction [Line Items]
Related party payable														1,400,000	613,000
Related Party Transaction, Purchases from Related Party														7,700,000	4,800,000
NR Therapeutics, LLC [Member] | Purchases Of Inventory [Member]
Related Party Transaction [Line Items]
Related party payable														175,000	153,000
Related Party Transaction, Purchases from Related Party														4,100,000	153,000
Tecton Group LLC [Member]
Related Party Transaction [Line Items]
Purchase of investment in equity-method investments														(705,000)	(615,000)
Nutrativa LLC [Member]
Related Party Transaction [Line Items]
Related party receivables														364,000	59,000
Revenue from Related Parties														125,000	28,000
Oova Inc [Member]
Related Party Transaction [Line Items]
Related party receivables															4,000
Revenue from Related Parties														28,000
Related party payable														43,000	43,000
Oova Inc [Member] | Investmen Made Related To Reimbursement Of Certain Distribution Costs Paid On Behalf Of Related Party [Member]
Related Party Transaction [Line Items]
Related party receivables														2,000
Kirin Secondment Agreement [Member]
Related Party Transaction [Line Items]
Related party payable														21,000	21,000
Related Party Transaction, Expenses from Transactions with Related Party														84,000
Kirin and Mitsui [Member]
Related Party Transaction [Line Items]
Repayments Of Lines Of Credit	$ 20,000,000
Related Party Transaction, Expenses from Transactions with Related Party														20,000,000
Annual fee			$ 20,000,000			$ 20,000,000
Line of Credit Facility, Maximum Amount Outstanding During Period			$ 20,000,000			$ 20,000,000
Kirin and Mitsui [Member] | Revolving Credit Facility [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party														4,900,000
Letter of credit Reimbursement																			$ 4,900,000
Annual fee																			$ 4,900,000
Security Deposit, Letter of credit										$ 4,900,000
Letter of credit expiration date										Dec. 3, 2019
Restricted interest-bearing account																$ 4,900,000
Restricted Cash														4,900,000
Kirin and Mitsui [Member] | Guarantee Fees Expenses [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party														203,000	352,000
Kirin and Mitsui [Member] | Guarantee Fees Expenses [Member] | Revolving Credit Facility [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party														134,000	237,000
Kirin and Mitsui [Member] | Feasibility Review Agreement [Member]
Related Party Transaction [Line Items]
Ownership interest								5.00%
Feasibility commercialization Amount								$ 500,000
Kirin and Mitsui [Member] | Mitsui Secondment Agreement [Member]
Related Party Transaction [Line Items]
Employment related expense															120,000
Related Party Transaction, Expenses from Transactions with Related Party															84,000
Services									$ 120,000
Kirin and Kyowa Hakko Bio [Member]
Related Party Transaction [Line Items]
Revenues														24,000	3,000
Receivables														0	0
Deferred Revenue														$ 98,000	0
Alternative Minimum Tax (AMT) Loan to Officers [Member]
Related Party Transaction [Line Items]
Ownership interest														5.00%
Outstanding loans														$ 0	$ 0
Repayment of Interest														$ 14,297

Related Party Transactions - Su

Related Party Transactions - Summary of loan amounts, options purchased, loan repayment amounts (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Amount Borrowed		$ 710,000
Paul Jacobson [Member]
Related Party Transaction [Line Items]
Amount Borrowed	$ 525,160	320,000
Shares and options purchased	801,000
Related Party Costs	556,813
Tom McKenna [Member]
Related Party Transaction [Line Items]
Amount Borrowed	525,160	250,000
Shares and options purchased	801,000
Related Party Costs	556,813
Will McCamy [Member]
Related Party Transaction [Line Items]
Amount Borrowed	334,020	130,000
Shares and options purchased	667,500
Related Party Costs	354,152
Scott Wheeler [Member]
Related Party Transaction [Line Items]
Amount Borrowed	101,460
Shares and options purchased	135,280
Related Party Costs	107,575
Kim Pearson [Member]
Related Party Transaction [Line Items]
Amount Borrowed	45,980	$ 10,000
Shares and options purchased	56,515
Related Party Costs	$ 48,751

Related Party Transactions - _2

Related Party Transactions - Summary of loans to certain executives officers to pay the AMT Associated (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Issued Loan to Certain Executive Officers		$ 710,000
Paul Jacobson [Member]
Related Party Transaction [Line Items]
Issued Loan to Certain Executive Officers	$ 525,160	320,000
Tom McKenna [Member]
Related Party Transaction [Line Items]
Issued Loan to Certain Executive Officers	525,160	250,000
Will McCamy [Member]
Related Party Transaction [Line Items]
Issued Loan to Certain Executive Officers	334,020	130,000
Scott Wheeler [Member]
Related Party Transaction [Line Items]
Issued Loan to Certain Executive Officers	101,460
Kim Pearson [Member]
Related Party Transaction [Line Items]
Issued Loan to Certain Executive Officers	$ 45,980	$ 10,000

Mergers and Acquisitions - Addi

Mergers and Acquisitions - Additional Information (Detail) - USD ($)	Apr. 26, 2021	Apr. 21, 2021	Jan. 06, 2021	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Asset Acquisition [Line Items]
Ownership interest					3.46%
Ownership Percentage		11.20%	4.00%	87.50%
Common Stock, Shares, Outstanding					52,554,214	12,323,830
Impairment loss on equity method investments					$ 0	$ 0
Non controlling interests of the acquiree asset acquisition					209,592
Write-off of acquired Drawbridge in-process research and development					$ 1,563,015
Common Class B [Member]
Asset Acquisition [Line Items]
Common Stock, Shares, Outstanding					0	0
Onegivity Health Inc
Asset Acquisition [Line Items]
Ownership interest						50.00%
Business combination stock options issued to the the key managers of the acquiree in a tax free exchange shares					1,959,335
Onegivity Health Inc | Common Class B [Member]
Asset Acquisition [Line Items]
Number of shares of equity interests issued or issuable to acquire entity					6,179,270
Common Stock, Shares, Outstanding					0
Onegivity Health Inc | Common Class B [Member] | Noncontrolling Interest [Member]
Asset Acquisition [Line Items]
Number of shares of equity interests issued or issuable to acquire entity					472,590
Drawbridge Health Inc
Asset Acquisition [Line Items]
Equity method investment net				$ 3,200,000			$ 3,200,000
Drawbridge Health Inc | Merger Agreement
Asset Acquisition [Line Items]
Ownership Percentage	11.20%
Equity Method Investment Percentage Acquired	76.30%				87.50%
Payment for net asset acquisition	$ 1,400,000
Drawbridge Health Inc | Net Asset Acquistion Of Drawbridge Investments
Asset Acquisition [Line Items]
Non controlling interests of the acquiree asset acquisition					$ 200,000
Write-off of acquired Drawbridge in-process research and development					$ 1,600,000
Equity interest					12.50%
Drawbridge Health Inc | Net Asset Acquistion Of Drawbridge Investments | Other Nonoperating Income (Expense)
Asset Acquisition [Line Items]
Gain loss on asset acquisition					$ 200,000
Drawbridge Health Inc | Equity Method Investment, Nonconsolidated Investee or Group of Investees
Asset Acquisition [Line Items]
Impairment loss on equity method investments					$ 3,000,000

Mergers and Acquisitions - Summ

Mergers and Acquisitions - Summary of the Assets and Liabilities Acquired Based on Their Fair Value (Detail)	Dec. 31, 2021USD ($)
Business Combination And Asset Acquisition [Abstract]
Cash	$ 11,823
Accounts receivable	8,686
Prepaid expenses and other current assets	711,389
Inventories	10,051
Property and equipment	914,716
Operating lease right-of-use asset	410,732
Intangible asset consisting of in process research and development	1,563,015
Other assets	22,782
Accounts payable	(701,242)
Other accrued expenses	(864,483)
Current portion of operating lease obligations	(263,509)
Long term operating lease, net of current portion	(147,223)
Net assets acquired	1,676,737
Less: non-controlling interest	(209,592)
Net assets acquired by Thorne HealthTech, Inc.	$ 1,467,145

Consolidated Variable Interes_3

Consolidated Variable Interest Entities - Schedule of Variable Interest Entities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Total assets	$ 175,299,877	$ 115,489,134
Revenues	185,246,025	138,454,924
Net loss	$ 7,253,423	(3,357,746)
Health Elements L L C [Member]
Variable Interest Entity [Line Items]
Total assets		0
Less liabilities		0
Net assets (liabilities)		0
Revenues		566,000
Net loss		(112,000)
Onegevity Health L L C [Member]
Variable Interest Entity [Line Items]
Total assets		1,728,000
Less liabilities		545,000
Net assets (liabilities)		1,183,000
Revenues		2,776,000
Net loss		$ (881,000)

Consolidated Variable Interes_4

Consolidated Variable Interest Entities - Additional Information (Details) - shares	Apr. 21, 2021	Jan. 06, 2021	Jul. 30, 2020	Jan. 01, 2020	Jul. 31, 2020	Mar. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Variable Interest Entity Ownership Percentage	11.20%	4.00%				87.50%
Health Elements L L C [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity Ownership Percentage			60.00%	60.10%
Onegevity Health L L C [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity Ownership Percentage			50.00%	45.00%	100.00%		50.00%
Investment Owned, Balance, Shares				50,000	50,000
Shares Owned, Increase in Number of Shares					58,252		58,252
Percentage of shares exchanged					60.00%
Additional shares issued in exchange					8,252

Inventories, net - Summary of I

Inventories, net - Summary of Inventories (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 22,620,773	$ 13,751,348
Work in process	422,196	7,224
Finished goods	18,413,853	14,808,931
Reserve for slow moving and obsolete inventory	(444,698)	(501,479)
Inventory, net	$ 41,012,124	$ 28,066,024

Property and Equipment, net - C

Property and Equipment, net - Components of Property and Equipment (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment	$ 36,107,408	$ 31,061,513
Less accumulated depreciation and amortization	(11,262,651)	(8,603,098)
In-process assets including deposits on new equipment	2,185,643	731,315
Property and equipment, net	27,030,400	23,189,730
Machinery and equipment
Property Plant And Equipment [Line Items]
Property and equipment	9,937,510	7,248,706
Furniture and fixtures
Property Plant And Equipment [Line Items]
Property and equipment	491,173	351,935
Office equipment
Property Plant And Equipment [Line Items]
Property and equipment	1,111,141	1,032,311
Leasehold improvements
Property Plant And Equipment [Line Items]
Property and equipment	19,431,916	18,858,225
Vehicles
Property Plant And Equipment [Line Items]
Property and equipment	98,282	98,282
Lab equipment
Property Plant And Equipment [Line Items]
Property and equipment	2,930,059	1,755,985
Purchased software
Property Plant And Equipment [Line Items]
Property and equipment	$ 2,107,327	$ 1,716,069

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
In Process Assets Depreciation	$ 0
Depreciation and amortization expense	$ 2,700,000	$ 2,200,000

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 27,739,745	$ 26,989,288
Accumulated amortization	(21,147,429)	(19,354,035)
Net Carrying Value	6,592,316	7,635,253
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Gross Carrying Value	6,500,000	6,500,000
Accumulated amortization	(3,737,500)	(3,412,500)
Net Carrying Value	2,762,500	3,087,500
Trade Names
Finite Lived Intangible Assets [Line Items]
Gross Carrying Value	8,640,000	8,640,000
Accumulated amortization	(6,866,667)	(6,360,000)
Net Carrying Value	1,773,333	2,280,000
Existing technology/reformulations
Finite Lived Intangible Assets [Line Items]
Gross Carrying Value	3,207,923	3,207,923
Accumulated amortization	(2,694,590)	(2,547,923)
Net Carrying Value	513,333	660,000
Research and development formulas
Finite Lived Intangible Assets [Line Items]
Gross Carrying Value	800,000	800,000
Accumulated amortization	(800,000)	(800,000)
Net Carrying Value
Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Gross Carrying Value	8,591,822	7,841,365
Accumulated amortization	(7,048,672)	(6,233,612)
Net Carrying Value	$ 1,543,150	$ 1,607,753

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Amortization of Intangible Assets	$ 1.8	$ 2.1
Goodwill	14.4
Payments under license agreements, Intangible Assets	1.5	1.6
Thorne Research Inc [Member]
Restructuring Cost and Reserve [Line Items]
Intangible assets Acquired from acquisition	$ 5	$ 6

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule Of Finite Lived Intangible Asset Weighted Average Remaining Life (Details)	12 Months Ended
	Dec. 31, 2021
Customer Relationships
Indefinite-lived Intangible Assets [Line Items]
Finite Lived Intangible Asset Weighted Average Remaining Life	8 years 6 months
Trade Names
Indefinite-lived Intangible Assets [Line Items]
Finite Lived Intangible Asset Weighted Average Remaining Life	3 years 6 months
Existing technology/reformulations
Indefinite-lived Intangible Assets [Line Items]
Finite Lived Intangible Asset Weighted Average Remaining Life	3 years 6 months
Licensing Agreements
Indefinite-lived Intangible Assets [Line Items]
Finite Lived Intangible Asset Weighted Average Remaining Life	4 years 3 months 18 days

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
2022	$ 1,637,067
2023	1,416,233
2024	1,105,817
2025	685,400
2026	358,734
Thereafter	1,389,065
Intangible assets, net	$ 6,592,316	$ 7,635,253

Investments - Additional Inform

Investments - Additional Information (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]
Equity securities invested	$ 400,000	$ 400,000
Ownership interest	3.46%

Equity-method Investments - Sch

Equity-method Investments - Schedule of Equity-method investments (Details) - USD ($)		Dec. 31, 2021	Dec. 31, 2020
Schedule Of Equity Method Investments [Line Items]
Carrying Amount		$ 963,685	$ 3,382,147
Drawbridge Health Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Carrying Amount	[1]	$ 0	$ 3,382,147
Economic Interest	[1]	87.50%	11.20%
Tecton Group LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Carrying Amount		$ 0	$ 0
Economic Interest		30.00%	44.40%
NR Therapeutics, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Carrying Amount		$ 963,685	$ 0
Economic Interest		49.00%	0.00%
[1]	On April 26, 2021, the Company entered into a merger agreement with Drawbridge Health, Inc., to acquire the majority of the remaining outstanding shares. See Note 4 for additional information related to the Drawbridge merger transaction.

Equity-method Investments - Sum

Equity-method Investments - Summary of income (loss) of equity-method investees (Details) - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Schedule Of Equity Method Investments [Line Items]
Income (loss) of equity-method investees		$ 3,664,058	$ 1,509,704
Related Party Transaction, Amounts of Transaction			710,000
Equity Method Investee [Member]
Schedule Of Equity Method Investments [Line Items]
Income (loss) of equity-method investees		3,664,058	1,509,704
Drawbridge Health Inc | Equity Method Investee [Member]
Schedule Of Equity Method Investments [Line Items]
Income (loss) of equity-method investees	[1]	3,173,106	894,689
Tecton Group LLC [Member] | Equity Method Investee [Member]
Schedule Of Equity Method Investments [Line Items]
Income (loss) of equity-method investees		704,637	615,015
NR Therapeutics, LLC [Member] | Equity Method Investee [Member]
Schedule Of Equity Method Investments [Line Items]
Income (loss) of equity-method investees		$ (213,685)	$ 0
[1]	Represents the Company’s proportionate share of net loss for the period of January 1, 2021 through April 26, 2021 (the date of merger).

Equity-method Investments - Add

Equity-method Investments - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Equity Method Investments [Line Items]
Ownership interest	3.46%
Tecton Group LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Ownership interest	30.00%	44.00%
Suspended loss	$ 138,566
NR Therapeutics, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Ownership interest	49.00%
Common Unit, Issuance Value	$ 750,000
Purchase of Common Units	49
Asset Impairment Charges	$ 0	$ 0

Debt - Additional information (

Debt - Additional information (Details) - USD ($)	Oct. 29, 2021	Oct. 13, 2021	Oct. 04, 2021	Feb. 12, 2021	Feb. 14, 2020	Dec. 31, 2018	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Feb. 11, 2022
Line Of Credit Facility [Line Items]
Purchased Equipment Aggregate Book Value							$ 1,900,000
Guarantee fees							$ 336,915	$ 243,040
Sumitomo Mitsui Banking Corporation [Member] | Guarantee Fees
Line Of Credit Facility [Line Items]
Guarantee fee expense								237,000
Line of Credit
Line Of Credit Facility [Line Items]
Line of Credit Facility, Current Borrowing Capacity						$ 20,000,000			$ 20,000,000
Line of credit facility, interest rate during period						0.25%
Long-term line of credit						$ 11,200,000			$ 11,200,000
Line of credit facility, expiration date						Dec. 31, 2023
Line of Credit | London Interbank Offered Rate (LIBOR)
Line Of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate							1.75%
Standby Letter of Credit [Member] | Other Accrued Expenses [Member]
Line Of Credit Facility [Line Items]
Accrued guarantee fees								13,000
Standby Letter of Credit [Member] | London Interbank Offered Rate (LIBOR) | Guarantee Fees
Line Of Credit Facility [Line Items]
Line of credit facility, maturity period									12 months
Line of credit facility, annual fee of guarantor, percentage									3.00%
Long-term line of credit						$ 4,900,000			$ 4,900,000
Line of credit facility, expiration date									Dec. 3, 2019
Line of credit facility renewal date									Oct. 31, 2037
Line of credit facility annual fees amount									$ 20,000
Standby Letter of Credit [Member] | Sumitomo Mitsui Banking Corporation [Member]
Line Of Credit Facility [Line Items]
Guarantee fee expense							$ 134,000
Line of credit facility, annual fee of guarantor, percentage	50.00%
Line of credit facility, guarantee fee	$ 4,900,000
2020 Credit Agreement [Member] | Financial Guarantee [Member]
Line Of Credit Facility [Line Items]
Percentage of guarantee fee on outstanding borrowings				1.20%	2.00%
2020 Credit Agreement [Member] | Sumitomo Mitsui Banking Corporation [Member]
Line Of Credit Facility [Line Items]
Proceeds from revolving line of credit					$ 20,000,000
2020 Credit Agreement [Member] | Sumitomo Mitsui Banking Corporation [Member] | Minimum
Line Of Credit Facility [Line Items]
Number of locking days based on interest rate					30 days
2020 Credit Agreement [Member] | Sumitomo Mitsui Banking Corporation [Member] | Maximum
Line Of Credit Facility [Line Items]
Number of locking days based on interest rate					365 days
2021 Credit Agreement [Member] | Sumitomo Mitsui Banking Corporation [Member]
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity										$ 20,000,000
Line of credit facility, interest rate during period		0.595%
Repayments of outstanding borrowing			$ 20,000,000
Repayment Of Debt Incremental Fees			$ 7,000
Credit agreement related expense							203,000	352,000
2020 and 2021 Credit Agreement [Member] | Sumitomo Mitsui Banking Corporation [Member]
Line Of Credit Facility [Line Items]
Debt issuance cost							$ 10,000,000	$ 10,000,000
Percentage of share holder guaranteed on total loan amount							50.00%	50.00%
Credit Agreements [Member] | Other Accrued Expenses [Member]
Line Of Credit Facility [Line Items]
Accrued guarantee fees								$ 351,000

Debt - Summary of Long Term Deb

Debt - Summary of Long Term Debt (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Notes Payable, Noncurrent	$ 1,577,807	$ 692,871
Less current maturities	(494,173)	(223,400)
Long-term debt	1,083,634	469,471
Notes payable Fixed interest 6.943, Maturity Due August 12, 2024 [Member]
Debt Instrument [Line Items]
Notes Payable, Noncurrent	286,255	346,436
Notes payable Fixed interest 6.943, Maturity Due July 15, 2023 [Member]
Debt Instrument [Line Items]
Notes Payable, Noncurrent	202,142	$ 346,435
Notes payable Fixed interest 4.89, Maturity Due March 20, 2025 [Member]
Debt Instrument [Line Items]
Notes Payable, Noncurrent	675,836
Notes payable Fixed interest 5.44, Maturity Due September 10, 2026 [Member]
Debt Instrument [Line Items]
Notes Payable, Noncurrent	$ 413,574

Debt - Summary of Long Term D_2

Debt - Summary of Long Term Debt (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2021USD ($)
Notes payable Fixed interest 6.943, Maturity Due August 12, 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	$ 30,917
Debt Instrument, Interest Rate, Stated Percentage	6.94%
Debt Instrument, Maturity Date	Aug. 12, 2024
Notes payable Fixed interest 6.943, Maturity Due July 15, 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	$ 30,917
Debt Instrument, Interest Rate, Stated Percentage	6.94%
Debt Instrument, Maturity Date	Jul. 15, 2023
Notes payable Fixed interest 4.89, Maturity Due March 20, 2025 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	$ 56,548
Debt Instrument, Interest Rate, Stated Percentage	4.89%
Debt Instrument, Maturity Date	Mar. 20, 2025
Notes payable Fixed interest 5.44, Maturity Due September 10, 2026 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	$ 8,250
Debt Instrument, Interest Rate, Stated Percentage	5.44%
Debt Instrument, Maturity Date	Sep. 10, 2026

Debt - Schedule of Aggregate Ma

Debt - Schedule of Aggregate Maturities of Long-term Debt (Details)	Dec. 31, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ 494,173
2023	493,044
2024	369,827
2025	148,170
2026	72,593
Thereafter	0
Long-term debt	$ 1,577,807

Leases - Additional Information

Leases - Additional Information (Detail)	Jul. 28, 2021USD ($)ft²	Dec. 31, 2021USD ($)ft²	Jan. 26, 2021ft²
Operating Leases, Rent Expense | $		$ 1,980,000
Lease Esclation Percent		2.00%
Security Deposit | $		$ 331,000
Area of Land	360,320
Security Deposit Liability | $		$ 4.9
New York
Area of Land		7,700
Lease Expiration Year		2022
Summerville, South Carolina
Lessee, Operating Lease, Term of Contract			5 years
Area of Land		272,000
Lessee, Operating Lease, Renewal Term			3 years
Lease Expiration Term		2037-10	2026-07
Maximum Allowance For Tenant Improvements | $	$ 1,260,000
Madison, Wisconsin
Area of Land		2,500
Lease Expiration Term		2024-10
Benicia, California
Area of Land		16,896
Lessee, Operating Lease, Renewal Term		5 years
Lease Expiration Term		2025-01
Minimum
Lessee, Operating Lease, Term of Contract		1 year
Minimum | Summerville, South Carolina
Area of Land			115,500
Maximum
Lessee, Operating Lease, Term of Contract		30 years
Maximum | Summerville, South Carolina
Area of Land			136,500

Leases - Summary of Operating a

Leases - Summary of Operating and Finance Leases (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Operating lease:
Operating lease right-of-use assets	$ 17,836,756	$ 17,740,816
Current portion of operating lease liability	2,633,236	2,603,930
Operating lease liability, net of current portion	27,605,739	27,284,356
Total operating lease liabilities	30,238,975	29,888,286
Finance lease:
Finance lease right-of-use asset	883,076	767,237
Current portion of finance lease liability	413,487	269,212
Finance lease liability, net of current portion	482,544	454,857
Total finance lease liabilities	$ 896,031	$ 724,069

Leases - Summary of Lease Expen

Leases - Summary of Lease Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating lease:
Operating lease cost(1)	$ 5,692,735	$ 5,062,144
Finance lease:
Amortization of leased assets	424,961	210,262
Interest on lease liabilities	52,511	22,947
Total lease cost	$ 6,170,207	$ 5,295,353
Weighted average remaining lease term (years)
Operating leases	13 years 8 months 23 days	15 years 6 months 10 days
Finance leases	2 years 3 months 29 days	7 days
Operating leases	9.20%	12.10%
Finance leases	6.10%	4.70%
Operating cash outflows from operating leases	$ 4,794,134	$ 5,399,423
Operating cash outflows from finance leases (interest payments)	52,511	22,947
Financing cash outflows from finance leases	377,880	177,461
Leased assets obtained in exchange for finance lease liabilities	540,433	694,108
Leased assets obtained in exchange for operating lease liabilities	$ 2,913,002	$ 4,259,688

Leases - Summary of Maturities

Leases - Summary of Maturities of Operating and Finance Lease Liabilities (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Lessee Lease Liabilities Payments Due [Abstract]
2022	$ 5,120,933
2023	3,497,422
2024	3,589,920
2025	3,559,583
2026	3,325,639
Thereafter	35,705,778
Total minimum lease payments	54,799,275
Less: imputed interest	24,560,300
Total operating lease liabilities	30,238,975	$ 29,888,286
Current portion of operating lease liability	2,633,236	2,603,930
Operating lease liability, net of current portion	27,605,739	27,284,356
2022	452,669
2023	326,112
2024	140,146
2025	16,764
2026	38,942
Total minimum lease payments	974,633
Finance Lease, Liability, Undiscounted Excess Amount	78,602
Total finance lease liabilities	896,031	724,069
Current portion of finance lease liability	413,487	269,212
Finance lease liability, net of current portion	$ 482,544	$ 454,857

Convertible Preferred Stock a_2

Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail) - USD ($)	Sep. 22, 2021	Jul. 05, 2018	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2018
Common Stock Shares Outstanding			12,323,830	52,554,214
Series E Convertible Preferred Stock [Member]
Conversion of Series E convertible preferred stock to common stock (in Shares)		27,011,500
Preferred Stock, Value		$ 138,400,000
Dividends Payable					$ 3,000,000
Temporary Equity, Shares Outstanding			27,011,500	0
Preferred Stock, Dividend Rate, Percentage			7.50%
Dividends, Preferred Stock			$ 266,918
Common Stock, Conversion Basis	one-to-one
Common Stock Shares Outstanding	27,011,500

Warrants -Schedule Fair Value M

Warrants -Schedule Fair Value Measurement Inputs and Valuation Techniques (Details)	Dec. 31, 2021	Dec. 31, 2020
Measurement Input Fair Market Value
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair market value	6.21	6.67
Measurement Input, Exercise Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair market value	6.74	6.74
Measurement Input Price Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair market value	8.5	9.5
Measurement Input, Price Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair market value	75	68
Measurement Input Annual Dividend
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair market value	0	0
Measurement Input, Risk Free Interest Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair market value	1.48	0.13

Warrants - Schedule of Fair Val

Warrants - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant liability	$ 2,058,566	$ 3,930,930
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant liability	$ 2,058,566	$ 3,930,930

Warrants - Summary Of Change in

Warrants - Summary Of Change in Fair value, as Determined by Level 3 inputs, for all Assets and Liabilities (Details) - Level 3 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance	$ 3,930,930	$ 2,018,443
Change in fair value	(1,872,364)	1,912,487
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance	$ 2,058,566	$ 3,930,930

Warrants - Additional Informati

Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Oct. 10, 2018	Jun. 23, 2010	Jul. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	May 10, 2011
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,450,000
Proceeds from Issuance of Warrants			$ 22.2
Class of Warrant or Right, Outstanding				113,030	113,030
Warrants, Fair Value Disclosure				$ 2.1	$ 3.9
Equity Based Warrants
Class of Warrant or Right, Warrants Exercised			2,168,485
Common Stock Warrants
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,532,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.74
Class of Warrant or Right, Expired date of Warrants or Rights		Jun. 23, 2020
Class of Warrant or Right, Outstanding				2,532,000
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,450,000					453,455
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.12					$ 6.74
Class of Warrant or Right, Expired date of Warrants or Rights	Oct. 11, 2028
Common Stock [Member] | Shareholders One
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,225,000

Share-based Compensation - Addi

Share-based Compensation - Additional Information (Details) - USD ($)

Dec. 01, 2021

Sep. 23, 2021

Sep. 22, 2021

Jul. 29, 2021

Jul. 14, 2020

May 01, 2019

Apr. 30, 2019

Jun. 30, 2020

Feb. 28, 2020

May 31, 2019

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Common Stock Options, Fair Value

$ 2,538,280

Exercise Price

$ 0.85

Promissory note payable issued in exchange for buyback of management options

$ (1,500,000)

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

1,959,335

1,959,335

Interest expense, net

$ 449,908

$ 1,125,472

Put Option [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount

$ 713,000

Share-based Payment Arrangement, Option [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition

9 months

Restricted Stock Units R S U [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Number of Shares Outstanding, Granted

3,879,350

Restricted Stock Units R S U [Member] | I P O [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Options Outstanding, Granted

875,760

875,760

Additional RSUs Issued, Shares

2,531,000

Two Thousand And Twenty One Equity Incentive Plan

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance

3,480,510

Additional Number Of Shares That May Be Reserved For Future Issuance Pursuant To The Plan

10,615,030

Share based compensation by share based award number of additional shares available for grant as a percentage of common stock outstanding

5.00%

Share based compensation by share based award additional shares available for grant

8,701,275

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount

$ 31,700,000

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition

3 years 10 months 24 days

Two Thousand And Twenty One Equity Incentive Plan | Common Stock [Member] | Restricted Stock Units R S U [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Number of Shares Outstanding, Granted

472,590

2010 Plan [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options Granted

13,106,416

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Shares Available For Issuance

949,510

2010 Plan [Member] | Tranche One [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options Granted

9,699,656

2010 Plan [Member] | Tranche One [Member] | Out Of Twenty Five Lakhs Thirty Eight Thousand And Two Hundred And Eighty Options Granted [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share Based Compensation By Share Based Award Options Excercised During The Period For Which Promissory Notes Have Been Issued

1,793,795

2010 Plan [Member] | Tranche One [Member] | Out Of Twenty Five Lakhs Thirty Eight Thousand And Two Hundred And Eighty Options Granted [Member] | Certains Of Management [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share Based Compensation By Share Based Payment Award Cumulative Number Of Options Granted

2,568,095

Share price

0.85

Related Party Transaction, Rate

5.00%

Debt Instrument, Maturity Date

Jun. 22, 2020

Promissory note payable issued in exchange for buyback of management options

$ (1,500,000)

2010 Plan [Member] | Tranche One [Member] | Out Of Twenty Five Lakhs Thirty Eight Thousand And Two Hundred And Eighty Options Granted [Member] | Put Option [Member] | Certains Of Management [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Option Indexed to Issuer's Equity, Indexed Shares

1,793,795

2010 Plan [Member] | Tranche Two [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options Granted

3,406,760

2010 Plan [Member] | Common Stock [Member] | Tranche One [Member] | Out Of Twenty Five Lakhs Thirty Eight Thousand And Two Hundred And Eighty Options Granted [Member] | Certains Of Management [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options Granted

1,793,795

Two Thousand And Twenty One Plan | Keys Of Management [Member] | Buyout Of Management Stock Options [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Related Party Transaction, Rate

5.00%

Promissory note payable issued in exchange for buyback of management options

$ (6,300,000)

Two Thousand And Twenty One Plan | Tranche One [Member] | Out Of Twenty Five Lakhs Thirty Eight Thousand And Two Hundred And Eighty Options Granted [Member] | Certains Of Management [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Settlement Of Share Based Liabilities

$ 23,800,000

Options Issued and Outstanding, Exercised

106,800

Two Thousand And Twenty One Plan | Tranche One [Member] | Out Of Twenty Five Lakhs Thirty Eight Thousand And Two Hundred And Eighty Options Granted [Member] | Keys Of Management [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Related Party Transaction, Rate

5.00%

Promissory note payable issued in exchange for buyback of management options

$ (700,000)

Share Based Compensation By Share Based Award Options Excercised Subject To Tax

1,793,795

Two Thousand And Twenty One Plan | Tranche One [Member] | Out Of Twenty Five Lakhs Thirty Eight Thousand And Two Hundred And Eighty Options Granted [Member] | Put Option [Member] | Certains Of Management [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Deferred Compensation Cash-based Arrangements, Liability, Current

$ 14,800,000

Stock Repurchased During Period Shares

667,500

Share-based Payment Arrangement, Cash Used to Settle Award

$ 23,100,000

Two Thousand And Twenty One Plan | Tranche One [Member] | Out Of Twenty Five Lakhs Thirty Eight Thousand And Two Hundred And Eighty Options Granted [Member] | Put Option [Member] | Certains Of Management [Member] | Relating To Remeasurement Of Options [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense

1,100,000

Two Thousand And Twenty One Plan | Share-based Payment Arrangement, Option [Member] | Selling General And Administrative Expenses [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Payment Arrangement, Expense

$ 2,800,000

10,000,000

Two Thousand And Twenty One Plan | Restricted Stock Units R S U [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Options Outstanding, Granted

2,531,000

875,760

Two Thousand And Twenty One Plan | Restricted Stock Units R S U [Member] | Selling General And Administrative Expenses [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Payment Arrangement, Expense

$ 1,800,000

Two Thousand And Twenty One Plan | Common Stock [Member] | Tranche One [Member] | Out Of Twenty Five Lakhs Thirty Eight Thousand And Two Hundred And Eighty Options Granted [Member] | Certains Of Management [Member] | Relating To Remeasurement Of Common Stock [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense

$ 9,000,000

Onegevity Merger [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options Granted

1,959,335

Onegevity Merger [Member] | I P O [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options Granted

1,959,335

1,959,335

Onegevity Merger [Member] | Restricted Stock Units R S U [Member]

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Options Outstanding, Granted

472,590

Share-based Compensation - Sche

Share-based Compensation - Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) - Stock Option Activity [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Opening balance	7,811,975
Options Outstanding, Granted	1,959,335
Exercise of stock options (in Shares)	39,614
Options Outstanding, Cancelled/forfeited	32,040
Options Outstanding, Closing balance	9,699,656	7,811,975
Options Outstanding, Vested and expected to vest	9,699,656
Options Outstanding, Exercisable	5,691,541
Weighted- Average Exercise Price, Opening balance	$ 4.66
Weighted- Average Exercise Price, Granted	7.65
Weighted- Average Exercise Price, Exercised	1.91
Weighted- Average Exercise Price, Cancelled/forfeited	5.12
Weighted- Average Exercise Price, Closing balance	5.28	$ 4.66
Weighted- Average Exercise Price, Vested and expected to vest	5.28
Weighted- Average Exercise Price, Exercisable	$ 4.29
Weighted Average Remaining Contractual Term (Years), Outstanding, Opening Balance		6 years 3 months 18 days
Weighted Average Remaining Contractual Term (Years), Outstanding, Closing Balance	6 years 2 months 19 days
Weighted Average Remaining Contractual Term (Years), Outstanding, Vested and expected to vest	6 years 2 months 19 days
Weighted Average Remaining Contractual Term (Years), Outstanding, Exercisable	5 years 8 months 23 days
Aggregate Intrinsic Value, Outstanding, Closing Balance	$ 12.3
Aggregate Intrinsic Value, Outstanding, Vested and expected to vest	12.3
Aggregate Intrinsic Value, Outstanding, Exercisable	$ 10.9

Share-based Compensation - Summ

Share-based Compensation - Summary of stock options outstanding (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Grant date fair value of stock options vested	$ 963,205	$ 963,205
Intrinsic value of stock options exercised	$ 219,813

Share-based Compensation - Sc_2

Share-based Compensation - Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range (Details)	Dec. 31, 2018$ / shares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price	$ 0.85

Share-Based Compensation - Sc_3

Share-Based Compensation - Schedule of Non Vested Restricted Stock Shares Activity (Details) - Restricted Stock Units R S U [Member]	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Number of Shares Outstanding, Opening balance	0
Number of Shares Outstanding, Granted	3,879,350
Number of Shares Outstanding, Released	472,590
Number of Shares Outstanding, Cancelled/forfeited	0
Number of Shares Outstanding, Ending balance	3,406,760
Number of Shares Outstanding, Vested and expected	3,406,760
Weighted- Average Grant-Date Fair Value, Opening balance | $ / shares	$ 0
Weighted- Average Grant-Date Fair Value, Granted | $ / shares	9.99
Weighted- Average Grant-Date Fair Value, Released | $ / shares	11.17
Weighted- Average Grant-Date Fair Value, Cancelled/forfeited | $ / shares	0
Weighted- Average Grant-Date Fair Value, Ending balance | $ / shares	9.82
Weighted- Average Grant-Date Fair Value, Vested and expected | $ / shares	$ 9.82
Two Thousand And Twenty One Equity Incentive Plan | Common Stock [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Number of Shares Outstanding, Granted	472,590

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of RSUs (Details) - Restricted Stock Units R S U [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Weighted-average grant date fair value of stock options granted	$ 9.99
Grant date fair value of RSUs vested	$ 0	$ 0
Intrinsic value of RSUs released	$ 0	$ 0

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current
Federal	$ 0	$ 0
State	411,919	176,758
Net income tax expense	$ 411,919	$ 176,758

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating losses	$ 19,538,932	$ 13,547,317
AMT/Federal credit	897,616	0
State credits	2,485,652	2,031,797
Lease liability ASC 842	7,271,783	7,152,442
Disallowed interest expense	164,921	164,984
Share-based compensation	495,960	0
Impairment	464,720	0
Other	691,010	976,746
Total deferred tax assets	32,010,594	23,873,286
Deferred tax liabilities:
Basis difference on fixed assets	(4,114,426)	(3,569,913)
Basis difference on intangibles	(1,427,816)	(1,066,468)
Prepaid expenses	(709,653)	(100,995)
Right-of-use asset ASC 842	(4,372,138)	(4,324,325)
Other	(72,714)
Total deferred liabilities	(10,696,747)	(9,061,701)
Net deferred tax asset	21,313,847	14,811,585
Less valuation allowance	(21,313,847)	(14,811,585)
Net deferred tax asset (liability) post valuation allowance	$ 0	$ 0

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Tax Rate Differs from Statutory Federal Tax Rate (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Federal income tax at the statutory rate U.S. federal rate	$ 1,851,313	$ (835,808)
State taxes, net of federal	325,416	128,075
Permanent items	693,699	2,571,620
Change in valuation allowance	(2,383,291)	(1,659,594)
Return to provision adjustments	8,665	0
Nondeductible expenses and other	(83,883)	(27,535)
Net income tax expense	$ 411,919	$ 176,758
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Federal income tax at the statutory rate U.S. federal rate	21.00%	21.00%
State taxes, net of federal	3.80%	(3.20%)
Permanent items	7.90%	(64.60%)
Change in valuation allowance	(27.00%)	41.70%
Return to provision adjustments	0.10%	0.00%
Nondeductible expenses and other	(1.00%)	0.70%
Effective income tax rate	4.70%	4.40%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018
Income Taxes [Line Items]
Operating loss carryforwards expiration, Description	If not utilized, the federal operating loss carryforwards incurred before January 1, 2020 will begin to expire in 2030. The federal operating losses incurred in 2019 and beyond do not expire. The state operating loss carryforwards do not expire.
Unrecognized tax benefits	$ 0	$ 0
Accrued interest or penalties to unreconized tax benefits	$ 0	0
Idaho and South Carolina [Member]
Income Taxes [Line Items]
Net operating loss carryforwards			$ 11,400,000
Net operating loss carryforward expiration date	Dec. 31, 2038
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	$ 70,200,000	50,100,000
Operating Loss Carryforwards Expiration Year	2030
Reduction In Tax NOLs Carryforward	$ 8,100,000
State [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	69,700,000	$ 50,100,000
Reduction In Tax NOLs Carryforward	$ 8,100,000

Employee Compensation Plans - A

Employee Compensation Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Compensation [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.00%
Matching contribution	100.00%
Defined Contribution Plan, Vesting Year	6 years
Defined Contribution Plan, Vesting Percentage	100.00%
Profit Sharing Contributions	$ 0.9	$ 0.7
Minimum
Employee Compensation [Line Items]
Defined Contribution Plan Percentage Of Base Compensation	3.00%
Maximum
Employee Compensation [Line Items]
Defined Contribution Plan Percentage Of Base Compensation	5.00%

Basic and Diluted Net Income _3

Basic and Diluted Net Income (Loss) per Share (Additional Information) (Details) - USD ($)	Sep. 22, 2021	Dec. 31, 2021
Earnings Per Share [Abstract]
Conversion of Series E convertible preferred stock to common stock	$ 27,011,500	$ 133,484,531

Basic and Diluted Net Income _4

Basic and Diluted Net Income (Loss) per Share - Schedule of the Calculate Net Income (loss) Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss) attributable to Thorne HealthTech, Inc.	$ 7,253,423	$ (3,357,746)
Undistributed earnings attributable to Series E convertible preferred stockholders	(3,507,892)
Numerator for basic EPS-net income (loss) available to Thorne HealthTech, Inc. common stockholders (A)	3,745,531	(3,357,746)
Change in fair value of warrant liability	(1,872,364)	1,912,487
Undistributed earnings attributable to Series E convertible preferred stockholders, basic	3,507,892
Undistributed earnings attributable to Series E convertible preferred stockholders, Diluted	(2,031,751)	0
Effect of dilutive securities	(396,223)	0
Numerator for diluted EPS-net income (loss) available to Thorne HealthTech, Inc. common stockholders	$ 3,349,308	$ (3,357,746)
Weighted average number of common shares outstanding - basic	27,478,411	9,985,800
Dilutive potential common shares	4,850,154	0
Denominator for diluted EPS-adjusted weighted average shares and assumed conversions	32,328,565	9,985,800
Basic EPS	$ 0.14	$ (0.34)
Diluted EPS	$ 0.10	$ (0.34)
RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential common shares	159,668	0
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential common shares	1,082,358	0
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential common shares	3,608,128	0

Basic and Diluted Net Income _5

Basic and Diluted Net Income (Loss) per Share - Schedule of the Calculate Net Income (loss) Per Share (Parenthetical) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share	4,850,154	0
Convertible preferred stock excluded computation of diluted EPS	19,611,089	27,011,500
Warrants And Stockbased Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the computation of earnings per share		4,200,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Annual Minimum Commitments (Detail) - Agreements With A Major Hospital For The Use Of Trade Names And Trademarks	Dec. 31, 2021USD ($)
Other Commitments [Line Items]
2022	$ 1,030,000
2023	562,500
Total	$ 1,592,500

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017
Grant | SEYCHELLES
Other Commitments [Line Items]
Regulated Operating Revenue, Other			$ 800
Period For Which The Performance Obligation Must Be Maintained			5 years
Royalty Agreement On Future Sales
Other Commitments [Line Items]
Payment Of Royalties	$ 616	$ 488

Subsequent Events (Additional I

Subsequent Events (Additional Information) (Details) - USD ($) $ in Millions	Feb. 28, 2022	Jan. 10, 2022	Jan. 01, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Ownership interest				3.46%
Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance			2,627,710
Percentage of the total Share outstanding			5.00%
Description of Members of Board of Directors		The board of directors of the Joint Venture initially will be composed of five directors, of which three shall be nominated by Thorne, and two by Mitsui. Each director shall be appointed for a term of office of one year and shall be eligible for re-election.
Subsequent Event [Member] | Nutrativa LLC [Member]
Subsequent Event [Line Items]
Consideration Transferred in cash	$ 15
Subsequent Event [Member] | Thorne Research Inc [Member]
Subsequent Event [Line Items]
Paid, Contributed in ownership Entity		$ 2.7
Ownership interest		51.00%
Subsequent Event [Member] | Mitsui and TM HealthTech Pte. Ltd. [Member]
Subsequent Event [Line Items]
Paid, Contributed in ownership Entity		$ 2.6
Ownership interest		49.00%